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In the past several years there have been major developments in the interventional 
treatment of acute ischaemic stroke. This thesis consists of four projects that I 
developed throughout my graduate studies.  
I started by working on setting up a phase 2 multicentre, randomised, controlled trial 
to assess the technical safety and efficacy of two new devices to be used in 
endovascular treatment: the ERIC retriever and the SOFIA distal access catheter. 
The trial has not yet finished, but partial results are presented.  
I went on to investigate the role of imaging in hyperacute stroke management. I 
developed a validated case archive of computed tomography angiography scans 
which was used for a radiological course. Assessing trainees reports pre- and post-
training showed that there was a significant improvement in rates of major errors and 
this study concluded that an intensive hands-on radiological course was effective.  
While the trial was running, I developed a new technical index of thrombectomy 
difficulty. This score uses computed tomography angiographic images to evaluate 
key factors for predicting the expected procedural difficulty. The results demonstrated 
an excellent inter-rater reliability making this potentially a powerful tool to help with 
decision making and procedural planning.  
Due to limited evidence for mechanical thrombectomy in the older population, I 
worked on a study to assess the safety and efficacy of this treatment. Patients had 
more comorbidities, more tandem occlusions, but still good reperfusion rates with a 
similar safety profile to the younger population. Clinical results at 3 months were 
poorer than in the younger population, but milder presenting clinical deficits and good 
reperfusion rates were predictors of good outcomes.    
This thesis will first discuss stroke with a review of the evidence for performing 
mechanical thrombectomy. The projects undertaken during my studies will be 
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Chapter 1. Introduction to Stroke and Thrombectomy 
 
The World Health Organisation (WHO) stroke definition is: “rapidly developing clinical 
signs of focal (at times global) disturbance of cerebral function, lasting more than 24h 
or leading to death with no apparent cause other than that of vascular origin” 
(Hatano, 1976).  
1.1 History of Stroke 
The earliest record of stroke being recognised as its own entity is from over 2400 
years ago by Hippocrates of Kos, the father of western medicine (Grammaticos and 
Diamantis, 2008). The ancient Greeks called this disease cerebral apoplexy which 
means “struck by lightning” as they had no other reasonable explanation for these 
symptoms.  
It was only many years later, in the 1600s, that Jacob Wepfer from Italy performed 
cadaveric dissections on patients affected by this disease process and discovered 
that the blood supply to the brain had been disrupted either in the form of a blocked 
or a ruptured intracranial artery (Pound, Bury and Ebrahim, 1997). Further research 
in the 1800s by Rudolf Virchow, the father of modern pathology, confirmed this theory 
and made advancements in the understanding of thromboembolic disease. It was 
Virchow who coined the more modern term cerebrovascular insult and from here on 
this was favoured instead of apoplexy (Leak et al., 2014).  
The layman term of “stroke” had been described in 1824 by a physician who noted 
that this term had been in use for centuries (Pound, Bury and Ebrahim, 1997). This 
word is likely to have its roots from one of the phrases: “the stroke of God’s hand”, 
“the mortal stroke”, “the stroke of God” or “the stroke of justice” (Pound, Bury and 
Ebrahim, 1997). All of these refer to the fact that people believed the patient afflicted 
by this disease had been struck by a higher power. The term stroke was used in a 
publication by the Chest and Heart Association in 1962 in a booklet put together by a 
multidisciplinary team titled: “Modern Views on “Stroke” Illness” (Pound, Bury and 
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Ebrahim, 1997). It is from this point forward that the term stroke as we know it has 
been in use regularly within the medical field. 
Among famous people, there have been several which have passed away due to 
stroke. A few of the iconic stroke victims are: Louis Pasteur, Charles Dickens, 




Figure 1 - Famous stroke sufferers 
A - Louis Pasteur, B - Charles Dickens, C - Nicolaus Copernicus, D - Alfred Nobel 
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1.2 Epidemiology  
Data from WHO shows that stroke was the 2nd most common cause of death 
worldwide in 2012, affecting 6.7 million people and representing 11.9% of all deaths 
(WHO, 2016), Table 1. 
 
  
Table 1 - Top 5 causes of death from 2000 to 2016 
Adapted from World Health Organization,  (WHO, 2016) 
 
A recent paper showed that the worldwide incidence of a first stroke in 2010 was 16.9 
million and the prevalence 33 million (Feigin et al., 2014). This is significant as it 
resulted in 102 million of years lost due to disability or death as measured by the 
disability-adjusted life years (DALYs). More worryingly however is the fact that over 
the past 20 years there has been an increase in stroke globally, especially in lower 
income countries. This is presumed to be due to an increase in the prevalence of risk 
factors for stroke such as: increasing population age, diabetes, high cholesterol,  
obesity and smoking (Giroud, Jacquin and Béjot, 2014). Feigin et al. estimate that if 
the current trends continue, in 2030 there will be almost 12 million deaths, 70 million 







































In the UK alone, the yearly incidence of stroke is 152,000 times per year and the 
prevalence is 1.2 million. 20% of women and 17% of men will have a stroke by the 
age of 75 (The Stroke Association, 2015). Stroke is the largest cause of complex 
disability in adults and half of stroke survivors will be dependent on others - either 
family, friends or professional carers - with regard to their activities of daily living 
(NICE, 2008b). Similar to the worldwide data, stroke accounts for 11% of all deaths in 
England and Wales (NICE, 2008b).  
It is important to focus efforts and develop innovations both on the preventive 
measures and the acute treatment of stroke to improve the outcome for this disease.  
1.3 Economic Cost of Stroke 
The most recent State of the Nation, Stroke Statistics publication from the Stroke 
Association gives a reliable and updated picture of the amount the UK government is 
spending on the acute and chronic management of stroke (The Stroke Association, 
2015). The average cost for the initial acute and rehabilitation care for one stroke 
patient is between £23,315 and £26,700. The total yearly amount spent is 
approximately £9 billion and this is divided as follows: 
• £4.4 billion (49%)  – health and social care 
• £2.4 billion (27%)  – informal care costs 
• £1.3 billion (15%) – productivity losses 
• £841 million (9%)  – benefits paid out 
This represents ~6% of total NHS (National Health Service) expenditure, which for 
the financial year of 2014/2015 stood at approximately 140 billion. It is a significant 
cost to healthcare spending, especially under the current economic climate. Cost 
effective strategies to help reduce the amount spent on stroke by leading to an 






1.4 Stroke Risk Factors 
Identifying the risk factors present, especially modifiable ones, is important because if 
these can be improved, they may reduce the severity, incidence and overall 
prevalence of stroke.  
The non-modifiable stroke risk factors cannot be altered and therefore can only be 
taken in consideration when reviewing everything else and assessing the risk of 
future stroke. There are multiple non-modifiable risk factors as recognised by the 
American Stroke and Heart Associations are (Meschia et al., 2014) including age, 
genetics and family history of stroke.  
The modifiable stroke risk factors however, could be improved with different medical 
or even surgical interventions. There have been several studies assessing these risk 
factors: hypertension, carotid stenosis, atrial fibrillation and diabetes mellitus, just to 
name a few, are among the medical conditions which are known to increase chances 
of stroke (Jamrozik et al., 2000; Meschia et al., 2014). 
In addition, modifiable lifestyle stroke risk factors such as cigarette smoking, obesity, 
physical activity, diet, alcohol and drug use are also important to acknowledge 
(Zhang et al., 2011; Meschia et al., 2014). 
If these conditions are identified and managed accordingly before any stroke or 
transient ischaemic attack (TIA) symptoms occur, that would be the ideal situation. 
However, many patients will present with TIA symptoms and these patients are at 
higher risk to have a recurrent event, which may well be a full-blown stroke.  
A paper described that interventions aimed at improving blood pressure control and 
aggressive medical treatment of hyperlipidaemia in their study population led to a 
significant decrease in atherosclerotic disease and ischaemic stroke (Bogiatzi et al., 
2014). These findings confirm the importance of assessing and managing any risk 






1.5 Stroke Classification 
Strokes can be either ischaemic or haemorrhagic in nature. It is largely recognised 
that approximately 87% of strokes are of ischaemic nature and the other 
approximately 13% are due to intracranial haemorrhage (Bogiatzi et al., 2014).  
 
1.5.1 Ischaemic stroke 
Ischaemic strokes are caused by blockage of an intracranial vessel leading to 
decreased perfusion of the brain tissue in the supplied territory and ultimately in brain 
infarction. Ischaemic strokes can be further categorised according to the Oxford 
Community Stroke Project Classification (OCSP) which relies on the initial clinical 
signs and symptoms into the following categories (Dewey et al., 2001; Donnan et al., 
2008): 
TACS – Total Anterior Cerebral Syndrome 
PACS – Partial Anterior Cerebral Syndrome 
POCS – Posterior Circulation Syndrome 
LACS – Lacunar Syndrome 
These categories have been demonstrated to correlate well with the findings on CT 
(computed tomography) scans, as long as lacunar strokes were accepted to be 
represented within the negative CT scan category (Pittock et al., 2003). 
 
1.5.2 Haemorrhagic stroke 
Haemorrhagic stroke accounts for approximately 13% of all strokes and this is further 
subcategorised into different causes (Feldmann et al., 2005; England et al., 2010). 
The most important of these are hypertensive haemorrhage, haemorrhagic 
transformation of a recent ischaemic infarct, aneurysmal subarachnoid haemorrhage, 
cerebral amyloid angiopathy and rupture of an intracranial vascular malformation.  
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Stroke symptoms due to intracranial haemorrhage may be indistinguishable from 
symptoms due to an ischaemic stroke. This is the reason why imaging plays an 
important role in the acute management of these patients and this will be further 
discussed in the imaging section.    
1.6 Signs and Symptoms of Stroke 
Clinical signs and symptoms are usually of sudden onset and will depend on the part 
of the brain affected. Generally, if a larger part of the brain is affected, patients will 
have more significant symptoms.  
The OCSP classification which has been described above is a good way of 
categorising the location of stroke. According to the different stroke categories, the 
main presenting clinical signs and symptoms were described in the original paper  
(Bamford et al., 1991). Stroke signs and symptoms include: motor or sensory deficits, 
visual field defects, dysphasia, ataxia. 
Total anterior circulation infarcts may present with higher cerebral dysfunction (e.g. 
dyspraxia), motor or sensory deficits and visual dysfunction.  
Partial anterior circulation infarcts have similar symptoms to an anterior circulation 
stroke but can be milder in character.  
Posterior circulation infarcts can present with ataxia, homonymous hemianopsia, 
cranial nerve palsies and possibly motor or sensory deficit. 
Lacunar infarcts can present with motor, sensory or less commonly higher function 
deficits or ataxic hemiparesis.  
In primary or secondary haemorrhagic stroke, the mass effect exerted by the 
haematoma may also exert compression of adjacent brain structures leading to 
additional neurological symptoms. There is also the issue that in some patients, there 
will be further haematoma expansion and development of adjacent brain oedema 




1.7 Causes of Ischaemic Stroke 
Determining the cause of stroke in each individual patient is important because this 
will influence both the short-term and the long-term treatment. One of the most cited 
studies that has looked at causes of ischaemic stroke and developed a validated 
method of classifying them was the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) (Adams et al., 1993; Adams and Biller, 2015). Based on this system, the 
Causative Classification System has been developed and offers the advantage of 
taking into account recent improvements in assessing patients with ischaemic stroke 
(Ay et al., 2007). Another system is the ASCOD (A: atherosclerosis; S: small-vessel 
disease; C: cardiac pathology; O: other causes; D: dissection), a phenotyping system 
which has been developed to also include dissection which is a more common cause 
in younger patients (Amarenco et al., 2013). According to this system, the different 
causes of ischaemic stroke are presented next. 
 
1.7.1 Atherothrombosis  
Atherothrombotic stroke can be diagnosed if there is evidence of significant 
atherosclerotic disease causing at least 50%, but usually more than 70% stenosis of 
the ipsilateral internal carotid artery (ICA). This diagnosis should also be considered if 
there is evidence of atherosclerosis affecting the aortic arch or the origin of the 
ipsilateral common carotid artery (Amarenco et al., 2013).  
 
1.7.2 Small vessel disease 
A stroke caused by small vessel disease can be diagnosed if there is evidence of two 
or more lacunar infarcts, which are deep strokes caused by a perforator artery. 
Microhaemorrhages and dilatation of perivascular spaces are also signs of small 




1.7.3 Cardiac pathology 
A cardiogenic stroke can be diagnosed if there is evidence of multi-territorial strokes 
(bilateral, supra and infra tentorial) and signs of systemic embolism due to a cardiac 
condition that may be due to atrial fibrillation, patent foramen ovale or a mechanical 
valve, just to name a few (Amarenco et al., 2013).  
 
1.7.4 Other Causes  
There are multiple other causes of acute ischaemic stroke that were mentioned in the 
original article, the top three being: dolichoectasia with complicated aneurysm; 
polycythaemia vera and systemic lupus (Adams et al., 1993). 
 
1.7.5 Dissection  
Finally, an acute dissection leading to stroke can be diagnosed either by CT or MRI 
(magnetic resonance imaging) as these can demonstrate the acute findings which 
range from subtle wall irregularity to a mural hematoma which can be flow limiting 
(Amarenco et al., 2013).  
Except for small vessel disease, the other causes of acute ischaemic stroke 
discussed above could potentially be treated with intravenous thrombolysis and/or 
mechanical thrombectomy if patients present early enough to hospital.  Before 
discussing treatment however, it is important to be able to diagnose the type of stroke 






1.8 Radiological Tests for Diagnosis 
In the acute stroke setting it is important to determine as soon as possible whether 
the patient suffers from an ischaemic or a haemorrhagic stroke event. The 
subsequent acute and then the secondary management will depend on the type of 
stroke. In the last 20 years, CT and more recently MRI have been used to 
differentiate between these two types of stroke and to exclude a stroke mimic. These 
techniques are further discussed below.  
 
1.8.1 Unenhanced CT Brain  
Patients presenting with signs and symptoms of acute stroke need to have urgent 
imaging assessment to evaluate for evidence of any intracranial haemorrhage and 
stroke mimics versus an acute ischaemic event. Studies have shown that 
approximately 30% of patients presenting with suspected acute stroke will have 
another pathological cause for their symptoms such as seizures, subdural 
haematomas, infections, etc. (Merino et al., 2013). 
The majority of hospitals in the UK will perform a non-contrast CT (NCCT) as an 
initial assessment due to the fact that this is quick, available 24/7 and easy to obtain 
(Department of Health, 2008; NICE, 2008a). Current imaging guidelines in the UK 
recommend brain imaging to be performed as soon as possible and within one hour 
from arrival to hospital if out of hours (Department of Health, 2008). 
The initial NCCT can demonstrate abnormalities at 3 hours from symptoms onset in 
up to 41% of patients having an acute ischaemic stroke (The IST-3 collaborative 
group, Wardlaw, 2015). Early infarct signs on CT can be difficult to appreciate as 
these changes can be very subtle. It is important to review for presence of brain 
swelling and sulcal effacement which could be reversed if there is timely reperfusion 
of the ischaemic brain tissue (Wardlaw and Mielke, 2005; Butcher et al., 2007). 
Hypoattenuation of the cortex or the deep grey matter is more likely to represent 
irreversibly infarcted tissue (Butcher et al., 2007). The presence of a hyper 
attenuated intracranial artery on NCCT, e.g. the dot sign, raises the suspicion of an 
intracranial thrombus (Wardlaw and Mielke, 2005).  
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To further improve detection of these subtle imaging findings, review of thin slices 
and using a narrower window width setting centred around 40 Hounsfield units with a 
window width around 10, a technique called “stroke window”, will help increase the 
contrast for the human eyes to be able to detect subtle pathology (Srinivasan et al., 
2006). The presence of underlying small vessel cerebrovascular disease, old 
infarctions or other brain pathology can make this assessment extremely challenging 
(Wardlaw et al., 2007).  Importantly, evidence of pathology such as old strokes, 
leukoaraiosis and brain atrophy should be considered when assessing patients for 
IVT (intra-venous thrombolysis) or thrombectomy, as they have been shown to 
predict poorer clinical outcomes and increased rates of intracranial haemorrhage post 
treatment (The IST-3 collaborative group, Wardlaw, 2015; Kongbunkiat et al., 2017).  
Specialist reporting by a neuroradiologist, although available only in certain centres, 
has been shown to be more accurate at detecting signs of acute stroke on NCCT 
(Wardlaw et al., 2010).  Scoring systems have been developed to improve detection 
of these subtle findings, the most widely used one is the ASPECTS (Alberta Stroke 
Program Early CT Score) score, and routine use of this tool helps with report 
consistency (Wardlaw et al., 2010).  A normal brain will have a total score of 10 and 1 
point is subtracted for each part of the following MCA territory parts that shows acute 
signs of infarction: caudate head, lentiform nucleus, internal capsule, insula, and then 
6 parts of the MCA cortex (M1 – M6) as illustrated in Figure 2 (Barber, Demchuk, 







Figure 2 - The APECTS score. 
This is composed of 10 regions. C=caudate, L=lentiform nucleus, IC=internal capsule, 
I=insular ribbon. M1 to M3 regions are at the level of the basal ganglia: M1=anterior MCA, 
M2=MCA lateral to insula, M3=posterior MCA. M4, M5 and M6 regions are at the level of the 
lateral ventricles, superior to M1 – M3. 
 
With the advent of artificial intelligence, automated calculation of the ASPECTS score 
can be performed. A study on 132 patients analysed the performance of the e-
ASPECTS software versus experienced neuroradiologists in assessing early 
ischaemic changes and concluded that e-ASPECTS is not inferior to 
neuroradiologists (Nagel et al., 2017).   
The main purpose of the NCCT in patients presenting with acute signs and 
symptoms of stroke is to exclude intracranial haemorrhage and other stroke mimics. 
Although a very useful tool which can help with predicting outcomes, NCCT has its 
limitations. Because of these, further research has been undertaken to the evaluation 
of CT angiography (CTA) and CT perfusion (CTP), which will be discussed next. 
 
1.8.2 CT Angiography 
Following the initial NCCT, CTA is a fast and reliable method to accurately detect 
whether there is an intracranial large vessel occlusion (LVO). It allows to clarify 
whether a more subtle hyper-dense intracranial artery shown on the initial NCCT 
represents an embolus. Additionally, it shows the entire arterial tree from the aortic 
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arch to the circle of Willis, allowing to detect any other extracranial pathologies which 
may be important, e.g. significant carotid stenosis. This additional scan is important 
as it may lead to a different treatment plan (e.g. IVT followed by endovascular 
thrombectomy) (Butcher et al., 2007; Berkhemer et al., 2015; Goyal et al., 2015). 
Some occlusion sites like the basilar artery, the M1 MCA (middle cerebral artery) or 
the ICA are well known to have poor recanalization rates and prognosis when only 
IVT is administered (Rha and Saver, 2007). In general, the recanalization rates with 
IVT are reported to be about 43%, but in some locations such as the carotid terminus 
(ICA-T) it can be 6% to 15% and in M1 MCA occlusions only 20% to 35% (Rha and 
Saver, 2007). Complete and fast recanalization is very important because this is what 
will ultimately affect long term clinical outcomes.  
Another useful tool for assessing the brain parenchyma for any early ischaemic 
changes is the evaluation of the CTA source images (Bhatia et al., 2011; Mortimer et 
al., 2013). Although on its own it is more reliable than the ASPECTS score from the 
NCCT, when both are combined, they have a good correlation with the patient’s 
clinical outcomes (Bhatia et al., 2011; Mortimer et al., 2013).   
CTA has been shown to have a good specificity and sensitivity for the detection of 
intracranial LVO and arterial stenoses (Menon et al., 2014). Additionally, this is 
important for the acute evaluation of the intracranial collateral circulation which is 
what will maintain the blood supply to the ischaemic penumbra potentially prolonging 
the time window to recanalization (Mortimer et al., 2013). It has been shown that the 
patient’s collateral status is an important factor influencing clinical outcomes after 
mechanical thrombectomy (Menon et al., 2014).   
Multiphase CTA has been developed to further assess the collateral status by 
providing additional temporal resolution. It is less affected by motion artefact and 
does not require  any additional contrast administration (Goyal et al., 2015). In 
addition, the actual thrombus is better estimated than on single phase CTA and it has 
been shown to improve the accuracy of detecting distal occlusions which may be 




1.8.3 CT Perfusion  
CTP is an additional tool available on most modern CT scanners which can provide 
additional information regarding the brain penumbra region, which is the salvageable 
ischaemic parenchyma, and the established ischaemic core, which represents the 
infarcted brain parenchyma (Schellinger, Fiebach and Hacke, 2003; Schramm et al., 
2004; Tan and Goddard, 2007; Department of Health, 2008; Lui et al., 2010; 
Eastwood, Lev and Provenzale, 2012). The CTP data is obtained by repeatedly 
acquiring brain images after an initial contrast bolus from which typically the cerebral 
blood volume (CBV), cerebral blood flow (CBF), mean transit time (MTT) and time to 
peak (TTP) are calculated (Schellinger, Fiebach and Hacke, 2003; Tan and Goddard, 
2007; Lui et al., 2010; Eastwood, Lev and Provenzale, 2012). Acquiring the CTP data 
usually has a higher patient radiation dose, although a dose of about 2mSv, similar to 
the NCCT, can be achieved if the scanner settings are carefully adjusted (Cohnen et 
al., 2006; Castillo, 2010). 
CTP is especially useful in strokes affecting the posterior circulation as these regions 
are usually very difficult to evaluate on NCCT due to artefact (Lui et al., 2010). To 
interpret CTP images, the MTT and/or TTP is evaluated as this demonstrates the 
amount of ischaemic brain parenchyma, while the CBV, if low, will correspond to 
already established infarction. The penumbral region will show a raised TTP, but a 
preserved or increased CBV; while the core infarct will show a raised TTP with a low 
CBV (Wardlaw et al., 2014). To help with interpretation, there has been development 
of automated software (e.g. Olea, RAPID). A study on the use of RAPID software 
revealed rare technical failures, reliability in helping to make clinical decisions and 
showed this tool to be faster than using automated perfusion-diffusion MRI scans (B. 
C. V Campbell et al., 2015). 
Finally, the acquired CTP data can be used to obtain a CTA of the circle of Willis in a 
similar way to the multiphase CTA, but with a lower resolution. As there is a temporal 
component, this CTA could be reformatted to demonstrate time resolved images and 
better assess intracranial vascular flow. Further studies on this technique to assess 




1.8.4 MRI and MRA 
MRI and MRA (magnetic resonance angiography) are both currently indicated in the 
UK in certain clinical situations (e.g. atypical strokes, dissections) and when there is 
uncertainty on the initial CT/CTA imaging (Department of Health, 2008; NICE, 
2008a). When compared to CT, MRI is more expensive to perform and less available 
especially out of hours (Department of Health, 2008; Kane et al., 2008). In addition, 
MRI takes a longer time compared to CT, there is the need to ensure all medical 
equipment is compatible with MRI, and overall is more difficult to tolerate by patients 
especially when they are unstable (Hand et al., 2005). All these factors together with 
the fact that MRI scans are more difficult to interpret and may require a specialised 
neuroradiologist opinion, limit its utility in hyperacute stroke initial evaluation.  
However, the possibility of using both DWI (diffusion weighted imaging) and PWI 
(perfusion weighted imaging) has significant advantages. PWI is able to demonstrate 
a focal area of hypoperfusion, while DWI can depict small areas of infarcted brain 
parenchyma, even in areas such as the posterior fossa that are usually more difficult 
to assess on CT/CTA. DWI abnormalities need to be assessed in conjunction with 
the ADC (apparent diffusion coefficient) map, because acute ischaemia will 
demonstrate a low ADC. Post stroke, the ADC values with gradually increase and 
return to normal over a period of 5 to 10 days (Lansberg et al., 2001). A mismatch 
between the DWI and the PWI can be used to identify patients that will benefit from 
hyperacute treatment and this was utilised as part of the inclusion criteria in a few 
trials: MR RESCUE, DEDAS, DIAS 2 (Furlan et al., 2006; Hacke et al., 2009; Kidwell 
et al., 2014). 
Another important subgroup of patients are those with an unknown time onset or 
wake-up stroke which account for 25 to 30% of patients with acute ischaemic stroke 
(Rimmele and Thomalla, 2014). A mismatch between the DWI and FLAIR (fluid 
attenuated inversion recovery sequence) sequences has been used as a substitute 
to time the onset of stroke between <3 to 4.5 hours and this mismatch has high 
positive predicted value (Aoki et al., 2010; Petkova et al., 2010; Thomalla et al., 
2011). The MR WITNESS trial demonstrated that it is safe to administer intravenous 
thrombolysis within 4.5 hours of stroke symptoms discovery in patients with unknown 
stroke onset time when using DWI:FLAIR mismatch on MRI (Schwamm et al., 2018).  
The WAKE-UP randomised control trial selected patients for thrombolysis 
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administration using DWI:FLAIR mismatch in patients with unknown time of symptom 
onset and concluded that they had better functional outcomes, but also more 
intracranial haemorrhages and deaths at 3 months (Thomalla et al., 2018). 
Other important MRI sequences which should be obtained in all stroke patients are a 
gradient echo (GRE) and/or susceptibility weighted imaging (SWI) as these can 
identify intracranial haemorrhage that could otherwise be overlooked on other 
standard sequences. GRE sequences can identify microhaemorrhages and this is 
important because if they are present, they may indicate a higher risk of 
haemorrhage, especially with IVT and may alter the hyperacute treatment (Linfante et 
al., 1999; Kidwell et al., 2002). 
Susceptibility-weighted imaging (SWI) can more readily detect acute brain 
haemorrhage and micro-bleeding areas in acute ischaemic stroke or haemorrhagic 
consequences of intra-arterial thrombolysis. It can reveal abnormalities impossible to 
detect with other methods (Skalski, Kessler and Bhatt, 2018), but SWI sequences 
may be more difficult to interpret and radiologists need to be aware of its different 
appearances depending on the magnetic field strength, in states of low blood flow or 
low level of oxygenation (Bosemani et al., 2014).  
 
1.9 Acute Treatment 
The long-term outcome for patients affected by acute ischaemic stroke depends on 
whether the affected ischaemic territory has been timely reperfused and to what 
extent. The possible outcomes range from full clinical recovery to death and this is 
commonly assessed on the modified Rankin Scale (mRS) (Banks and Marotta, 
2007), see Appendix A - Modified Rankin Scale. 
The introduction of stroke unit care has been shown to significantly benefit stroke 
patients with reduction in the odds of death, dependency or institutionalised care that 
was seen across all groups of patients (Trialists’Collaboration, 2013). Until a few 
years ago, the only approved acute treatment for acute ischaemic stroke has been 
intravenous thrombolysis. More recent advancements in technology have allowed for 
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endovascular treatments and devices to be developed and their efficacy have been 
proven in multiple recent clinical trials (Lackland et al., 2018). 
 
1.9.1 Intravenous Thrombolysis 
The earliest records of using a medical thrombolytic drug was in 1958 when 
Sussman and Fitch started to administer intravenous fibrinolysis to several patients 
which had a confirmed LVO on angiography (Sussman and Fitch, 1958). They did 
demonstrate that complete or partial recanalization was achievable, but there were 
doubts about the usefulness of this intervention. However, this initial case series 
opened the gate for further research into this drug.  
Subsequently, randomized controlled trials in patients presenting with acute 
ischaemic stroke started in the late 1980s. Different intravenous thrombolytic 
medications were used, but the earlier one which was streptokinase, did not 
demonstrate efficacy across several trials (Multicentre Acute Stroke Trial-Italy 
(MAST-I) Group, 1995; Donnan et al., 1996; Group, 1996). 
The search continued and in 1995 a trial comparing alteplase versus placebo 
demonstrated that the intervention group was at least 30% more likely to have mild or 
no disability at three months after the stroke event, when treated within three hours of 
symptom onset (The National Institute of Neurological Disorders and Stroke tPA 
Stroke Study Group (NINDS)., 1995). Compared to the other studies, the patients 
within this trial received faster treatment (<180 min).  
Later, in 2008, the ECASS III trial (Hacke et al., 2008) compared again alteplase 
versus placebo, but administered it 3 to 4.5 hours after the onset of symptoms. The 
findings showed a favourable outcome (OR 1.4) and concluded that alteplase is 
underused due to delayed patient presentation. Next, the IST-3 trial (Sandercock et 
al., 2012) found that administration of IV tPa (intravenous tissue plasminogen 
activator) up to 6 hours after onset of symptoms is still beneficial, even for patients 
older than 80 years of age. In 2014 the VISTA meta-analysis underpinned the 
approval of intravenous thrombolysis with alteplase as a treatment for patients 




1.9.2 Thrombectomy Development 
There is a significant number of patients for which IV tPA cannot be administered due 
to the time delay at presentation and to the long list of absolute and relative 
contraindications. In recent years there have been significant advancements in 
endovascular devices for clot retrieval and thrombectomy is now a proven treatment 
which has been approved by NICE (NICE, 2016).  
The first historical usage of an intra-arterial treatment in acute ischaemic stroke was 
the local administration of a thrombolytic drug in the vessel of interest in order to 
promote clot lysis (Del Zoppo et al., 1998; Suarez et al., 1999; Ernst et al., 2000). 
The PROACT II study was a randomized controlled trial comparing an intra-arterial 
infusion of recombinant prourokinase versus placebo in patients presenting with 
acute ischaemic stroke and with evidence of a proximal MCA occlusion on 
angiography (Furlan et al., no date). This study demonstrated that patients within the 
intervention group had significantly higher recanalization and better long term 
outcomes (Furlan et al., no date; Del Zoppo et al., 1998). This type of treatment 
however was not recognized by NICE and if delivered, this was done off label. Some 
practitioners used other intra-arterial infusions in a similar fashion to try and improve 
clot lysis and other interactive agents administered were tPA, abciximab, etc (Abou-
Chebl et al., 2005).  At that time, no advanced clot retrievers were available and later 
on the results of the SYNTHESIS trial (Ciccone et al., 2013) performed in 362 
patients, comparing endovascular therapy with IV tPA in patients presenting with 
acute ischaemic stroke within 4.5 hours showed that endovascular therapy is not 
superior to IV tPA treatment. 
In addition to this type of treatment, some neurointerventionists used the method of 
clot disruption by using a microwire which had a J or C shape at its tip. This was 
done by blindly doing multiple passes through the clot and thus achieving a 
mechanical clot disruption. The results with this kind of technique were variable.  
Together with the introduction of flexible intracranial balloons which were originally 
designed for angioplasty and / or coiling via the balloon remodelling technique, a new 
method emerged which was basically another type of mechanical clot disruption by 
performing angioplasty of the occluded segment (Ringer et al., 2001). 
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After the development of intracranial stents which had their primary use for stent 
assisted coiling of aneurysms, it was incidentally discovered that they could 
potentially be used in thrombectomies. The SARIS trial (Roth et al., 2010; Levy et al., 
2011), which was a pilot, study demonstrated that deploying a stent in an acutely 
occluded vessel had high recanalization rates and good clinical outcomes. This 
procedure however requires dual antiplatelets and this was a major disadvantage for 
the technique. 
These different methods were used off-label by different groups to treat patients and 
as anecdotal evidence grew, eventually the understanding that mechanical 
thrombectomy could potentially result in significant improved outcomes in acute 
ischaemic stroke is what led the way to further progress. The belief that this 
treatment has the potential to change the potentially devastating outcomes in acute 
ischaemic stroke due to LVO is what led the way in the quest for the development of 
specific, purpose built thrombectomy devices.   
 
1.10 Mechanical Thrombectomy Devices 
1.10.1 First generation – Merci retriever 
The first device made specifically for this purpose was the Merci retriever and this 
was approved by the FDA in 2004 (Gobin et al., 2004). This device had basically a 
corkscrew at its distal tip which would be screwed into and so engage the clot before 
retrieving it. The catheter used to deliver this device was placed into the common 
carotid artery, at its bifurcation, and a balloon inflated to obtain blood flow reversal. 
Even with this precaution however, a relatively long course of catheter retraction was 
often necessary, and this was not ideal from a mechanical point of view as the 
captured thrombus could become disengaged and / or fragmented. Even allowing for 
these negative points, the Merci trials demonstrated an overall revascularisation rate 
of 43% to 55% (Smith et al., 2005; W.S. Smith, 2006; Flint et al., 2007). The IMS III 
trial (Broderick et al., 2013) demonstrated that unfortunately this was not associated 
with a significant increase in good clinical outcomes, which were defined as patients 
being functionally independent and correlated to a post stroke mRS of ≤ 2.  
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The ultrasound assisted microcatheter devices (EkoSonic Endovascular System and 
EKOS MicroLysUS catheter) were first introduced in the early 2000’s. The 
microcatheter was placed within the thrombus and allowed the thrombolytic agent to 
be infused inside the clot while at the same time the device would create ultrasound 
vibrations to reach clot thrombolysis faster (Mahon et al., 2003). The idea is that this 
combination accelerates thrombolysis as the ultrasound generates radial pressure 
that speeds up the dispersion of the drug (Kuliha et al., 2012). This system was 
considered less damaging than the rotational devices and after successful partial 
recanalization, further endovascular treatment with angioplasty and stenting was 
carried out.  
 
1.10.2 Second generation – Penumbra aspiration system 
The Penumbra aspiration system was marketed in 2008 and this technique involved 
macerating the thrombus by repeatedly passing a separator through the clot while at 
the same time applying suction to remove the dislodged fragments and to prevent 
distal embolization (The Penumbra Pivotal Stroke Trial Investigators, 2009). This 
technique used a large catheter (5 French) to deliver the system very close to the 
proximal aspect of the clot. To achieve this, a more flexible large bore catheter able 
to navigate through the intracranial vasculature was developed and used. This was 
essentially an intermediate catheter with a wide diameter which was delivered co-
axially, its advantages being that it could deliver higher suction and thus remove 
more material, but because of its size it had also a major disadvantage in that it was 
more difficult to navigate distally. However, once this catheter was in position, the 
thrombectomy procedure could be performed without having to navigate again the 
device to the clot as was the case for the Merci device.  
The Penumbra catheters were further improved and in 2012 the Max catheters were 
introduced. These are available in three different sizes and have a larger proximal 
lumen to increase aspiration efficiency while at the same time being more flexible to 
allow for easier navigation.  Whereas previous catheters needed to be advanced 
over a microcatheter, especially when advancing past the ophthalmic artery, this 
catheter due to its multiple transition zones giving it greater support and flexibility, 
could be advanced with only a guiding microwire.  
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1.10.3 Third generation – Stent retrievers 
The first case in which a stent retriever device was used, according to literature, was 
in 2007 in Cleveland (Kelly, Furlan and Fiorella, 2008) with an Enterprise stent and 
then this technique was again used in 2008 in Germany with a Solitaire stent (Pérez 
et al., 2012). These devices are basically stents which are deployed intracranially, 
allowed to expand and engage the thrombus before being retrieved with concomitant 
suction via a large bore catheter, Figure 3 . 
 
 
Figure 3 - Trevo stent with thrombus 
This is a picture of a Trevo stent used to retrieve the shown thrombus in a patient 




The microcatheter is first placed past the thrombus, then via unsheathing the stent is 
deployed and expanded with radial force applied externally as it engages the clot. 
While the stent is open, there is restoration of blood flow to the ischaemic brain 
territory, and once the clot is fully engaged, the stent is retrieved into the guiding 
catheter. The advantage of this technique is that there is no permanent stent 
deployed intracranially and the need for keeping patients on dual antiplatelets is 
avoided. The recanalization rate with stent retriever devices was found to be superior 
to the previous devices (primarily MERCI) in randomised controlled trials published 
as early as 2012 (Nogueira et al., 2012; Saver et al., 2012). The MR CLEAN trial 
compared endovascular treatment, done primarily with stent retrievers, with standard 
medical treatment and it was the first trial to favour endovascular treatment 
(Berkhemer et al. 2015). It showed improved outcomes in functional independence in 
the endovascular group (32.6% versus 19.1%) with a similar safety profile. 
Subsequent trials confirmed this benefit and a meta-analysis from 2016 with 
individual patient data from five trials showed that for every 2.6 patients treated 
endovascularly, disability was reduced by one point on the mRS (Goyal et al., 2016). 
These findings marked a turning point in the treatment of acute ischaemic stroke with 
endovascular techniques. 
1.10.4 Fourth generation – Aspiration technique 
The newest thrombectomy technique has developed in part due to advancements 
being made with regards to the large bore distal access catheters. The developments 
of Distal Access Catheters (DAC) resulted in larger bore catheters, with improved 





Figure 4 - Distal access catheter 
Distal access catheter mounted over a delivery microcatheter and a microguidewire 
which are used to bring the DAC to the thrombus interface. 
 
The aspiration technique uses the advantages of the DACs. The catheter size is 
chosen according to the vessel size, with the largest possible catheter chosen for the 
particular vessel which is occluded. The DAC is advanced to the proximal end of the 
thrombus and aspiration is applied to engage the clot. Once this is confirmed, the 
catheter is withdrawn under continuous aspiration via both the DAC and the guiding 
catheter with the expectation that the engaged clot will basically be “vacuumed” and 
sucked with the force applied. This technique has the advantage of being faster than 
the stent retriever technique and if it does not work, the guiding catheter is already in 
place and a stent retriever device can be placed swiftly and thrombectomy attempted 
again (Tsang et al., 2018).   
     
1.10.5 Future generations 
This is a very rapidly developing field with multiple other purpose specific devices 
being developed and evaluated. Just over the past decade, at least four different 
types of devices have been used. The need to improve recanalization rates is what 





has been driving these technological advancements, however it is important to 
remember that ischaemic brain tissue can only survive for a limited period of time and 
in all thrombectomy cases it is important to judiciously assess the patient and if 
ischaemic changes are already established, recanalization may be futile and may 
even lead to disastrous complications. 
1.11 Acute Ischemic Stroke Treatment Pathway 
In order for patients to achieve good outcomes after an acute ischaemic stroke due to 
an intracranial large vessel occlusion, there is an important sequence of events that 
needs to take place. This is very important and the sooner the steps in the patient’s 
journey are done to enable acute treatment, such as administration of IV tPA and 
mechanical thrombectomy if suitable; the higher the chances of a good clinical 
recovery post stroke. Below are the steps involved in initial recognition and acute 
management of patients with acute stroke symptoms: 
A) Acute stroke symptoms need to be recognized by the patient or bystanders 
B) Call for help promptly 
C) Ambulance needs to transfer patient rapidly to the correct medical facility 
D) Once in hospital, a quick assessment by a team that has the correct skills is 
needed to correctly diagnose the type of clinical stroke 
E) Rapid imaging to assess both the brain and vasculature 
F) Correct radiological interpretation of the scan 
G) Prompt delivery of appropriate hyperacute treatment (IV tPA +/- mechanical 
thrombectomy) 
My thesis consists of multiple projects that are present along this pathway with an 
aim to research and improve delivery of care specifically affecting points E, F and 





Figure 5 - Acute stroke care patient pathway 
All the points demonstrated here are necessary to be done in a fast and efficient 
manner to achieve the best clinical results possible. The research presented in this 
thesis specifically affects points E, F and G along this pathway.   
1.12 Aims of Thesis 
Now that the significance, potential outcomes, economic burden, newly developed 
acute interventional treatment for acute ischaemic stroke have been described, it is 
important to recognize the need for further research in this field.  
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As mentioned earlier, most thrombectomy retriever devices were not specifically 
developed to perform intra-arterial thrombectomy. A novel retriever device has been 
developed called ERIC (Embolus Retriever with Interlinked Cages) and this device 
may be more suitable for performing thrombectomy as it was developed specifically 
for this purpose. Another device which may also be used during thrombectomies 
called SOFIA (Soft torqueable catheter Optimized for Intracranial Access) distal 
access catheter (DAC) has also been recently developed by Microvention Terumo 
Inc. (Alisa Viejo California).     
I will look at the technical efficacy and safety of these two devices as part of a phase 
2 trial that I have worked on called STABILISE (Stroke: an evaluation of 
Thrombectomy in the Ageing Brain – including where IV thromboLysis IS 
contraindicatEd).  
The acute interventions for acute ischaemic stroke have been developing very rapidly 
in the past few years and multiple studies have been published during the timespan 
of my thesis. As new evidence became available, this was incorporated and reflected 
in my work. There was the need to have a major amendment less than a year into the 
STABILISE trial to introduce the new SOFIA catheter and to allow for new techniques 
to be permitted that had developed since the start of the study.  
Chapter 2 will look at the evidence for intra-arterial thrombectomy, discuss the main 
trials that have been published in the past few years and their results.  
Chapter 3 will discuss the STABILISE trial, from the methods and aims of the study to 
the progress to date and the presentation of partial, blinded results.  
Chapter 4 will present a project I worked on after new imaging guidelines were 
developed and will summarize a study focused on improving the CT Angiogram 
interpretation in AIS.  
Chapter 5 is devoted to the development of a technical index of thrombectomy 
difficulty to facilitate rapid decision making for time critical thrombectomy assessment 
in AIS.  
Chapter 6 will present a multi-centre study on acute thrombectomy performed in the 
older population, patients that are 80 years of age and older, looking at the efficacy 
and safety in this subgroup. 
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Chapter 7 will provide a short synthesis and summary discussion of the previously 




Chapter 2. Literature Review 
As discussed in the previous chapter, there has been recent growing evidence for the 
treatment of acute ischaemic stroke due to LVO. As this mounting evidence was 
being published, there were significant changes to the hyperacute management of 
patients and new societal guidelines published. The objective of this chapter is to 
determine whether the literature shows that performing mechanical thrombectomy in 
patients with acute ischemic stroke due to a large vessel occlusion leads to better 
overall clinical outcomes. I will present the evidence for performing acute intra-arterial 
thrombectomy in patients presenting with acute ischaemic stroke that is shown on 
imaging to be due to an intracranial LVO. The evidence for treating both early and 
late presenting patients will be discussed, especially with regards to the clinical 
efficacy at 90 days and the safety of this treatment.  
During my studies I collaborated on a systematic review and meta-analysis of trials 
that compared intra-arterial thrombectomy with or without concomitant IV tPA 
administration with best medical care, including IV tPA (Flynn et al., 2017). This 
allowed me to develop skills in data extraction, analysis planning and statistical 
analysis. This project also allowed me to develop my interpersonal skills and learn 
how to collaborate effectively with others as I was involved with the manuscript 
revision.  
Working on this collaborative project has allowed me to develop the basic research 
skills and self-reliance to write this chapter of my thesis. I used the search strategy 
which I had learned from the systematic review paper to complete and update the 
presented work. Some of the papers presented here are also discussed in the project 
on which I collaborated, but the way the evidence is organised and presented is very 
different, making this chapter an original and up to date review of literature. 
Importantly, this chapter discusses the most recent trial evidence regarding 
mechanical thrombectomy in patients with stroke presenting later. Additionally, 
although the evidence is more limited, I also chose to discuss the evidence for 
performing mechanical thrombectomy in the posterior circulation because this can be 
very disabling, and patients can also show significant benefit from endovascular 




2.1 Materials and Methods 
For this systematic literature review, I selected the randomized controlled trials which 
had at least 10 adult patients with acute ischaemic stroke symptoms, who had 
imaging performed to demonstrate LVO and then received mechanical thrombectomy 
with modern devices or best standard medical care. If available, data on the 
comparator arm of the study, such as IV tPA or best supportive care, was also 
collected. For the outcomes assessed, studies needed to have a 90-day follow-up 
evaluated on a scale such as the mRS or NIHSS among others, and they also 
needed to report safety and mortality data at 90 days. From the studies that met the 
eligibility criteria, the secondary outcomes as reported were also collected.  
 
2.1.1 Literature Search  
The search strategy has been described in the meta-analysis paper on which I 
collaborated (Flynn et al., 2017).  This was performed with the help of an experienced 
information scientist and the search was performed up to mid-February 2015. The 
search strategy used relevant MeSH (Medical Subject Headings) and thesaurus 
keywords, such as acute stroke, intra-arterial, mechanical, thrombectomy, stent-
retrievers, etc. The bibliographic databases and trial registries that were searched 
included MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, 
International Standard Randomised Controlled Trial Number Register and 
ClinicalTrials.gov. Studies that were published before January 2009 were not 
included as they used older mechanical thrombectomy devices. Selected papers 
were assessed for quality by looking at the study design, participants, intervention 
delivered, and outcomes assessed. For inclusion the study needed to be in one of 
the following categories: randomized control trial, non-randomised trial, controlled 
before-and-after study or cohort study with prospective assessment. Single center 
studies, case control studies, cross-sectional study or case series were excluded. 
Participants had to be adult patients presenting with acute ischaemic stroke. For the 
interventional arm at least 10 participants had to receive mechanical thrombectomy 
for the paper to be included. Finally, in the outcomes section papers selected had to 
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have a follow-up at 90 days on a standardised scale that could be either the mRS, 
Oxford Handicap Scale, Barthel Index or the NIHSS.    
I extended my search and from February 2015 to December 2018 any additional 
relevant papers that were published were selected. This search was performed by 
me including all data extraction. My search was performed via MEDLINE and 
EMBASE using the same relevant keywords and MeSH terms as described above 
and all papers had to be in English. In addition, I also decided to discuss a few other 
relevant studies and have added a meta-analysis that included patient level data as it 
has data from five trials that were pooled together. The evidence for performing 
mechanical thrombectomy in the posterior circulation is more limited, but I also 
included a few studies on this as these are also important. 
For all the studies that are presented next, I used a structured data extraction form to 
retrieve the information for each study group population, the intervention performed 
and then the outcomes. 
2.2 Results 
The 7 randomised controlled trials that have looked at patients presenting early, 
within 6 hours of symptom onset, each have had slightly different inclusion criteria, 
but overall, they have all shown benefit of mechanical thrombectomy with improved 
functional outcomes at 3 months.  
The 3 randomised controlled trials that have included patients presenting later, from 8 
up to 24 hours after initial symptoms onset, have also shown benefit of mechanical 
thrombectomy when using imaging criteria for patient selection.     
Since the publication of these trials, there were a few meta-analyses performed, with 
the most crucial one being an individual patient meta-analysis which accumulated 




2.2.1 Anterior Circulation Thrombectomy Trials   
MR CLEAN was the first prospective, multicentre, randomized trial of mechanical 
thrombectomy to demonstrate the beneficial effects of endovascular therapy when 
compared to the current best medical management (Berkhemer et al., 2015).  
Patients were randomized either to mechanical thrombectomy plus medical treatment 
or medical treatment alone, with most patients in this category receiving IV tPA.  To 
be eligible for the trial, patients had to have a proven LVO in the anterior cerebral 
circulation on imaging and to have the thrombectomy done within 6 hours from stroke 
symptom onset.  The primary outcome of this trial was clinical outcome at 90 days as 
assessed on the mRS.  A total of 500 patients were enrolled across 16 sites in the 
Netherlands with 233 patients assigned to mechanical thrombectomy and the other 
267 patients to medical treatment.  Most thrombectomies (82%) were performed 
using retrievable stents, which at the time had already been shown to be superior to 
the first-generation Merci device. Results demonstrated clinical independence at 90 
days, as assessed by an mRS of 0-2, to be significantly in favour of endovascular 
treatment: 76/233 (32.6%) versus 51/267 (19.1%), OR 2.05, 95% CI 1.36 – 3.09.  
There was no significant difference in safety and mortality outcomes in the two 
groups during the follow-up period of 90 days.  
Data from this trial was further analysed to determine whether there is a correlation 
between timelines to achieve reperfusion and clinical outcomes (Fransen et al., 
2016).  Data for the patients enrolled in the trial was analysed in terms of procedural 
timelines: stroke symptom onset to groin puncture and then to reperfusion.  The 
primary outcome was again based good functional outcomes with an mRS of 0 – 2. 
Their results showed significant positive correlation for a shorter time to reperfusion 
(p=0.04), but no significant correlation to the start of the procedure as assessed by 
the time of the groin puncture.  In addition, they showed that the treatment effect of 
mechanical thrombectomy is highest the sooner patients are treated successfully.  
Further analysis suggested that the likelihood of achieving clinical independence at 3 
months reduces by 5% per hour of treatment delay reaching 40% at 8 hours.   
For patients originally enrolled in the MR CLEAN trial, long-term outcomes at 2 years 
after initial treatment have also been published (van den Berg et al., 2017).  Outcome 
data was available for 391 (78.2%) of the original 500 patients, while death 
information was available for 459 (91.8%) patients. Clinical outcomes at 2 years as 
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assessed on the mRS were statistically significant and positive for endovascular 
thrombectomy (adjusted cOR 1.68, 95% CI 1.15 to 2.45, p=0.007).  In addition, as a 
secondary outcome they assessed the quality of life by using the European Quality of 
Life questionnaire (The EuroQol Group, 1990) and this was also statistically 
significant and in favour of patients that were treated acutely with mechanical 
thrombectomy (p=0.006). Mortality data at 2 years, although lower for patients 
treated with mechanical thrombectomy, was not statistically different among the two 
treatment groups.  Overall, they concluded that the initial better outcomes with 
endovascular treatment versus best standard care at 3 months were maintained in 
the long-term at 2 years follow-up.   
SWIFT PRIME was another multicentre randomized controlled study assessing 
mechanical thrombectomy and IV tPA versus IV tPA alone which was performed 
across 39 centres in North America and Europe (Saver et al., 2015).  To be eligible 
for the trial, patients had to have imaging performed to confirm a LVO in the anterior 
cerebral circulation and salvageable brain tissue as assessed on the ASPECTS 
score and CT perfusion.  This is one of the first trials to use CT perfusion to assess 
the penumbral region that represents potentially salvageable brain tissue.  Patients 
aged between 18 - 80 years old were enrolled in the trial and they had to have a 
good clinical baseline (mRS of 0 - 1).  Patients with mild strokes were excluded as 
there was a trial requirement to have an NIHSS (National Institutes of Health Stroke 
Scale) of 8 - 30. Endovascular treatment was performed with the Solitaire stent 
retriever (Medtronic, Minneapolis, MN, USA) and had to be done within 6 hours from 
onset of acute ischaemic stroke symptoms.  The primary outcome was assessment 
of independence using an mRS of 0 - 2 at 90 days.  This study was stopped early 
due to efficacy with a total of 196 patients being enrolled, with 98 receiving 
endovascular treatment and another 98 receiving best medical treatment. Functional 
independence at 90 days was significantly higher in the interventional group as 
compared to the control group: 59/98 (60%) versus 33/93 (35%) (p<0.001).  There 
were no significant differences in safety and mortality outcomes between the two 
groups. 
EXTEND-IA was a prospective, multicentre, randomized trial of mechanical 
thrombectomy that enrolled a total of 70 patients with anterior circulation acute 
ischaemic stroke among 10 centres in New Zealand and Australia (B. C. V. Campbell 
et al., 2015). Patients were eligible for the trial if they could receive IV tPA within 4.5 
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hours after onset of stroke symptoms, have a groin puncture within 6 hours with 
recanalization by 8 hours. They needed to have vascular imaging to demonstrate an 
occlusion in the anterior cerebral circulation and salvageable brain tissue on CT 
perfusion. There was no age or stroke severity restriction and patients enrolled 
needed to be independent at baseline, as assessed by a score of 2 or less on the 
mRS. This trial used the Solitaire stent retriever for performing mechanical 
thrombectomy. The study was stopped early, after the publication of the MR CLEAN 
trial results, due to efficacy. In the intervention group 35 patients received mechanical 
thrombectomy in addition to IV tPA and in the control group 35 patients received best 
medical management with IV tPA. Four patients initially randomised to mechanical 
thrombectomy, did not have this procedure done due to major deterioration or major 
improvement. The primary outcome showed that 25/29 (86%) patients that 
underwent endovascular treatment had good revascularization as assessed by an 
mTICI (modified treatment in cerebral ischemia) of 2b/3. For secondary outcomes, 
there were 25/35 (71%) patients in the endovascular group that achieved 
independence at 90 days compared to 14/35 (40%) patients in the IV tPA only group. 
Their analysis showed that 3.2 patients need to be treated with endovascular therapy 
for one patient to achieve independence at 90 days. No statistically significant 
differences were shown for safety and mortality outcomes between the two groups.  
THRACE was another multicentre, prospective, randomized controlled trial 
comparing mechanical thrombectomy and IV tPA with IV tPA alone (Bracard et al., 
2016).  This trial enrolled a total of 414 patients, 204 in the interventional group and 
208 in the control group, across 26 centres in France.  To be eligible for the study, 
adult patients aged 18 to 80 had to have a proven LVO on imaging, either in the 
anterior or posterior cerebral circulation, either on CTA or MRA.  This trial did not 
have any other imaging-based criteria such as a minimal ASPECTS score or CT 
perfusion to demonstrate a significant penumbra. The primary outcome was to 
assess clinical functional independence at 3 months consisting of an mRS of 0-2. 
Ten patients were excluded from the final results: four due to being lost to follow-up 
and another six having missing data.  Their results showed that patients in the 
interventional group who received mechanical thrombectomy in addition to IV tPA 
had better functional outcomes at 3 months when compared to the control group (OR 
1.55, 95% CI 1.05–2.30, p=0.028).  There was no statistically significant difference 
between the two groups in terms of safety or mortality.  
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REVASCAT was a prospective, randomized, multicentre controlled trial conducted in 
Spain and enrolled patients across 4 centres randomising them either to best medical 
treatment with IV tPA in the control group or mechanical thrombectomy in addition to 
best medical treatment, including IV tPA, in the interventional group (Jovin et al., 
2015). This trial was stopped early due to loss of equipoise after the positive results 
from the other thrombectomy trials were reported. Patients could be enrolled if they 
presented within 8 hours of stroke symptoms onset and had a presenting NIHSS ≥6. 
Patients needed to be adults aged 18 - 80 and have a baseline mRS ≤1. The LVO 
had to be confirmed on either a CTA or MRA scan and in addition they needed to 
have an ASPECTS score ≥7 on CT or 6≥ on DWI MRI.  The mechanical 
thrombectomy procedure was performed with the Solitaire stent retriever. Their 
primary outcome was the clinical outcome at 90 days as assessed on the mRS and 
secondary outcomes included the infarct volume on CT or MRI at 24 hours.  A total of 
206 patients were enrolled with 103 in each group. Their results demonstrated that 
patients in the interventional group had significantly better outcomes when compared 
to the control group at 90 days with 45/103 (43.7%) vs 29/103 (28.2%) achieving 
independence (OR 2.1, 95% CI 1.1 – 4). Similarly, the follow-up imaging 
demonstrated that there was a statistically significant reduction in the volume of 
infarcted brain at 24 hours in between the two groups: 16 mls in the interventional 
group vs 39 mls in the control group, p=0.02.  No statistically significant differences 
were demonstrated between the two groups with regards to either safety or mortality. 
Patients that were enrolled in the REVASCAT trial have had their long-term 
outcomes at one year follow-up published (Dávalos et al., 2017). Data was available 
for 205 out of the total 206 enrolled patients. Significantly better outcomes with 
mechanical thrombectomy were sustained to the 12 months end-point with both 
reduced disability and higher rates of functional independence as assessed on the 
mRS (mRS=0–2; 45/103 vs 31/103 patients; aOR 1·86, 95% CI 1·01–3·44). Patients 
quality of life at 1year follow-up was assessed using the European Quality of Life 
questionnaire and this also showed significantly better outcomes in the interventional 
group as compared to the control group (p=0·01). There was no statistically 
significant difference in mortality rates at 1 year. They concluded that these positive 
results are significant for the assessment of long-term cost-effectiveness of 
endovascular treatment in acute ischaemic stroke.  
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PISTE was a prospective, multicentre, randomized controlled trial enrolling patients 
across 10 UK centres and randomizing patients to either IV tPA alone or IV tPA with 
mechanical thrombectomy (Muir, Ford and Messow, 2017).  Adult patients, with no 
upper age limit, needed to have either CTA or MRA to demonstrate a LVO on 
imaging with <1/3 of the MCA territory demonstrating early changes of acute 
infarction.  In addition, there was a time limit of 90 minutes from imaging to groin 
puncture with a maximum of 6 hours from symptom onset to cannulation of the target 
occluded vessel.  Operators could use any CE marked device for performing the 
mechanical thrombectomy.  The primary outcome was functional independence at 90 
days as assessed by an mRS of 0 - 2.  A total of 65 patients were recruited in the 
study with 33 of them being assigned to the interventional group and another 32 to 
the control group. The trial was stopped early, and the primary outcome was not 
statistically significant in the intention to treat population, however the patients that 
were allocated to mechanical thrombectomy achieved independence in a greater 
proportion compared to those allocated to IV tPA alone 57% vs 35% and this was 
statistically significant (OR 4.92, 95% CI 1.23 – 19.69, p=0.021). Rates of post-
procedural intracranial haemorrhage and mortality up to 90 days were not 
significantly different in the two groups.  
THERAPY was a prospective, multicentre, international randomized controlled trial 
which enrolled patients in Germany and the United States and evaluated mechanical 
thrombectomy performed with the aspiration technique and concurrent IV tPA 
administration compared to treatment with IV tPA alone in patients with acute 
ischaemic stroke due to a proven LVO and a thrombus length of ≥8mm (Mocco et al., 
2016).  Adult patients aged 18-85 with a proven LVO on CTA measuring ≥8 mm, with 
an NIHSS score of ≥8 and occlusion of the anterior cerebral circulation (ICA or MCA) 
were eligible for the study. The primary outcome was assessed in terms of 
percentage of patients achieving functional independence at 90 days as assessed by 
an mRS of 0-2, with an intention to treat analysis. Like other trials, this was stopped 
early due to the results of the MR CLEAN trial being presented and the concern that 
this was unethical to be continued. The study included 108 patients with 55 allocated 
to mechanical thrombectomy plus IV tPA and 53 patients to IV tPA alone. The results 
did not reach statistical significance however they were in favour of mechanical 
thrombectomy performed with aspiration and IV tPA (OR 1.76, 95% CI 0.86–3.59, 
P=0.12). There were no significant differences in between the two groups in terms of 
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safety outcomes: serious adverse events, symptomatic intracranial haemorrhage or 
mortality at 90 days. 
EASI was a single centre randomized care trial in Canada which enrolled patients 
that were considered for endovascular thrombectomy treatment based on their 
clinical presentation (Khoury et al., 2017).  This was a pragmatic trial with a relatively 
broad inclusion criteria for adult patients presenting ≤ 5 hours from stroke symptom 
onset or evidence of clinical to imaging mismatch, having an NIHSS ≥ 8 and either a 
suspected or definitively proven proximal intracranial LVO in the anterior or posterior 
circulation.  Patients were randomized either to best standard care or best standard 
care and mechanical thrombectomy.  The primary outcome was assessing rates of 
functional independence at 3 months by an mRS ≤ 2.  This study was stopped early 
after the publication of the MR CLEAN results.  A total of 77 patients were enrolled, 
40 patients in the mechanical thrombectomy intervention group and 37 patients in the 
control group. There was no statistically significant difference in reaching the primary 
outcome in between the two groups. No statistically significant difference was 
demonstrated between the two groups in terms of safety or mortality. 
 







THRACE REVASCAT PISTE THERAPY EASI 
n 500 196 70 414 206 65 108 77 
Process times (min, median) 
Onset to IV 
tPA 
85 110 127 150 117 120 108 145 
Onset to 
reperfusion 
332 N/A 248 303 355 251 N/A N/A 
TICI 2b-3 59% 88% 86% 69% 66% 87% 70% 77% 
Outcomes 
mRS 0-2 at 
90 days 
33% 60% 71% 53% 44% 51% 38% 20% 
Mortality 19% 9% 3% 12% 18% 9% 12% 11% 
 
Table 2 - Comparison of early intra-arterial thrombectomy main outcomes  
in the interventional arms of the presented mechanical thrombectomy trials 
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2.2.2 Thrombectomy Trials Within an Extended Time Window 
ESCAPE was a prospective, multicentre, randomized controlled trial performed 
across the world and recruiting from 22 centres (Goyal et al., 2015).  This study 
recruited adult patients with no upper age limit who had a good baseline as assessed 
on the Barthel Index (Mahoney and Barthel, 1965) with a score of ≥90.  Patients 
needed to have an NIHSS ≥5, a large cerebral artery occlusion demonstrated on 
CTA and an ASPECTS score of ≥6.  In addition, patients had to have good collateral 
circulation either shown on CTA or multiphase CTA.  For patients that met these 
inclusion criteria, they could be enrolled up to 12 hours after the initial stroke 
symptoms onset. Most patients recruited and treated were within 6 hours, with only a 
small minority being within the 6 to 12 hours window. Their overall results reflect their 
whole population, but this was the first published trial who pushed the boundaries of 
mechanical thrombectomy to include patients presenting in a later time window.  A 
total of 316 patients were included in the study with 165 being randomized to 
thrombectomy and another 150 patients being randomized to standard medical 
therapy.  This trial was stopped early after preplanned statistical analysis of the first 
300 patients which occurred after the results of the MR CLEAN study.  Their results 
showed that mechanical thrombectomy, even in this slightly delayed timeline, had 
significantly better outcomes at 90 days: 87/164 (53%) versus 43/147 29.3% of 
patients achieving an mRS of 0 - 2.  In addition, the study also showed lower death 
rates in the interventional group with 17/164 (10%) versus 28/147 (19%) in the 
control group, (p=0.004).  Like other trials, there was no statistically significant 
difference in intracranial haemorrhage rates. 
DAWN was a prospective, multicentre, randomized controlled trial randomizing 
ischaemic stroke patients who were last seen well in the past 6 - 24 hours either to 
mechanical thrombectomy or standard care (Nogueira et al., 2017).  Patients had to 
have a proven occlusion of the anterior cerebral circulation on imaging and a 
mismatch between the severity of the clinical deficit at presentation and the already 
established infarct volume as assessed either by DWI MRI or CT perfusion, both via 
automated software (RAPID, iSchemaView).  Patients needed to have a good clinical 
baseline as assessed by an mRS of 0 – 1.  Although there was no upper age limit, 
there were 3 groups of clinical to imaging mismatch in which patients were 
categorized according to their age. Patients younger than 80 years were allocated 
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either to a group with an NIHSS score ≥10 and an infarct volume <31 mls or to a 
second group with an NIHSS score ≥20 and an infarct volume of 31 - 50 mls.  
Patients of age 80 and older were placed in a separate group and they needed to 
have an NIHSS score ≥10 and an infarct volume <21 mls. The study had two primary 
end-points: the utility-weighted mRS at 90 days and the functional independence as 
assessed by an mRS of 0 – 2 at 90 days. This trial was also stopped early due to the 
results of a pre-specified interim analysis. Results demonstrated significantly better 
outcomes in the thrombectomy group as assessed by both co-primary endpoints: the 
utility-weighted mRS (adjusted difference 2.0 points; 95% credible interval 1.1 - 3.0; 
posterior probability of superiority >0.999) and the mRS with 49% vs 13% achieving 
independence in the thrombectomy group versus the control group (adjusted 
difference 33 percentage points; 95% credible interval 21 - 44; posterior probability of 
superiority >0.999). Reperfusion was achieved in 84% of the patients in the 
thrombectomy group with a median time of 13.6 hours (IQR 11.3 – 18.0) from when 
patients were last known well. Maintained recanalization at 24 hours was 
demonstrated in 77% of the patients within the thrombectomy group versus 36% for 
those in the standard care group. Safety and mortality were not statistically different 
between the interventional and control arms. One extra patient achieved functional 
independence at 90 days for every 2.8 patients that were treated with thrombectomy 
plus standard best medical care. 
The DEFUSE-3 trial was a multicentre, randomised controlled trial similarly assessing 
the efficacy of mechanical thrombectomy in an extended time window, from 6 – 16 
hours after patients were last known well (Albers et al., 2018). This was conducted 
across 38 centres in USA. Patients needed to have LVO in the anterior cerebral 
circulation, an established infarct of less than 70 mls, a penumbra to infarction ratio of 
1.8 or more and at least 15mls of penumbral region as assessed by CT perfusion or 
MRI diffusion perfusion imaging with the aid of automated software (RAPID, 
iSchemaView). Imaging to groin puncture for patients randomized to endovascular 
treatment had to be within 90 minutes, similar to other previous trials. Thrombectomy 
was performed with any FDA approved device and operators were allowed to 
perform carotid angioplasty and/or stenting if necessary. The primary outcome was 
the mRS at 90 days. The trial was stopped early after an interim analysis due to 
efficacy with a total of 182 enrolled patients, 92 to the interventional arm and the 
other 90 to the control arm. The mRs at 90 days was more favourable for the group 
that received endovascular therapy plus standard medical treatment compared with 
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standard medical treatment alone with 45% versus 17% achieving functional 
independence at 90 days (p < 0.0001) respectively. The mechanical thrombectomy 
group had a mortality rate at 90 days of 14% compared to 26% for the medical 
therapy group and this did not reach statistical significance, p=0.05. 
Table 3 outlines the main outcomes in the interventional arms of the presented late 
window trials.  
 ESCAPE DAWN DEFUSE-3 
n 315 206 182 
Process times (min, median) 
Onset to IV tPA 110 N/A N/A 
Onset to reperfusion 241 816 726 
mTICI 2b/3 72% 84% 76% 
Outcomes 
mRS 0-2 at 90 days 53% 49% 45% 
Mortality 10% 19% 14% 
 
Table 3 - Comparison of late intra-arterial thrombectomy main outcomes  
in the interventional arms of the presented late window mechanical thrombectomy trials 
2.2.3 Meta-analysis 
A few meta-analyses comparing the outcomes in patients who have had mechanical 
thrombectomy versus those that were treated with best medical treatment have been 
published in the past few years. One of the most important ones is the one published 
by the HERMES collaborators which had individual patient level data (Goyal et al., 
2016).  This included data from 5 trials: MR CLEAN, ESCAPE, REVASCAT, SWIFT 
PRIME and EXTEND IA, with these trials having data accumulated from December 
2010 to December 2014.  As presented previously, in these trials, patients with acute 
ischaemic stroke symptoms due to LVO secondary to a thrombus in the anterior 
circulation were assigned randomly to either receive endovascular thrombectomy up 
to a maximum of 12 hours from symptom onset or best medical management, 
including IV tPA administration. The primary outcome of this meta-analysis was to 
assess the clinical outcome at 90 days on the mRS.  In addition, they also performed 
subgroup analysis for the primary outcome.  A total of 1287 patients had their data 
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analysed with 634 receiving mechanical thrombectomy and the other 653 receiving 
best medical management. As expected from the previously published trials, this 
meta-analysis confirmed the efficacy of mechanical thrombectomy with significant 
reduced disability at 90 days in the endovascular group as compared with the control 
group (p<0.0001, adjusted cOR 2.49, 95% CI 1.76–3.53).  Impressively, this meta-
analysis showed that for every 2.6 patients that received endovascular treatment, 
one patient had a reduction in disability by 1 point at 90 days on the mRS. Further 
subgroup analysis also confirmed the benefit of mechanical thrombectomy for 
patients that were randomized later than 300 minutes from symptom onset (cOR 
1.76, 95% CI 1.05 – 2.97), patients that could not be administered IV tPA (cOR 2.43, 
95% CI 1.30 – 4.55), as well as patients that were aged 80 years and older (cOR 
3.68, 95% CI 1.95 – 6.92). They concluded that endovascular thrombectomy is 
beneficial for most patients that present acutely with ischaemic stroke due to LVO in 
the anterior circulation. Safety data, including intracranial haemorrhage and mortality 
up to 3 months, did not significantly differ between the two groups.  
The HERMES collaborators have used the same patient level data from the 5 trials to 
assess the effects of time to successful endovascular treatment and clinical 
outcomes at 3 months (Saver et al., 2016).  For this meta-analysis, the primary 
outcome was assessing the degree of clinical functional independence based on the 
mRS at 3 months.  They had a total of 390 patients who achieved good reperfusion 
with mechanical thrombectomy. Their data analysis demonstrated that for each 1-
hour delay to good reperfusion, outcomes were worsened both in terms of disability 
and functional independence.  The faster the mechanical thrombectomy was 
successful, the better outcomes for the patients at 3 months.  In this patient cohort, 
for every 9 minutes delay to good reperfusion, 1 in every 100 treated patients had a 
drop of 1 point on the mRS. The initial benefit of performing mechanical 
thrombectomy was shown to be obsolete in patients who had their groin puncture at 
7.3 hours from initial stroke symptoms onset. There was however no significant 




2.2.4 Posterior Circulation Thrombectomy Evidence 
The main endovascular thrombectomy trials focused on anterior circulation LVO with 
only limited data on this type of treatment in patients having acute, ischaemic 
posterior circulation strokes. One of the more recent studies published on mechanical 
thrombectomy in the posterior circulation was the ENDOSTROKE study which was a 
multicentre registry performed in Germany and Austria enrolling patients from the 
beginning of 2011 until June 2013 (Singer et al., 2015). They enrolled all consecutive 
adult patients with a confirmed basilar artery occlusion on conventional cerebral 
angiography and they had a total of 148 patients. The registry had both prospective 
and retrospective data, as 21 of their patients were treated before the registry was 
started and data was entered subsequently. Although most procedures were done 
with modern devices such as stent retrievers and suction catheters, they still had a 
minority of patients that were treated with the MERCI device (n=9).  Like other 
studies, their primary outcome was good clinical function as defined by an mRS of 0-
2 at least 3 months after the initial thrombectomy procedure.  Angiographic data was 
reviewed in a blinded core lab which assessed the collateral circulation and the 
recanalization using the TICI (Thrombolysis in Cerebral Infarction) score.  They had 
overall good rates of recanalization with a TICI score of 2B/3 in 79% of cases.  Their 
results demonstrated that 34% of patients had reached clinical independence after 
90 days in keeping with a good clinical outcome.  Predictive factors for recanalization 
were the use of a stent retriever and better collateral status.  Independent predictors 
of clinical outcome on multivariate analysis were baseline NIHSS, collateral status 
and using MRI before performing mechanical thrombectomy.  Intracranial 
haemorrhage post procedure occurred in 6% of patients and this was significantly 
higher in patients that were treated with both intra-venous and intra-arterial 
thrombolysis in addition to mechanical thrombectomy in comparison to other 
treatments strategies used (p=0.038).  Another significant finding was that mortality 
was almost double (47% vs 28%) in patients with poor reperfusion as assessed by 
TICI score of 0-2 when compared to TICI 2b-3 recanalization (p=0.044).   
There is also a meta-analysis which looked at basilar artery occlusion and treatment 
with mechanical thrombectomy, specifically assessing the use of modern stent 
retrievers (Phan et al., 2016).  They included a total of 17 studies: 6 being 
prospective single centres studies, 10 being retrospective single centres studies and 
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the final one being a retrospective multicentre study.  Studies included had data on 
mechanical thrombectomies performed from 1998 to 2014 and included both older 
and newer devices and techniques.  Treatment with a stent retriever was undertaken 
in 77% of procedures, IA thrombolytic medication only was used in 21% of 
procedures while the rest were done with other techniques (e.g. Merci device, 
Penumbra aspiration catheter). They demonstrated that good recanalization rates 
were achieved in 80% when performing thrombectomy with stent retrievers and 
clinically 42.8% of patients achieved good outcomes (mRS ≤2). When comparing 
stent retriever mechanical thrombectomy versus conservative medical treatment 
(antiplatelets/anticoagulants) they showed that good outcome rates are almost 
double with endovascular treatment.  However, when looking at stent retriever 
thrombectomy versus treatment with IV tPA there was no significant difference in 
good clinical outcomes, although there is a suggestion that mortality rates are 
reduced by approximately 10-20%.  Rates of symptomatic intracranial haemorrhage 
were similar in patients receiving IV tPA and patients treated with mechanical 
thrombectomy.  They concluded that further randomized controlled trials are needed 
to assess the clinical efficacy of mechanical thrombectomy in the posterior circulation 
as compared to current best standard medical treatment. 
2.3 Discussion and Limitations 
With the publication of these trials in the past few years, the acute treatment of 
ischaemic stroke due to LVO has changed dramatically worldwide. Additionally, there 
have been campaigns to try and educate the general population about signs and 
symptoms of acute stroke such as the “Act Fast” campaign in the UK (Dombrowski et 
al., 2013) to ensure that patients present quickly to the nearest emergency 
department so that they have the greatest chance at receiving the best evidence-
based treatment. These campaigns have been shown to have an effect, however 
they need to be continuous as their effects may trail off after several months once 
they are stopped (Advani, Naess and Kurz, 2016). We know that the brain will infarct 
over a period of several hours and this is faster in certain people compared to others: 
fast progressors being patients in whom the brain will infarct generally within a 3 to 6 
hour window and slow progressors where it is believed their collaterals are 
maintaining perfusion beyond 6 hours (Rocha and Jovin, 2017). There are different 
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randomised controlled trials assessing neuroprotective agents as these may be able 
to further extend our time window for mechanical thrombectomy; for example, the 
ESCAPE-NA1 trial (NCT02930018) will test NA-1 as a neuroprotective agent in 
patients selected for mechanical thrombectomy. For patients that are in the fast 
progressing category these agents may be able to slow down the rate of infarction 
until reperfusion is achieved. On this basis offering endovascular thrombectomy for 
patients with proven LVO is now shifting from a time-based decision to an imaging-
based decision with the imaging of choice left to the local centres with options 
including the ASPECTS score, CTA or multiphase CTA to assess collaterals, CT or 
MRI perfusion imaging to assess the infarct core and penumbra.  
Although the HERMES meta-analysis allowed for subgroup analyses to be 
performed, further data is still needed as these subgroups were under represented 
and there is ongoing research being performed. Older patients represented 15% of 
those within the HERMES meta-analysis and since it was published, further 
retrospective studies have been performed. Similarly, another 15% of the patients 
from the HERMES meta-analysis could not be given IV tPA and there are ongoing 
studies assessing this subgroup. 
There is still further research to be done, as there is not yet enough evidence 
regarding mechanical thrombectomy in certain patients subgroups. Patients with a 
proximal LVO on imaging and mild clinical stroke symptoms as assessed by a lower 
NIHSS score may also benefit from mechanical thrombectomy. There are other 
patients who have a significant clinical deficit, but a more distal LVO for example in 
the distal M2 or even M3 MCA branches. There is another subgroup of patients with 
already established significant ischaemic changes, as assessed by a high ASPECTS 
score or large core infarct, and it is still unclear what is the best management for 
them. For patients that present with tandem occlusions, such as one in the cervical 
ICA and a simultaneous one in the MCA territory for example, it is still not clear 
whether the intracranial occlusion or the cervical occlusion should be treated first. In 
terms of the actual procedure, although most trials have used stent retrievers, first 
pass aspiration is now being used more frequent and further data is needed to guide 
us as to which technique should be attempted first.  Finally, different centres use 
different types of anaesthesia and there is another debate whether conscious 




After the publication of these trials, there was a huge impact on the management of 
patients presenting with acute stroke due to LVO worldwide. Changes to the 
European and North American guidelines have already been implemented and now 
reflect the findings of these trials by recommending mechanical thrombectomy in 
suitable patients, including patients presenting in the later window in the North 
American guidelines (Casaubon et al., 2015; NICE, 2016; Wahlgren et al., 2016; 




Chapter 3. STABILISE Trial 
This chapter will focus on the STABILISE (Stroke: an evaluation of Thrombectomy in 
the Ageing Brain-[including] where IV thrombolysis IS contraindicated) trial which was 
developed to allow investigation of two new devices to be used in acute ischaemic 
stroke. These intracranial tools: ERIC, Embolus Retriever with Interlinked Cages, and 
SOFIA, Soft torqueable catheter Optimized For Intracranial Access, DAC are being 
investigated. All aspects of the trial will be discussed, including the development of 
the protocol, the ethical submission, the trial running, and initial blinded results will be 
presented.  
3.1 Scientific Background and Rationale 
As discussed in the previous chapters, an acute large vessel intracranial occlusion 
may lead to significant clinical deficits, including dependency and mortality. In 
patients that present within a relatively early time window, advanced imaging may 
show an irreversible central infarcted zone, surrounded by a territory with reduced 
blood flow, the penumbra. This salvageable area is the target for performing 
endovascular treatment, aiming to recanalize the occluded artery, restore blood 
perfusion to the brain and avoid further extension of the necrotic territory. 
At the time of developing the protocol for the STABILISE study, the evidence of 
efficacy for thrombectomy devices had been limited to case series and prospective 
observational studies. These were set out to establish the mechanical characteristics 
and performance devices with respect to the limited end-point of vessel 
recanalization. Even though there were high rates of recanalization, clinical outcomes 
have been poorer than expected which could have been due to reperfusion of non-
viable brain tissue as this has no clinical benefit and poses an increased risk of 
intracranial haemorrhage. Although now there is enough evidence demonstrating that 
mechanical thrombectomy is superior to IV tPA, at the time of developing the 
STABILISE protocol, some of these ground-breaking trials were still ongoing. In 
addition, the randomized controlled trials which had concluded by 2013 mostly 
excluded the older population (patients of age 80 and above) and included few 
patients with contraindications to IV tPA. Importantly, patients with contraindications 
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to IV tPA account for >50% of patients with LVO stroke in routine practice 
series/registries. Further studies more truly representative of the general patient 
population were needed. Additionally, at the time, the non-randomised literature in 
the real-world patient population was also very limited with published studies 
reporting average ages far younger than seen in routine clinical practice. 
As discussed in the first chapter, initial thrombectomy devices were mostly based on 
stents designed as an adjunct to intracranial aneurysm endovascular coiling and 
unexpectedly found to be useful in stroke. As a result, they were not optimized to 
access distal and/or tortuous vessels or those with long occlusions. Tortuous vessels 
are more common in the older population and patients with hypertension, while 
longer clots are less likely to respond to IV tPA (Kamalian et al., 2013).  
The new ERIC retrieval device was specifically designed for thrombectomy and has 
potential advantages in older patients with tortuous vessels and long clots.  It has 
been designed to be less traumatizing with lower radial pressure exerted on the 
arterial walls, the interlinked cages having more flexibility and leading to less clot 
fragmentation. ERIC is made from nitinol, an alloy composed of nickel and titanium in 
roughly equal proportions. This material is highly biocompatible, has good shape 
memory and super elasticity. One of the advantages of the ERIC device is that it is 
better adapted for distal access as it needs a smaller calibre delivery catheter of 
0.017”, while other stent retrievers require at least a 0.021” delivery microcatheter. 
Additionally, there is no requirement to wait a few minutes for the thrombus to 
integrate as is required for the standard stent retrievers. This can help with achieving 
an even faster recanalization and in cases where multiple passes are required, being 
able to save approximately 5 minutes per attempt is significant, keeping in mind that 
up to 1.9 million neurons can die per minute treatment is delayed (Saver, 2006).    
The second device being assessed in this trial, the SOFIA DAC has an ultra-soft final 
segment, but still very good proximal support, allowing excellent navigation in 
challenging tortuous vessels and good steerability around bifurcations. Being 
available in either a 5-French or 6-French size this could be brought up to the clot 
interface intracranially and be used for clot aspiration either on its own or with 





Figure 6 - ERIC Retrieval Device 
Picture courtesy of Microvention Terumo Inc.  
 
In addition, the ERIC retriever device offers more flexibility as there is the ability to 
select a device of smaller or larger diameter and the operator can decide how many 
clot retrieval baskets to deploy depending on the vessel diameter and the clot length, 
Figure 6. This may prove to be very effective in reaching more distal thrombi and 
offering a more personalized treatment approach depending on the patient’s anatomy 
and thrombus length.  
Figure 7 demonstrates how the ERIC device and SOFIA DAC work together to 
remove the thrombus. When the SOFIA device is placed under suction with an open 
ERIC device that is engaged in thrombus, it causes pinching of the thrombus 
between the two devices and plunges the clot into the inner lumen effectively 







Figure 7 - ERIC and SOFIA Thrombectomy 
a - SOFIA DAC advancing toward the ERIC device which is integrated with the 
thrombus 
b - SOFIA DAC partially engaging the ERIC retrieval device and capturing the 
thrombus before retrieval 










3.2 Scientific Trial Objective 
It is hypothesised that mechanical thrombectomy using the new ERIC retriever and 
SOFIA DAC will have at least an equivalent rate of occluded vessel recanalization as 
other standard modern thrombectomy devices. The clinical functional recovery in this 
group of patients will be assessed at long term using the mRS at 3 and 12 months. 
The primary objective of the trial is to determine if these new thrombectomy devices 
can be used successfully in the general population presenting with LVO acute 
ischaemic stroke. The mTICI recanalization rate as assessed by a blinded core lab is 
the primary efficacy assessment.  
It is hypothesized that vessel tortuosity and/or brain collaterals are linked to 
outcomes of mechanical thrombectomy and if a link can be established, the aim is to 
develop a clinically useful assessment tool. The use of early MRI post LVO stroke to 
determine complications of mechanical thrombectomy and to direct patient 
management will be investigated. Finally, it is hypothesised that outcomes are 
independently linked to patients age and will assess if there is any influence 
regarding the type of device used to perform mechanical thrombectomy. These 
formed the basis for the secondary objectives of this trial: to determine the safety of 
these thrombectomy devices and plan the design of a phase III clinical trial, to 
determine mechanical thrombectomy procedure safety in the general stroke 
population including the older population patients, and finally to assess the use of 
early MR imaging after thrombectomy as a biomarker of clinical outcome. 
The primary outcome was recanalization rate by using the mTCI scale as assessed 
by an independent, blinded core laboratory assessment. This primary outcome was 
selected as it was thought to best represent the ability of the new thrombectomy 
devices to retrieve the thrombus. The strength of this primary outcome is that it is 
assessed on a standardized scale that is already commonly used by 
neurointerventionists and it can be relatively easy to assess in a blinded fashion. The 
primary outcome is also relevant as it assesses the actual ability of the clot retrieval 
device to successfully remove the intracranial thrombus. The weakness of this 
assessment is that it may not necessarily correlate with the final clinical outcomes of 
these patients. 
Due to the above, the secondary outcomes also included clinical patient outcomes, 
procedural safety and study feasibility. The study feasibility was important as this 
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being a pilot project, it would help guide whether further investigation of these 
devices in a trial can be feasible in terms of patient recruitment. Both clinical 
outcomes and procedural safety are also very important to assess, as being able to 
perform a safe procedure with the new devices was of paramount importance. If the 
devices proved to have more unexpected complications, then that could lead to these 
devices not being utilised because they could negatively affect clinical outcomes. 
Finally, clinical outcomes at 3 and 12 months were collected, and this is very 
important as that is the ultimate measure of the intervention, but the weakness of this 
outcome is that many other factors other than the devices used can potentially 
influence it.  
3.3 Ethics and Trial Funding 
I worked on the ethics submission at the beginning of my studies, and with help from 
my supervisor and the rest of the team from the Newcastle Institute of Ageing and 
Stroke research, this was submitted in 2014, Appendix B – STABILISE Ethics 
Application. After a meeting with the ethics committee, where a few changes to the 
protocol were requested, we received confirmation that the ethics committee 
approved the study from the NRES Committee North East – Newcastle & North 
Tyneside, 04/07/2014, ref: 14/NE/0113 see Appendix C – STABILISE Ethics 
Approval Letter. The trial’s ISRCTN (International Standard Registered Clinical/Social 
Study Number) registration number is 15698516. 
This trial was jointly and equally funded by the National Institute for Health (NIHR) 
Newcastle University Biomedicine Research Centre based at Newcastle upon Tyne 
Hospitals NHS Foundation Trust and Newcastle University; and MicroVention 
Terumo Inc.  
3.4 Methods 
Below I will synthetize the STABILISE trial methodology. In chapter 7, I will further 
discuss other types of possible methods that could have been used for this study.  
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3.4.1 Trial Design and Running  
This is a UK multicentric, prospective, phase II, single-blinded, randomised controlled 
trial comparing novel thrombectomy devices, ERIC retriever and SOFIA distal access 
catheter, with standard aspiration and/or stent based thrombectomy in male and 
female patients aged ≥18 years with acute LVO ischaemic stroke.  Patients were 
randomised to either the novel thrombectomy devices or to standard thrombectomy 
devices in a 2:1 ratio. 
Potential participants were identified on referral to participating acute stroke services 
and were assessed for study suitability using the inclusion and exclusion criteria, see 
Appendix D – STABILISE Inclusion and Exclusion Criteria. Data collected for routine 
clinical care was used for clinical trial documentation and I worked on developing the 
Case Report Form for collecting all required data, Appendix E – STABILISE Study 
Workbook. Once this was finalised, I worked together with the trial statistician and IT 
developer to make an electronic case report form, capturing the same data, for ease 
of use for the enrolling sites. This was available via secure login from: 
https://macro.infermed.com/NewcastleCTU/Login/LoginForm.aspx?IsUniInstance=true.  
Additionally, I worked on a thrombectomy procedural sheet to capture data that was 
required during the procedure, Appendix F – STABILISE Thrombectomy Treatment 
Details. Consent was obtained either from the patient or their family or in cases 
where this was not possible from an appropriate consultee. I have had the chance to 
work on the patient and consultee information and consent forms as well, Appendix G 
– STABILISE Patient Information Sheet, Appendix H – STABILISE Consent Form, 
Appendix, Appendix I –STABILISE Consultee Information Sheet, Appendix J – 
STABILISE Consultee Declaration. Please also refer to Appendix K – STABILISE 
Protocol, Appendix L - Stabilise Trial - Patient Pathway Flowchart. 
The data monitoring committee was established, and I developed a charter to ensure 
these external experts are able to assess the progress of the trial and assess the trial 
safety data, Appendix M – STABILISE DMC Charter. 
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3.4.2 Trial Protocol Amendments  
During the STABILISE trial, there was one protocol amendment which covered 
multiple issues.  One of the most important modifications made were due to changes 
with regards to the technical aspect of thrombectomy as this is a very rapidly 
changing field. At the beginning of the trial, distal access catheters were not widely 
used, but as these started to be used more regularly in clinical practice, there was 
difficulty with recruiting other centres and a lag in patient recruitment. Other changes 
were related to the trial inclusion criteria to allow inclusion of patients aged 18-50 
years, initially excluded, and also patients with lower NIHSS score between 6-9, 
initially only NIHSS of 10+, as there was newly published data during the course of 
the trial which did not demonstrate any age or NIHSS specific cut off effects for 
clinical benefit from mechanical thrombectomy.  These changes have been made to 
allow extension of the trial to other centres and to increase the recruitment rate which 
was slower than initially predicted. Due to the overall slow recruitment the trial was 
extended, and it will be finalised on the 30th of April 2019. 
 
3.4.3 Eligibility Criteria  
The trial recruited male and female patients aged ≥18 years with clinically significant 
acute ischaemic stroke. Eligible patients had to have vascular imaging in the form of 
either a CTA, MRA or DSA (digital subtraction angiography) to demonstrate an 
intracranial LVO. Patients that were also eligible for IV tPA had this additional 
treatment initiated as per standard clinical practice.  After ensuring that mechanical 
thrombectomy is feasible within the trial timescale, consent for the trial was obtained 
and the patient was then randomized.  Details of both the inclusion and exclusion 




3.4.4 Participant sites 
This trial was run at 4 UK sites: Addenbrookes Hospital in Cambridge, Royal Victoria 
Infirmary in Newcastle, Queen’s Medical Centre Campus in Nottingham and 
University College London in London. Centres selected were from HSRCs 
(hyperacute stroke research centres) who were all approached and invited to 
participate in this trial and who expressed a willingness to join. All centres had to 
demonstrate that neurointerventionists had the level of experience necessary for 
performing neuroendovascular procedures as delineated for the PISTE trial that was 
ongoing in the UK when STABILISE started. This stated specifically that operators 
needed to have performed at least 120 neurovascular procedures per operator in the 
last 3 years with at least 10 mechanical thrombectomy procedures in the last 18 
months for all site operators. All operators had to be comfortable with using both the 
ERIC and SOFIA devices, which were already available for use across the country 
and extra training, if required, was made available. A thrombectomy pathway had to 
be already in place plus evidence of mechanical thrombectomy outcomes 
documented (eg. local audit). In addition, there was a requirement to have IV 
thrombolysis available during extended hours, consultant stroke/neurology cover for 
administering IV tPA, an established local protocol for advanced stroke imaging and 
regular multidisciplinary stroke/neuroradiology meetings in operation.  
Recruitment started in October 2014 and the last patient was recruited in January 
2018. Figure 8 shows the recruitment of patients in the STABILISE trial. Recruitment 
was slower than anticipated and overall challenging. Many different issues combined 
together lead to those difficulties and the trial had to be extended. Once the trial 
opened at the first site in Newcastle, there was a plan to rapidly expand it to other 
sites. Unfortunately, there were changes to the documentation needed for enrolling 
new sites that happened concomitantly and this resulted in significant delays in 
obtaining the required paperwork for getting the trial started at other sites. Because 
this is such a fast-moving field, the type of mechanical thrombectomy preferred by 
operators had slightly changed during the course of the trial. Because of this it was 
necessary to allow for different techniques to be performed as part of the trial, leading 
to a protocol amendment, and this also contributed to further delays and slower 
recruitment rates. At the beginning of the trial, thrombectomy being not yet proven or 
within guidelines, consenting was also challenging due to clinical equipoise and 
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constraints of staff being able to explain everything and gain consent in an 
emergency situation. Finally, patient preference may also have proved a part in the 
slow recruitment, initially because the treatment was not proven yet and later on 




Figure 8 - STABILISE Trial Recruitment 
 
3.4.5 Consent and Randomisation Methods 
Patients were first screened if eligible for the trial and then consented before 
proceeding to randomisation. If patients were able to give consent themselves, this 
was performed and the Patient Information Sheet and STABILISE Consent Form 
were used (Appendix G – STABILISE Patient Information Sheet, Appendix H – 
STABILISE Consent Form). For patients unable to give consent due to lack of 
capacity, appropriate consent was taken from their next of kin or if no family member 
was available, an assent process followed where a medical doctor that was not 
involved in performing the trial and had the patient’s best interests at hand signed the 






















STABILISE Recruitment Over Time 
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STABILISE Consultee Declaration forms were used (Appendix I –STABILISE 
Consultee Information Sheet, Appendix J – STABILISE Consultee Declaration).  
Patients were randomised to either the novel thrombectomy devices or standard 
thrombectomy devices in a 2:1 ratio (SOFIA/ERIC to control) by using stratification by 
age (18-65 vs >65 years) and NIHSS severity of stroke at presentation (NIHSS 
scores of 6-15 versus 16+). The randomization system was based at the Newcastle 
Clinical Trials Unit (NCTU) and the randomisation was web based and accessed 
using a secure password protected website link: https://apps.ncl.ac.uk/random. 
  
3.4.6 Statistical Method 
The STABILISE trial has a comprehensive Statistical Analysis Plan that was authored 
by the Trial Statistician and has to be agreed by the Trial Steering Committee (TSC) 
before any comparative analysis is undertaken or any unblinded data is released. 
Due to this being an early clinical phase trial, most of the analyses were planned to 
be descriptive, on an intention to treat basis.  
The sample size calculation was performed by the trial statistician. The number of 
patients required in the trial was determined by achieving a specified recanalization 
rate in the interventional arm, with an acceptable error level, that would justify a 
subsequent larger scale trial. If a recanalization rate lower than 75% is used to reject, 
while a recanalization rate higher than 90% is used to further investigate the ERICTM 
or SOFIATM devices, a minimum recruitment of 67 patients to the interventional arm 
will permit α and β error levels of 2.5% and 10% respectively by using the Fleming-
A’Hern single stage early phase trial methodology. If there is a higher than expected 
drop-out rate of 20%, this would increase the recruitment target to the interventional 
arm to 80 patients. 
The primary outcome is based on an independent core lab judgement that is blinded 






3.5 Trial Results 
3.5.1 Patient Population 
A total of 68 participants were recruited to the study with the baseline clinical 
characteristics presented in Table 4. Two patients were initially included in the study, 
but were removed, one because consent had not been obtained prior to the 
procedure and the other one withdrew. Once these 2 were removed, there was a 




























3.5.2 Demographics and Baseline Imaging Data 
There were 26/68 (38%) females and 42/68 (62%) males with a median age of 72 
(IQR 59 - 79), Table 4, a total of 15/68 (22%) participants were aged 80 or more.  
The prevalence of hypertension was 37/66 (56%), atrial fibrillation was present in 
22/66 (33%) and current or prior smoking history in 37/66 (56%). 
The median NIHSS score at presentation was 18 (IQR 13–23). All participants had 
vascular assessment in the form of a CTA to establish evidence of LVO. In addition, 
3/66 (5%) patients had MRI and 2/66 (3%) patients had MRA on initial imaging 
assessment. The most common location of the target occlusion was the proximal M1 
MCA segment in 49% (32/66) of patients, next the distal M1 MCA segment in 29% 
(19/66) followed by the proximal M2 MCA in 28% (18/66), Table 5. An ICA occlusion 
was present in 23% (15/66) patients and tandem type ICA-T occlusions were present 
in 14% (9/66) of patients. There were an additional 9% (6/66) of participants who had 
a posterior circulation large arterial occlusion. The intracranial occlusion location in a 
certain patient could be in one or more of these regions and the number of patients 
with additional tandem occlusions, e.g. ICA and M1 MCA, will only be available once 
unblinded data is released. The median baseline ASPECTS score is not yet available 






































Table 4 - STABILISE Patient Characteristics 






Basic Demographics Total Population (n=68) 
Median Age (years) 72 (59-79) 
Men 42 (62%) 
Women 26 (38%) 
 Past Medical History Population (n=66) 
Hypertension 37 (56%) 
Diabetes Mellitus 9 (14%) 
Atrial Fibrillation 22 (33%) 
Heart Disease 18 (27%) 
Previous Stroke  7 (10%) 
Previous Endarterectomy / Carotid 
stent 
1 (2%) 
Smoking (current) 9 (14%) 
Smoking (former) 28 (42%) 
 Clinical Characteristics Population (n=65) 
Baseline mRS  
     0 35 (54%) 
     1 25 (38%) 
     2 5 (8%) 
Baseline NIHSS 18 (13 – 23) 




Imaging and Treatment Characteristics 
Population 
(n=66) 
Intracranial Occlusion Location  
(>1 in certain patients)  
ICA 15 (23%) 
ICA-T 9 (14%) 
M1 Proximal 32 (49%) 
M1 Distal 19 (29%) 
M2 18 (28%) 
VA 2 (3%)                    
Basilar distal 3 (5%) 
PCA 1 (2%) 
Other 1 (1%) 
 
















3.5.3 Treatment Details 
IV tPA was administered in 90% (55/61) of patients at a median time of 115 (IQR 89 
– 159) minutes from symptom onset.  Procedures were performed under conscious 
sedation in 79% (52/66) of patients.  General anaesthesia was used in 21% (14/66) 
of patients, Table 6. 
 
Treatment Details and Process Times Population (n=61) 
Treatment with intravenous alteplase 55 (90%) 
Process times (min) 
 
Onset to IV tPA (min) 115 (89 - 159) 
Onset to Reperfusion (min) 258 (215 - 311) 
Anaesthesia details Population (n=66) 
CS (conscious sedation) 52 (79%) 
GA (general anaesthetic) 14 (21%) 
Reperfusion (mTICI) Population (n=59) 
0 3 (5%) 
1/2a 9 (15%) 
2b/3 47 (80%) 
 
Table 6 - STABILISE Treatment Details and Timelines  









3.5.4 Radiological Outcomes 
Good grade reperfusion as assessed by an mTICI 2b or 3, was achieved in 80% 
(47/59) of participants for which data is available, within a median time of 258 
minutes (IQR 215 - 311) from symptom onset. 
 
3.5.5 Clinical Outcomes 
The median NIHSS at 24 hours improved to 9 (IQR 4-19) from 18 at initial 
presentation. A good functional outcome as assessed by an mRS of 0 - 2 was 
achieved at 3 months in 44% (25/57) of participants and in 36% (20/55) at 12 
months, Table 7 and Table 8. 
 
Outcomes Population (n=66) 
NIHSS at 24 hours 9 (4-19) 
mRS at 90 days Population (n=57) 
     0-2 25 (44%) 
     3-6 32 (56%) 
mRS at 12 months  Population (n=55) 
     0-2 20 (36%) 
     3-6 35 (64%) 







Mortality at 12 months 12 (18%) 
 
Table 7 - STABILISE Trial Clinical and Safety Outcomes 




3.5.6 Safety and Mortality 
Symptomatic intracranial haemorrhage was present in 5% (3/66) of patients. 
Asymptomatic intracranial haemorrhage was detected in 20% (13/66). Other 
procedural and peri-procedural complications include: intracranial vessel rupture in 
1/66 (2%), new ischaemia in a different intracranial arterial territory in 12/66 (18%), 
groin haematoma in 3/66 (5%), common femoral artery pseudoaneurysm in 1/66 
(2%) and limb ischemia in 1/66 (2%). The 12 months mortality rate was 18% (12/66). 
 
 
Table 8 - STABILISE Trial mRS from Baseline to 12 Months 








0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
12 months mRS (n=55)
90 Days mRS (n=57)
Baseline mRS (n=66)
mRS at Baseline, 90 Days and 12 Months  
post Thrombectomy  
mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5 mRS 6
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3.6 Discussion and Limitations 
After the market release of the SOFIA DAC and ERIC retrieval device, while the 
STABILISE trial was ongoing, there have been a few studies that reported on the 
efficacy, safety and clinical outcomes in patients who had mechanical thrombectomy 
with these devices. 
A pilot study from one centre in Switzerland evaluated the safety and efficacy of the 
ERIC device on 36 consecutive patients who underwent mechanical thrombectomy 
and in which this was used as either a single (28 patients) or rescue (8 patients) 
device (Nedeltchev et al., 2015). Their results showed good recanalization rates as 
assessed by a TICI 2b/3 result in 30/36 (83%) of patients and favourable outcomes 
(mRs ≤2) at 90 days in 33% of patients.  Symptomatic intracranial haemorrhage was 
present in 8.3% (3/36) of patients and mortality at 90 days was 27.8% (10/36). They 
concluded that performing mechanical thrombectomy with the new ERIC retriever is 
safe and effective.  
A multicentre, prospective study enrolling patients from 3 different centres in France 
assessed 34 consecutive patients with LVO who underwent thrombectomy with the 
ERIC device (Raoult et al., 2016). As a first line device, ERIC achieved successful 
recanalization (TICI 2b/3) in 20/24 (83.3%) patients and the overall recanalization 
rate when ERIC was used either as a first- or second-line device was 27/34 (79.4%), 
which is similar with the results of the Switzerland study. Clinical independence at 90 
days as assessed by an mRS of 0 – 2 was achieved in 15/31 patients (48.4%). This 
study also commented on the fact that the ERIC retrieval device has the advantage 
of capturing and removing the thrombus without the extra time delay required by the 
usual stent retrievers which once deployed need a few minutes for clot integration 
before retrieval. 
The largest study was performed at one centre, in Copenhagen, in a retrospective 
fashion and included a total of 316 patients, 59 of which had mechanical 
thrombectomy with the ERIC device (Steglich-Arnholm et al., 2017).  Using a 
propensity score matched analysis they found 57 matched pairs and procedures 
done with the ERIC devices versus classic stent retrievers were then analysed. The 
rates of recanalization achieved with the ERIC device were 86% and were similar to 
the 81% rate achieved with the classic stent retrievers. A good 90 days clinical 
outcome as assessed by an mRS of 0-2 was achieved in 46% of patients treated with 
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the ERIC device versus 40% with other stent retrievers. Adverse events were also 
compared and were similar with 28% for ERIC versus 30% for other stent retrievers. 
Interestingly ERIC was significantly faster at achieving recanalization, this was 
reported at 67 minutes versus 98 minutes for other stent retrievers (p=0.009); 
furthermore, another rescue device was used less often in patients where ERIC was 
initially used; 18% versus 39%, p=0.02. 
Another prospective study based on a multicentre registry from France had patient 
data from 8 centres and they assessed all patients treated with the new ERIC device 
over a 13 months period (Pierot et al., 2017). The findings of this study are similar 
with the other ERIC studies showing a high rate of good recanalization TICI 2b/3 in 
27/31 (87.1%) and excellent recanalization TICI 3 in 22/31 (71.0%). They compared 
their results with THRACE and HERMES studies and even though they had a higher 
rate of ICA and tandem occlusions, poorer ASPECTS scores but slightly less severe 
NIHSS scores, they showed that ERIC performed well overall despite these factors.  
A retrospective study performed in Germany and Switzerland collected data from two 
centres from patients that were treated with mechanical thrombectomy due to an 
anterior circulation thrombus and were treated either with the new ERIC device or 
other stent retrievers (Gruber et al., 2018). They had a total of 183 patients with the 
1st device in 49% (90/183) of procedures being performed being the ERIC device and 
in the other 51% (93/183) a standard stent retriever. Good recanalization, mTICI 
2b/3, was achieved in 82% (74/90) patients treated with ERIC versus 57% (53/93) in 
the other group, which was statistically significant with p<0.001. Additionally, 
switching to another device (ERIC or another stent retriever) after failed 
recanalization with the 1st device of choice was shown to increase final recanalization 
rates, up to 87% if the 1st device of choice was ERIC and up to 79% if the 1st device 
of choice a standard stent retriever. Good clinical outcomes (mRS ≤2) were reported 
in 50% (45/90) when the procedure was started with the ERIC device and 35% 
(32/93) for standard stent retrievers.  After adjusting for baseline patient data and 
procedural characteristics, the rates of good clinical outcome were found to be 
associated with the patient’s age, baseline NIHSS, carotid-T occlusion and the 
requirement for general anaesthesia; rather than the type of device used.  Safety and 
mortality data were comparable in both groups.   
An interesting case report showed that the ERIC retrieval device achieved successful 
recanalization of a calcified clot located in the MCA in an 82 years old patient (Kwak 
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and Park, 2018). They reported that imaging showed a 3,7 mm calcified occlusive 
thrombus and a first attempt to remove this via aspiration failed. Retrieval with the 
ERIC device was successful on the first attempt and the patient did well achieving 
clinical independence with an mRS of 1 at 90 days. Calcified intracranial thrombi are 
rare, but can be challenging to recanalize once lodged in the intracranial arterial 
vasculature, being more resistant to IV tPA and having lower recanalization rates (up 
to 13%) compared to atherogenic or cardiogenic emboli (Dobrocky et al., 2018). 
A retrospective study using the direct aspiration first pass technique (ADAPT) 
collected data from 52 patients with M2 occlusion who underwent thrombectomy by 
direct aspiration with large distal access catheters: SOFIA 5 - 0,055” / AXS Catalyst 6 
– 0,060” (Grieb et al., 2019).The successful revascularization rate was 92,3%, 
achieved with the use of additional stent retrievers in 6 patients. Good recanalization 
mTICI 2b-3 was reached in 86.5% (45/52) patients and excellent mTICI 3 
recanalization in 61,5% (32/45) patients. At 90 days, 55,8% (29/52) patients had 
achieved independence with an mRS between 0 and 2. Their conclusion was that 
DACs used alone are safe and effective for mechanical thrombectomy in acute M2 
MCA occlusions. They emphasized the advantage of not deploying stent retrievers in 
smaller vessels to avoid distal embolization and vasospasm. No cases of sICH 
(symptomatic intracranial haemorrhage) occurred, and the asymptomatic ICH 
(intracranial haemorrhage) rate was low at 3.9% (2/52). 
These studies affirmed the need for a larger study to evaluate the ERIC retriever and 
SOFIA DAC. Preliminary blinded results from the STABILISE trial are very limited. 
When looking at the older people recruited into the study, this was 22% (15/68) which 
is not a very low rate, higher that other prior studies, but possibly more could have 
been recruited. Although the STABILISE trial did not have an upper age limit, lower 
overall recruitment into this age group could represent numbers of older patients 
being referred for thrombectomy from other hospitals, as well as patients having a 
good function at baseline as assessed by the clinical team, as only patients with a 
baseline mRS of 0 to 2 could be enrolled. Older people living in nursing homes with 
significant comorbidities leading to a lower mRS were most likely not considered for 
this trial and there is the potential that due to these stringent requirements, especially 




Partial results in the present study show that the majority of patients had M1 51/66 
(77%) and M2 18/66 (28%) MCA occlusions, 22/66 (33%) had atrial fibrillation and 
37/66 (56%) were hypertensive, comparable to previous studies (Goyal et al., 2016). 
The STABILISE trial achieved good mTICI 2b - 3 reperfusion in 80% (47/59) of 
patients in a median time of 258 minutes (IQR 215 - 311). The blinded STABILISE 
trial results show that thrombectomy performed either with a combination of 
ERIC/SOFIA devices or contemporary stent retriever or aspiration devices is efficient, 
and our results appear to be comparable with the recently published ERIC and 
SOFIA studies, but final unblinded data from the trial is still awaited. Our patients had 
a higher total rate of intracranial haemorrhage of 25% (16/66) compared to 10% 
(60/629) in the data from the HERMES meta-analysis and this may be due to the fact 
that patients were assessed at 24 hours with MRI including a GRE or SWI sequence 
that can show microhaemorrhage which could be easily missed on an unenhanced 
CT, which is routinely performed in clinical practice. The rates of sICH were 3/66 
(5%) similar to data from other studies, e.g. 4.4% (28/634) in the HERMES meta-
analysis (Goyal et al., 2016). Preliminary results show that a good functional outcome 
with an mRS of 0-2 was achieved in 44% (25/57) at 90 days, and 36% (20/55) at 12 
months, but again this data is incomplete.    
The final data from the STABILISE trial is still in the process of being finalised, after 
which it will be analysed by the trial statistician and then I will be involved with writing 
the paper so that the results from the trial can be disseminated. 
 
3.7 Conclusion 
To my knowledge, the STABILISE trial will be the first multicentric, randomized 
control trial to assess the new ERIC and SOFIA devices. Preliminary, blinded data 
shows overall good recanalization rates in this study and a good clinical outcome at 
90 days similar to other major trials. Once the trial results are finalized and access to 
the unblinded data given, I plan to work on writing up the trial paper and submitting it 




Chapter 4. CTA Project 
 
Once the STABILISE trial was open to recruitment at the Royal Victoria Infirmary in 
Newcastle, it became apparent that the initial CTA imaging for patients which could 
potentially have a LVO infarct is of utmost importance. No patients had been 
recruited in the trial in the first three months and a central point to be considered was 
the importance of obtaining the initial required CT/CTA imaging within a limited time 
window post symptom onset. As the benefits of thrombectomy were already proven, 
the diagnosis of LVO stroke needed to be urgently improved so that patients could be 
swiftly referred to the neurointerventionists for treatment. This was especially 
important for general district hospitals which would first need to fully assess the 
patient and perform the required imaging before arranging transfer to a tertiary 
centre. The STABILISE trial highlighted the fact that there was a lack of patients 
being referred for mechanical thrombectomy from the neighbouring district general 
hospitals. One of the problems was that their local radiology departments were not 
comfortable with performing and interpreting acute CTA scans to assess for signs of 
acute stroke and / or LVO. This is what motivated me to start the CTA project to see 
whether the imaging diagnosis of these patients and then their subsequent 
management can be improved. 
4.1 Audit of CTA Practice 
4.1.1 Introduction 
In the North East teaching hospitals, out of hours CT/CTA scans are provisionally 
reported by a specialist radiology trainee before being reviewed by a consultant. At 
the Royal Victoria Infirmary, the supervising on call neuroradiology consultant, 
although available for giving a second opinion at any time, will generally review all 
scans and document any disparities within one to twelve hours. Local imaging 
guidelines for patients presenting with acute ischaemic stroke symptoms were 
introduced at the Royal Victoria Infirmary in 2013. These guidelines recommend that 
patients with a suspected LVO should have their imaging prioritised and that the CT 
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angiogram should be performed immediately after the unenhanced CT brain. A fast 
and accurate assessment of all patients potentially suitable for acute interventional 
management is critical to offer the best possible treatment and I was interested to 




I performed an audit to assess the performance against the local Royal Victoria 
Infirmary guidelines for CT/CTA imaging in patients presenting with acute ischaemic 
stroke symptoms. The guidelines had five points which were used as criteria for the 
audit: 
I. All patients with acute ischaemic stroke symptoms 
II. Presenting within <9 hours of symptom onset 
III. Suitable for thrombolysis and/or thrombectomy 
IV. Immediate CT and CTA needs to be performed 
V. CTA to cover from the aortic arch through to the circle of Willis 
The three main aims of the audit were to: 
I. Assess compliance with the local guidelines 
II. Evaluate the rate of clinically relevant imaging findings 




A retrospective review was performed by assessing all consecutive patients identified 
from the stroke electronic database admitted with possible ischaemic stroke from 
01/07/2013 to 31/01/2014. Data was extracted by using electronic sources and 
reviewing patient notes in selected cases. The data extracted and collated into an 
Excel file included the following fields for every patient assessed: patient ID, age, 
sex, stroke symptom onset, stroke type and side, date and time of CT scan, CT 
findings, whether CTA was indicated and whether it was performed, explanation if 
CTA was indicated but not performed, CTA timing, adequacy of CTA scan, CT scan 
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radiation dose, timing of CT/CTA report, report changes after consultant 
neuroradiology review, other imaging obtained (ultrasound or MRI), whether the 
patient had thrombolysis, thrombectomy, carotid endarterectomies/stenting, medical 
treatment and any other relevant information. 
 
4.1.4 Results 
The audit period was for a total period of seven months, from 01/07/2013 to 
31/01/2014. In total 364 patients were assessed, 174 (48%) females and 190 (52%) 
males with a median age of 77, range 27 – 101.  
CTA was indicated in 42% (153/364) and from those, it was performed in 75% 




Figure 10 - Acute CTAs 
Acute CTA was indicated in 42% and from these patients, it was performed in 75%. 
 
 
Results showed that CTA was indicated but not performed in 38/153 (25%) of 
patients and the reason for this was assessed, Figure 11. For the majority of patients 








Yes (115/153) No (38/153)
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guidelines, there was a valid reason such as a contraindication to thrombolysis, 
improving symptoms, already established stroke, etc. For 7/38 (19%) of these 
patients, no valid reason was identified, Figure 11. Overall compliance with 
performing acute CT/CTA imaging was very good with 95% (146/153) of patients 
having immediate imaging as per local guidelines. 
 
 
Figure 11 - Reasons for CTA not being performed acutely 
 
Further analysis was performed to assess the adequacy of the CTA scans, in 
particular to assess whether all the vascular territory was imaged according to 
guidelines, from the aortic arch through to the circle of Willis. After reviewing all the 
CTA images on our local PACS (Picture Archiving and Communication System), 










CTA's Not Performed 
Thrombolysis contraindicated (12/38) Unsuitable for thrombolysis (6/38)
Symptoms resolved or improving (6/38) Symptoms unlikely to be stroke (2/38)
Established stroke (2/38) Renal impairment (1/38)
Patient refused thrombolysis (1/38) Cannulation not possible (1/38)




Figure 12 - Adequacy of CTA imaging 
Percentage of adequate CTA scans with coverage from the aortic arch through to the circle of Willis. 
 
Assessing when the scans were performed, showed that the majority 58%, (210/364) 
were done out of hours (outside of normal office hours, from 9AM to 5PM), see 
Figure 13. 
 










Week-days in hours 154/364 Week-days out of hours 126/364 Week-ends 84/364
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As expected based on this, most scans (57%) were initially reported by the on-call 
radiology registrar before being reviewed and attended by a neuroradiology 
consultant, typically within 1 to 12 hours; Figure 14. 
 
 
Figure 14 - CT/CTA scans reporting 
The initial report was provided in the majority by the on-call specialist radiology registrars. 
 
Out of a total of 206 scans initially reported by the radiology registrars, 11 (5%) of 
them had not been reviewed at the audit time by a consultant. The rest of the scans 
had all been reviewed by a neuroradiology consultant and an amendment was 
documented on the PACS system. From these, 25% (48/195) had a documented 
discrepancy, which was further classified as minor or major. A minor discrepancy was 
a finding on the scan which would not affect immediate patient management, while a 
major discrepancy would impact on the acute care of the patient. 12% (24/195) of the 
reports, after being reviewed by a neuroradiology consultant, had a documented 
major discrepancy. 
Important incidental findings are also significant when reviewing scans. Out of the 
115 CTA scans reviewed, 2 patients (2%) were found to have an incidental lung 




Specialist Registrar 206/364 Consultant 158/364
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Assessing how long it took for reports to be available on PACS after the imaging was 
performed, showed that it was faster to have a report at the weekends, with an 
average time of 54 minutes, Figure 15. This is most likely because out of hours 
reports are finalised by the on-call registrar, while during normal office hours, the 
radiology registrar will put a provisional report which will be reviewed and then 
finalised by a neuroradiologist, thus taking longer to complete.  
 
 
Figure 15 - Average reporting times 
This is reported in minutes from the initial time of the CT/CTA scan to when the report was 
finalised on PACS. 
 
In terms of clinical patient management, 11% (40/364) received intravenous 
thrombolysis and one patient was offered but refused this treatment. A total of 37 out 
of these 40 patients had an acute CTA performed. 
2% (6/364) of patients had a mechanical thrombectomy procedure performed and all 



















Average Reporting Times (min) 
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2% (7/364) had either a carotid endarterectomy or a carotid stenting performed 
during the same admission. Another 3 patients were considered for treatment but 
were found to be unsuitable, 2 patients had already a previous endarterectomy while 
1 patient had a previous stent in place. 
Upon review of discharge letters, all 364 patients had their secondary prevention 
medications reviewed and amended as needed before hospital discharge. 
 
4.1.5 Discussion 
The local imaging guidelines introduced at the Royal Victoria Infirmary in 2013 have 
been largely successful with 95% of patients presenting with symptoms of acute 
ischaemic stroke being adequately assessed with CT and CTA. Although the majority 
(80%) of CTA scans were of adequate quality, in 20% the aortic arch was not 
visualised, and this is an area that needs further improvement.  
Most (58%) scans were performed out of hours, either in the evenings/nights or at the 
weekends. Because of this, most (57%) scans were reported initially by a radiology 
registrar, before being reviewed by a consultant. 25% of all the scans reviewed by a 
neuroradiology consultant had amendments, with 12% having a major amendment 
documented which if identified earlier could have potentially changed the initial 
patient management.  
The patient management was affected by these imaging examinations, with 11% 
receiving intravenous thrombolysis, 2% having an acute thrombectomy, 2% having 
carotid endarterectomy or carotid stenting and 100% having their long-term 
preventive medications reviewed and adjusted. 
The findings of this audit were presented locally at the Royal Victoria Infirmary and 
also regionally, at the northern radiologists annual scientific meeting in the summer of 
2015. This has helped to bring awareness about the importance of performing acute 
CT/CTA imaging in patients that are likely to have a large vessel occlusive acute 




This project has raised the issue of CTA training within the region, as there were both 
minor and major discrepancies recorded and the possibility of further improvement of 
reporting skills needed to be further explored. 
4.2 Development of Validated CTA Teaching Archive  
Next, I worked on developing a validated case archive of CTA scans. The studies 
selected were from patients that presented with clinical signs and symptoms of acute 
stroke to a tertiary hospital, Royal Victoria Infirmary, where their initial CTA scans 
were reported by radiology trainees.  
Reviewing the scan data from the CTA audit performed, a validated case archive 
comprising 50 CTA scans was developed by having each scan reviewed by 3 
neuroradiologists, two consultants and one fellow, and noting all the findings. There 
was a mixture of normal scans, scans with significant acute findings and others with 
significant incidental findings. All of these were specifically chosen to cover normal 
anatomy and most pathologies that could be encountered when reporting these types 
of studies. A total of 6 normal scans were included, specifically selected to 
demonstrate how to methodically assess a scan and include commonly encountered 
normal variants. The abnormal scans included such pathologies as intracranial 
occlusions, carotid stenoses and dissections, previous endarterectomies and other 
important incidental findings such as aneurysms, mass lesions, etc.  
Reviewing the patients case notes and electronic records was used to obtain the 
presenting clinical details, the subsequent management and clinical outcomes up to 
the usual neurological follow-up, between 3 to 6 months. This data, together with the 
findings from the CTA scan was used to make a report type document for each 
patient that included 3 sections: a) Clinical Details, b) Brain CT / CTA Imaging, see 







Sample CTA case from validated case archive: 
a) Clinical Details 
• 75 years old lady 
• Presents with 2 ½ hours of dysphasia  
• PMHx: right sided endarterectomy one year ago for right amaurosis fugax, 
hypertension and hypercholesterolemia 
• Normally lives on her own and she is independent (mRS1) 
 
 
Figure 16 – Axial CT and CTA brain 
Videos: https://bit.ly/2vmh2P8 (left) and https://bit.ly/2UUCtpE (right) 
 




b) Brain CT/CTA Imaging 
NECT 
• No acute infarct 
• Mild to moderate periventricular small vessel disease and lacunes 
CTA 
• Calcified atheroma at the left CCA bifurcation with significant stenosis of the 
left ICA at its origin. There is a small calibre left ICA distal to this stenosis.  
• There is a kink affecting the proximal right ICA (SRS 9, IM68) which is 
indicative of the previous endarterectomy.  
• Also make note of the right foetal posterior communicating artery (occurs in up 
to 30% of the population) and an absent right P1 PCA. 
c) Clinical Course 
• A left carotid endarterectomy was performed 5 days later. 
• Within hours the patient developed two focal areas of haemorrhage within the 
left MCA territory thought to be secondary to reperfusion injury.  
• She was managed conservatively and was discharged 12 days after initial 
admission to the local stroke and rehabilitation unit. 
• The patient spent another 2 months and 2 weeks in rehabilitation before being 
discharged home (mRS 3). 
• At her last clinic follow up 4 months after initial presentation, she has residual 
moderate dysphasia but otherwise is able to look after herself (mRS 2). 
4.3 CTA Course Development and Validation 
As a follow-up to the audit and the validated CTA case archive, I developed a 
simulated radiology training course for reviewing CTAs of patients presenting with 
hyperacute ischaemic stroke.  
In summary, this project was developed with the aim of assessing if an intensive one-
day course training radiology registrars how to read CTA studies improves their 
reporting skills. This project was very successful, and I wrote and published a paper 
about it (Cora et al., 2017), see Appendix O – CTA Training Paper. 
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Training days were organised at the MacLab, a specific, purpose-built radiology 
centre where the Osirix 64-bit software is running as a teaching PACS system on 12 
Apple 27 retina iMacs. Each full day course consisted of a few didactic lectures: 
• Evidence for performing CT / CTA Imaging 
• How to read CTAs including applied neurovascular anatomy and implications 
on decision making 
• Radiographic considerations 
• Osirix software review (if necessary) 
This was followed by hands-on training, where each attendee could review between 
15 to 20 scans, and they each had access to an iMac station, Figure 18. 
 
 
Figure 18 - CTA course in the MacLab facilty 
 
This led to the creation of a full day training course, see Appendix N – CTA Training 
Day Agenda. 
Course days were organised in such a way as to ensure that all the radiology 
trainees were able to attend one of the sessions, which were spread over several 
months. I then reviewed the reports of the radiology trainees pre and post CTA 
training day, blinded as to whether reports were pre or post course, including 
neuroradiologists’ amendments to their reports, to assess whether it had impacted on 
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their reporting performance and confidence. CTA reports, indicated for an acute 
stroke, reported by the trainees were reviewed and the rates of both minor and major 
errors were documented.  
A total of 252 CTA reports done by 48 radiology trainees were assessed. Pre-
training, the total discrepancy rate was 37%, 12% major and 25% minor errors. After 
the CTA training course day, the total discrepancy rate was 34%, 4% major and 30% 
minor errors. The reduction in the rate of major discrepancies was significantly 
reduced, p=0.037.  
A survey done after the course showed that 73% of trainees reported being more 
confident with these types of CTA studies after attending the training. Importantly, 
this one-day intensive course based on a validated case archive of CTA scans in 
acute stroke significantly reduced major discrepancies in the interpretation skills for 
radiology trainees.  
Parallel to this project, the developed course (Appendix N – CTA Training Day 
Agenda) was approved by the Royal College of Radiologists for 6 CPD points and it 
was delivered to general radiologists working in district general hospitals and to 
stroke physicians. The cases were also made available via a website I designed and 
linked to an online PACS type platform, hosted at the MacLab and running a web 
Osirix version.Course attendees could continue reviewing cases from home via a 
secure connection, Figure 19 and Figure 20 (with video link). 
 
 









The feedback from both these groups was very good, leading to a very successful 
course in the North East of England and the Royal College of Radiologists is 




Chapter 5. Development of a New Thrombectomy Technical Index 
 
One of the objectives from the STABILISE trial was to attempt the development of a 
tortuosity scoring tool. Unfortunately, the trial results are not finalised, and I was not 
able to make an assessment linking arterial tortuosity and collateral brain circulation 
to clinical outcome post thrombectomy after LVO stroke. However, as I found this 
concept very interesting, I decided to work on a project to determine whether a 
technical score predicting the difficulty of a thrombectomy procedure would be 
clinically useful.  
As discussed in previous chapters, mechanical thrombectomy can be performed in 
patients with contraindications to IVT and in those presenting later than 4.5 hours’ 
time frame for which IVT is licensed (Department of Health, 2008). Thrombectomy 
can be technically very challenging especially in the older population patients with 
tortuous atherosclerotic vasculature.  
One of the challenges when performing an acute thrombectomy procedure is 
navigating the arterial tree with different guidewires, catheters and any other required 
devices. Once the arterial (usually femoral) puncture has been performed, the next 
step is to navigate from the aortic arch, via the great vessels, into the intracranial 
circulation and then into the occluded target artery. Obtaining an angiogram of the 
arterial vasculature is essential for planning and performing the procedure. Tortuous 
vessels with atherosclerotic disease can pose a great challenge, especially when 
there are time constraints present, such as in acute stroke patients, where timely 
cerebral perfusion restoration is required.  
In this chapter, I will discuss a newly developed technical scoring index that allows 
neurointerventionists to reliably predict the difficulty of a thrombectomy procedure.  
This could usefully inform: (a) decisions on the techniques to be used (route of 
arterial access, equipment, general anaesthetic versus sedation, first pass 
thrombectomy technique: e.g. aspiration, stent retriever or a combination) and (b) 
structure information provided to patients/relatives during assent conversations. 
However, due to the time critical nature of thrombectomy any such assessment tool 





Five domains were included in the Thrombectomy Technical Difficulty Index (TTDI) 
based on relevant literature of factors affecting the difficulty when performing a 
mechanical thrombectomy: aortic arch; vascular tortuosity; stenotic disease; clot 
burden score; and any other extra anatomical or pathological problems.  
Before deciding which components to include, I reviewed the available literature on 
all these factors. Although not many papers were available with regards to performing 
thrombectomies, there were papers on technical aspects for performing carotid 
stenting, angiography and body interventional procedures, as discussed in the 
following paragraphs. Vascular tortuosity, for example, was described as being an 
anatomical factor that affects ease of navigation when performing endovascular 
procedures (Schwaiger et al., 2015). For the development of this score, the aortic 
arch and the target vessel tortuosity were factors that are important. In addition, 
stenotic disease can increase the complexity of a procedure and can potentially lead 
to complications, another factor which was important to include when assessing 
CTAs for mechanical thrombectomy. More specific to removing the thrombus 
intracranially, there is evidence showing that clot location and length has an impact 
on the recanalization rate (Kaschka et al., 2016).  In addition, there is the potential for 
other potential complications resulting in a more challenging mechanical 
thrombectomy procedure, such as patients having previously had grafts or bypasses. 
These other types of miscellaneous potential issues were also considered when this 
score was designed. Before proceeding with the testing of this new score, all these 
factors, as well as their weighting, were reviewed by 5 consultants 
neurointerventionists for both face and content validation. All these different factors 
that need to be assessed when performing the scoring are discussed next in more 
detail.  
5.1.1 Aortic Arch 
The configuration of the aortic arch can lead to significant delays if it is difficult to 
navigate. More complex arch anatomy may require more fluoroscopy time, different 
technique and equipment. If there is significant atherosclerotic disease and 
calcifications, this may release scrapping debris during catheterisation (Keeley and 
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Grines, 1998). The aortic arch elongation classification has been previously 
described and is divided into different grades according to perceived increased 
navigational difficulty (Lin et al., 2005):  
• Grade I: great vessels are all arising normally from the top of the aortic arch  
• Grade II: great vessels origins are between the perpendicular lines from the 
inner and outer curve of the aortic arch 
• Grade III: innominate artery origin is proximal to a perpendicular line from the 
inner curvature of the aortic arch or is arising from the ascending aorta 
 
5.1.2 Vascular Tortuosity 
Internal carotid artery tortuosity has been reported in 35% of 1438 patients who 
underwent conventional angiography in a study done by Weibel and Fields (Weibel 
and Fields, 1965). More severe vessel tortuosity has been observed in the ageing 
population and linked to factors including hypertension, diabetes and atherosclerotic 
disease (Han, 2012) – risk factors which are commonly observed in stroke patients. A 
recent study by Schwaiger et al. demonstrated that mechanical thrombectomy in the 
anterior circulation was significantly less often successful in patients with larger 
vessel angles (Schwaiger et al., 2015). 
 
5.1.3 Stenotic Disease 
Asymptomatic moderate carotid stenotic disease, defined as ≥50% but <70% 
stenosis, has been shown to be present in up to 7.5% of the population, while 
asymptomatic severe carotid stenotic disease, defined as ≥70% stenosis, has been 
shown to be present in up to 3.1% of the general population in a meta-analysis 
including 23706 participants (de Weerd et al., 2010). Arterial stenoses due to 
atheroma can lead to significant procedural complications. The possibility of 
unsuccessful thrombectomy, embolus dislodgement or increased procedural time 




5.1.4 Clot Burden Score 
The Calgary CTA Study Group developed a classification score to assess the 
thrombus load within the anterior circulation - Clot Burden Score (CBS), and 
demonstrated that it could be used to predict outcome at 3 months (Puetz et al., 
2008). A recent study performed on 34 patients with acute occlusion of the distal ICA 
and/or M1 MCA segment who were treated with mechanical thrombectomy, showed 
that the clot location and extent as assessed via the CBS had a significant impact on 
the recanalization rate and overall clinical outcome (Kaschka et al., 2016).   
 
5.1.5 Extra anatomical or pathological problems 
Any other additional anatomical or pathological problems which may be encountered 
in rare instances, but which could significantly affect the outcome of the procedure 
should also be considered. It is known that anatomical variations of the aortic arch 
could be present in approximately 11% of the population and this may increase 
procedural time due to difficulties with vessel cannulation and are associated with 
possible neurological complications (Faggioli et al., 2007).  
 
5.2 Development of the Thrombectomy Technical Difficulty Index 
The TTDI was designed to be used in conjunction with CTA examinations prior to 
performing a thrombectomy procedure. It underwent clinical face and content validity 
assessment by 5 consultant neurointerventionists who suggested minimal 
refinements to the new proposed score.  
The total TTDI score represents a technical difficulty index (scores of ≤ 4 
representing minimal difficulty, > 4 and < 8 representing mild to moderate difficulty, 
and ≥ 8 representing severe difficulty) by summing the scores assigned to each of 
the five domains, see Appendix P – Thrombectomy Technical Difficulty Index (TTDI). 
There was no further specific weighting of the score as this was done with a limited 
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number of patients. I plan to perform a larger prospective study, where this score can 
be used and then refined to see whether certain factors should have a different 
weighting.   
 
5.2.1 Aortic arch elongation  
Examples of the three-standard different aortic arch elongation grades were used as 
an aide memoire, Figure 21. 
 
Figure 21 - Aortic Arch Elongation Classification 
  
Grade I Grade II Grade III 
   
Score = 1 Score = 2, or 3 if  
there is extra appreciable 
atheroma 
Score = 3, or 4 if  




5.2.2 Head and neck target artery tortuosity 
A three-point qualitative scale was utilised. The descriptions with illustrative examples 
of the scale used are shown in Figure 22. 
   
None/Mild Moderate Severe 
   
Less than 30° 
deviation from the 
normal expected 
centre of blood flow  
Approximately between 
30° to 60° angle deviation 
from the normal expected 
centre of blood flow 
affecting the target vessel 
More than 60° angle 
deviation from the normal 
expected centre of blood 
flow, including any tight 
kinks, loops or spiral twists 
Score = 0 Score = 1 Score = 2 
 






5.2.3 Target artery stenosis 
Any target artery stenosis was classified as follows: <50%, 50 – 69%, 70 – 95% and 
acute occlusion / critical stenosis and assigned scores of 0, 1, 2 and 3 respectively, 
see Appendix P – Thrombectomy Technical Difficulty Index (TTDI)Appendix P – 
Thrombectomy Technical Difficulty Index (TTDI).   
 
5.2.4 Clot burden score  
For this domain, a previously described clot burden score (Puetz et al., 2008) was 
used for patients with anterior circulation strokes, Figure 23 . A score of 10 is normal 
and points are subtracted depending on the thrombus location. For posterior 
circulations strokes, there is no accepted clot burden scoring. Therefore, a simple 
thrombus scoring tool was utilised: 
● Minimal to mild thrombus: PCA or another single branch beyond basilar tip, or 
Isolated basilar clot (<1/3 occluded) – score 0 
● Moderate thrombus: <2/3 Basilar trunk + another vessel with clot occlusion, or 
>2/3, but not entire basilar trunk occluded – score 1 
● Severe thrombus: Vertebral + >1/3 basilar vessel clot, or 3/3 basilar affected, 














Figure 23 - Clot burden score in the anterior circulation 
There is a total of 10 points and the score is calculated by subtracting points according to clot 
location: 2 points are subtracted for thrombus in the supraclinoid ICA and each of the 
proximal and distal halves of the MCA trunk. 1 point is subtracted for thrombus in the 
infraclinoid ICA, in the A1 ACA segment and for each affected M2 MCA branch. For example 
a carotid T occlusion with thrombus in the distal ICA, the proximal A1 ACA and the proximal 







5.2.5 Additional problems (e.g. variant anatomy)  
A further single point can be added (at the discretion of the neurointerventionist) if 
any other problem that could potentially lead to procedural difficulty is identified: 
tandem occlusion, aortic coarctation, common brachiocephalic trunk (bovine arch), 
variant origin of the vertebral artery, right aortic arch, double aortic arch and any 
other variant anatomy / pathology - including known severe PVD, International 
Normalized Ratio/Prothrombin Time is significantly prolonged or other arterial access 
problem. A maximum of 1 point can be added irrespective of the number of issues.  
5.3 Patient Selection and Data Collection 
A consecutive sample of 30 patients who underwent mechanical thrombectomy at the 
Royal Victoria Infirmary from October 2013 to May 2016 with a comprehensive CT 
angiogram (CTA) as part of their initial assessment were used to assess the reliability 
and validity of the TTDI.  
CTA scans were imported from our local PACS system and fully anonymised. One 
senior consultant INR (interventional neuroradiologist), Phil White, with more than 10 
years’ experience reviewed each case and assigned an expected procedural 
thrombectomy difficulty rating for each case: minimal, mild to moderate or severe 
difficulty. These ratings were used as the reference standard for assessing the extent 
of agreement (intra-class correlation coefficient, ICC) between the TTDI scores 
assigned to each patient by the 7 INRs. The ICC was also used to assess the extent 
of agreement of the 7 INRs with the expert opinion.  Landis and Koch provided 
guidelines for interpreting ICC values and, specifically, values between 0.61 to 0.80 
indicate substantial agreement, with values of 0.81 to 1.0 indicating almost perfect to 
perfect agreement (25).   
A total of 7 INRs (4 senior, 3 junior) used the TTDI to assess each case. No clinical 
details were provided, except what was present on the scans and whether the 
thrombus was on the right/left side or in the anterior/posterior circulation. The total 
time that each INR took to assess all cases with the TTDI was recorded.  
The TTDI category for each case assessed by the 7 INRs was subsequently 
analysed with reference to data on actual procedure duration, number of devices 
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used, recanalization using the mTICI grading of angiographic reperfusion and 90 day 
mRS (obtained from interrogation of thrombectomy procedure notes, patients’ notes 
and clinical letters). For this analysis, each patient was attributed a consensus 
thrombectomy difficulty score by using the average TTDI score as assessed by the 4 
senior INRs. Appropriate tests of differences (independent t tests and Mann-Whitney 
U tests) were used to establish whether actual data on procedures differed as a 
function of TTDI categories (due to the small number of severe cases, analyses were 
conducted using cases assigned as minimal and mild to moderate difficulty).  
 
5.4 Results  
Thirty patients, 19 males and 11 females, of median age 72 (range 33 – 87) were 
assessed. They had a median NIHSS of 18.5 (IQR = 13.5 – 22.5). Occlusion location 
was present in the M1 MCA in 18/30 (60%), ICA in 5/30 (17%), M2 MCA in 3/30 
(10%), basilar artery in 3/30 (10%) and vertebral artery in 1/30 (3%). Treatment with 
IV tPA was administered in 16/30 (53%) of patients. Symptom onset to groin 
puncture was achieved in a median of 216 min (IQR 188 – 285). Symptom onset to 
reperfusion was achieved in a median time of 276 min (IQR 228 – 333).  
Neurointerventionists recoded the total time to look at all cases and this resulted in a 
range of between 2 to 4 minutes to assess a single case with the TTDI. 
 
5.4.1 Reliability Analysis 
Intra-class correlation coefficient (ICC) between ratings from the 7 INRs was 0.89 
(95% CI = 0.81 to 0.94), indicating almost perfect agreement. Once the TTDI score 
was categorised into a difficulty grading (minimal, mild to moderate, severe), the ICC 
was 0.85 (95% CI = 0.75 to 0.92).  
The ICC for the TTDI scores between the reference expert opinion and the other 7 




5.4.2 Validity Analyses 
Out of the 30 patients, 15 patients (50%) were assigned a minimal level of difficulty 
(TTDI ≤ 4), 13 patients (43%) were assigned as mild to moderate difficult (TTDI >4 to 
<8) and 2 patients (7%) as severe difficulty (TTDI ≥8).  
Mean procedure duration was 46 (SD=20), 73 (SD=36) and 59 minutes for the 
patients in the minimal, mild to moderate and severe categories respectively. Further 
analysis showed that there was a trend towards increase in fluoroscopy times from 
the minimal to the mild to moderate category. The mean difference for procedure 
duration between minimal difficulty cases compared to mild to moderate [-27.61 mins, 
95% CI = -50.02 to -5.19 mins) was statistically significant (t = -2.437 [df=26], p < 
0.05). 
The mean number of thrombectomy devices used was 1.1, 1.3. and 2 for the patients 
in the minimal, mild to moderate and severe categories respectively. The mean 
number of devices between cases assigned as minimal and mild to moderate 
difficulty was not statistically significant (p > 0.05). 
Good recanalization rates (mTICI 2b/3) were achieved in the majority of patients 
within the minimal and mild to moderate category, and in half of the patients within 
the severe category, Table 9. mTICI between cases assigned as minimal and mild to 
moderate difficulty was not statistically significant (p > 0.05). 
 
mTICI Minimal Difficulty 
 
N = 15 





N = 2 
0 3 (20%) 1 (8%) 1 (50%) 
1 1 (7%) 2 (15%) 0 
2A 0 0 0 
2B 4 (27%) 3 (23%) 1 (50%) 
3 7 (47%) 7 (54%) 0 
 




The mRS at 90 days post thrombectomy as a function of TTDI category is shown in 
Figure 24. 53% (8/15) of the patients assigned a minimal difficulty category TTDI 
(score ≤ 4), had a good outcome (mRS 0-2). For patients within the mild to moderate 
category, only 8% (1/13) had a good outcome, with approximately half with mRS = 3. 
For patients in the severe difficulty category, neither of the 2 patients had good 
functional outcome; despite good recanalization being achieved in one of these 
patients.  mRS between cases assigned as minimal and mild to moderate difficulty 
was not statistically significant (p > 0.05). 
 
 
Figure 24 - mRS outcomes  
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mRS at 90 Days Post Thrombectomy as a function of TTDI 
category 




Previous studies based on carotid artery stenting analysed multiple factors 
associated with a higher procedural complexity including: femoral arterial access, the 
arch anatomy, carotid artery tortuosity, stenotic grade and calcification (Choi et al., 
2004). Similarly, for mechanical thrombectomies different anatomical and 
pathological factors, including thrombus location and length have the potential to 
impact significantly on the procedure and its final outcome. 
A clinical tool to assess technical difficulty of undertaking thrombectomy for acute 
stroke was developed. The TTDI demonstrated excellent inter-rater agreement 
between the raters, including difficulty ratings assessed by expert opinion. This 
demonstrates the TTDI is reliable for use in clinical practice.  
The fluoroscopy time was not longer for the patients in the severe category, 
presumably because only 2 patients were in this sub-group and one of the cases was 
abandoned as ICA access was not possible. A trend towards using more devices 
with increasing difficulty grade was demonstrated. Good recanalization with a mTICI 
score of 2b/3 was achieved in 3/4 of patients within the minimal and mild to moderate 
categories and within 1/2 of the severe category, again showing a trend towards 
better procedural success for patients with lower scores.   
Most importantly, there was a statistically significant difference in length of procedure 
between minimal and mild to moderate difficulty categories, with shorter times for 
patients with minimal technical index scores on the TTDI, which provides evidence of 
the predictive validity of the TTDI.     
Interestingly, it appears that the score predicts mRS at 90 days better than it predicts 
procedural time to reperfusion. It suggests that procedural times increase together 
with the difficulty score, except for patients in the severe difficulty category. This 
could be because in one of the patients in the severe category, the procedure was 
abandoned due to access failure, essentially failure to reach the target vessel. This 
procedure was therefore significantly shorter as no thrombectomy passes were 
performed. Another potential confounding factor is that the score may also correlate 
with patients’ frailty rather than just being an indicator of the procedural difficulty. We 
know that patients with more cardiovascular comorbidites such as hypertension, will 
have more challenging arteries, but also these patients may have health problems 
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that affect multiple other organ systems. It would be very useful in future studies, to 
assess the patients’ frailty index and correlate that to this scoring tool.     
There are however several limitations. This is a small study of only 30 consecutive 
patients in a single centre. The score was not developed with different weighting of 
each factor and further work is needed to validate and improve this score. A larger 
prospective multicentre study using this scoring tool and then performing binary 
logistic regression to test which components are associated with outcomes can 
potentially help with guidance as to which factors are more important. The score can 
then be refined with each factor being weighted accordingly. 
There were also difficulties with assessing very long clots as the vessel of interest 
could not be adequately visualised. In these instances, the contralateral circulation 
was assessed for an approximation, although this does have its limits, for example in 
extensive ICA clots, there may be a very tight stenosis that is not fully appreciated. 
This approach cannot always be performed with clots in the posterior circulation. 
Another limitation is that there were patients which had thrombectomy in 2013 and 
early 2014 using older intra-arterial thrombectomy techniques. Subsequently distal 
access catheters have been developed.   
To my knowledge, the TTDI is unique and there is no other technical difficulty 
assessment tool currently being used for thrombectomy procedures. A previous small 
study of carotid stenting has shown that anatomical vascular assessment using 
contrast enhanced MR angiography prior to surgery, altered the operative technique 
in 38% of patients and the procedure was aborted in 5% due to unfavourable 
anatomy (Timaran et al., 2007).  
The newly developed TTDI is a promising tool that can be used before performing a 
thrombectomy. It allows the neurointerventionists to take a few focused minutes to 
fully consider all the factors which may influence the procedure. In addition, it can 
lead to good discussions with the referring neurology team and help with developing 
a tailored treatment plan for each patient, considering both the risks and potential 
benefits of the procedure. It can help with decisions regarding anaesthesia (local 
sedation versus a general anaesthetic), whether there are any possible access 
issues (possibility of needing a prepared ultrasound machine nearby or whether a 
different access site should be considered), if for example the aortic arch is of higher 
grade and/or the great vessels are tortuous, it may prompt the interventionist to start 
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the procedure directly with a different catheter better suited for those situations. 
Depending on the clot burden, it may also help with deciding how to perform the 
initial pass: stent retriever, direct aspiration or a combination of both. The TTDI score 
together with the clinical picture may also be used for consenting purposes, possibly 
predicting the chances of success and relating this information to the patient and/or 
relatives. This may be very useful in the older patient population (≥80) where 




This study may affect thrombectomy planning and delivery, however further work is 
needed to assess the TTDI using prospective cases in different centres and in a 
larger number of patients, to better evaluate its usefulness for decision making prior 















Chapter 6. Thrombectomy in the Older Population 
 
The Stroke Research Group where I was based at during my postgraduate studies 
was part of the Institute of Neuroscience and Institute for Ageing.  As I was learning 
more about stroke and mechanical thrombectomy during my studies, it became 
evident that there is a relative lack of evidence regarding the efficacy, safety and the 
clinical outcomes post mechanical thrombectomy in the older population. I set out to 
perform a collaborative research project on this topic which I found very interesting.  
Stroke types, clinical signs and symptoms and the evidence for thrombectomy have 
already been discussed in the first two chapters of my thesis. The HERMES meta-
analysis confirmed that there is clinical benefit in performing mechanical 
thrombectomy in patients that are of 80 years of age and older, but only a small 
number of patients were in this age group (Goyal et al., 2016). Even though the 
benefit of thrombectomy remains, increasing age is a negative predictor of clinical 
outcome (Goyal et al., 2016). The incidence of ischaemic stroke is higher in the older 
population and post stroke mortality triples for patients 85 years or older (Mozaffarian 
et al., 2015). With increasing life expectancy worldwide, the older population who will 
present with clinical signs and symptoms of acute ischaemic stroke and who may 
potentially be considered for acute mechanical thrombectomy will increase. It is 
expected that from 2010 to 2050, the number of strokes will more than double and 
the majority of this increase will be among older patients of age 75 and older 
(Mozaffarian et al., 2015).  Older patients presenting with stroke have higher 
morbidity and mortality, receive less evidence-based care, have prolonged stays in 
hospital and are more likely to be discharged to an institution/rehabilitation centre 
(Mozaffarian et al., 2015).  
This was designed as a retrospective study aiming to provide further data from 
contemporary routine clinical practice to assess endovascular thrombectomies 





6.1 Materials and Methods 
6.1.1 Study Population 
The project was performed in three high volume international neurointerventional 
centres that perform acute thrombectomies: Newcastle, UK; Ottawa, Canada and 
Boston, USA.  Data was collected on all consecutive thrombectomies performed from 
January 1, 2015 to June 31, 2018 on patients who were 80 years or older at time of 
their procedure. Institutional review board approval was obtained at each institution 
and the ethics board waived the need for patient consent.  
All patients who had an attempted thrombectomy procedure with stent-retrievers, 
aspiration devices or a combination of both were reviewed in a retrospective fashion. 
 
6.1.2 Inclusion criteria 
All patients were assessed clinically in accordance with the local institutional 
guidelines. They needed to have a baseline mRS of 0-2 as assessed by the 
neurology stroke physician at the time of presentation and a clinical deficit resulting in 
an NIHSS score of 6 or higher to be suitable for the intervention. The brain 
parenchyma was assessed with a NCCT brain first to exclude intracranial 
haemorrhage.  The ASPECTS score on NCCT had to be ≥6 or a significant mismatch 
as assessed by the local team had to be demonstrated on CTP. CTA was utilized to 
document a LVO, either as a single, multiphase or dynamic time resolved angiogram 
depending on the neurointerventional centre. Patients with an occlusion of the ICA, 
M1 MCA, proximal M2 MCA, P1 PCA or basilar artery were eligible for interventional 
treatment. 
After the publication of the DAWN and DEFUSE 3 trials (Nogueira et al., 2017; Albers 
et al., 2018), patients who presented between 6 to 24 hours from symptom onset, 
including wake-up strokes, meeting either the DAWN or DEFUSE 3 trials imaging 




6.1.3 Endovascular procedure 
Patients who met the inclusion criteria underwent mechanical thrombectomy. If the 
patients were eligible, IV thrombolysis was also administered.  
Procedures were performed with modern devices in use since 2015 with the choice 
of the technique left to the individual operator. Techniques included the use of stent 
retrievers with or without a balloon guiding catheter, aspiration performed via large 
bore distal access catheters or a combination (Deshaies, 2013; Kang and Park, 
2017).  
All patients had imaging within 24 hours post thrombectomy, mostly in the form of a 
CT scan, with some patients having MRI with GRE (gradient echo) or SWI 
sequences. 
 
6.1.4 Data Collection and Clinical Follow-up 
Data collected for each patient included basic demographics, risk factors for stroke, 
acute clinical and radiological findings and treatment details. Primary outcomes were 
the recanalization rates using the mTICI score and the 90 days clinical outcome as 
assessed by the mRS. Secondary outcomes included: stroke onset to treatment time; 
stroke onset to IV tPA administration; stroke onset to reperfusion; procedural and 
peri-procedural complications; and outcomes at 24 hours post-thrombectomy using 
the NIHSS. 
Different sources were used to accumulate this data including clinical patient’s notes, 
local PACS, electronic healthcare records including discharge letters and follow-up 
clinical visits. All regular follow-up visits were performed according to local clinical 
protocols. Some patients did not have a clinical 3 months follow-up visit, mostly due 
to transfers from other hospitals, and for this ethical approval was obtained and the 




6.1.5 Statistical methodology 
All statistical analyses were performed using SPSS statistics software v25 (IBM 
Corporation, New York, USA). Descriptive statistics for all data are presented as 
medians and ranges for continuous variables and as numbers and percentages for 
categorical variables. Univariate analyses were performed using the Fisher’s exact 
test for categorical data and the Student t test for continuous data. A p < 0.05 was 
considered statistically significant. Statistically significant variables were then used 
for the construction of a binary logistic regression model. OR with 95% CI were 
calculated. 
 
6.1.6 Patient Population 
A total of 168 patients aged 80 or greater were treated with mechanical 
thrombectomy. Twelve patients were excluded: 10 due to site of arterial occlusion 
being not proximal anterior circulation and another 2 patients due to incomplete data. 
One hundred and fifty-six patients were left for the analysis. 
 
6.2 Results 
6.2.1 Demographics and Baseline Imaging Data 
There were 108/156 (69%) females and 48/156 (31%) males with a median age of 85 
(range 80 to 103) with baseline clinical characteristics shown in Table 10. There was 






Basic Demographics Population (n=156) 
Median Age (years) 85 (81 - 90) 
Men 48 (31%) 
Women 108 (69%) 
Past Medical History 
Hypertension 120 (77%) 
Diabetes Mellitus 33 (21%) 
Atrial Fibrillation 98 (63%) 
Smoking (recent or current) 26 (17%) 
Clinical Characteristics 
Baseline NIHSS 20 (15 - 23) 
Baseline glucose (mmol/L) 6.4 (5.5 - 8.3) 
Imaging Characteristics 
 
ASPECTS at baseline 9 (8-10) 
Intracranial Occlusion Location 
 
M1 MCA 84 (54%) 
ICA T 30 (19%) 
Tandem 21 (14%) 
M2 MCA 21 (14%) 
Collateral Status 
 
Good 83 (53%) 
Moderate 45 (29%) 
Poor 28 (18%) 
Data are median (IQR), n(%), or mean (SD). 
 
Table 10 – Patient clinical and imaging characteristics 
 
The median NIHSS score was 20 (IQR 15–23). On NCCT, the median ASPECTS 
score at baseline was 9 (IQR 8–10). The most common location of the target 
occlusion was the M1 MCA segment in 54% (84/156) of patients. ICA-T and other 
tandem occlusions were present in 33% (51/156) of patients. There was a minority of 
M2 MCA occlusions 14% (21/156). Collaterals were good in 53% (83/156) of patients 
treated as assessed on a previously described qualitative scale of poor, moderate 
and good (Miteff et al., 2009). 
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Treatment Details and Process Times 
Treatment with intravenous alteplase 97 (62%) 
Process times (min)  
Onset to IV tPA (min) 103 (75 - 137) 
Onset to Reperfusion (min) 240 (175 - 305) 
Anaesthesia details  
CS (conscious sedation) 132 (85%) 
GA (general anaesthetic) 17 (11%) 
CS transformed to GA during case 7 (5%) 
Reperfusion (mTICI)  
0 27 (17%) 
1/2a 23 (15%) 
2b/3 106 (68%) 
Data are median (IQR) or n(%). 
 
Table 11 - Thrombectomy Treatment Details and Timelines 
 
6.2.2 Treatment Details 
Intravenous thrombolysis was administered in 62% (97/156) of patients at a median 
time of 103 minutes from symptom onset.  Thrombectomy procedures were 
performed under local anaesthesia/conscious sedation in 85% (132/156) of patients.  
General anaesthesia was used in 11% (17/156) of patients and in 5% (7/156) 
conscious sedation had to be converted to general anaesthesia, Table 11. 
 
6.2.3 Radiological Outcomes 
Good grade reperfusion as assessed by mTICI 2b or 3 score, was achieved in 68% 
(106/156) of patients with a median time of 240 minutes (IQR 175 - 305) from 
symptom onset, Table 11. 
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6.2.4 Clinical Outcomes 
The median NIHSS at 24 hours improved to 12 from 20 at presentation. A good 
functional outcome at 3 months as assessed by an mRS of 0 - 2 was achieved in 
26% (40/156) of patients, Table 12. 
 
Outcomes 
NIHSS at 24 hours 12 (6-12) 
mRS 0-2 at 90 days 40 (26%) 
mRS 3-6 at 90 days 116 (74%) 
Safety outcomes at 90 days 
Asymptomatic intracranial haemorrhage 18 (12%) 
Symptomatic intracranial haemorrhage 9 (6%) 
Mortality  64 (41%) 
Data are n(%). NIHSS=National Institutes of Health Stroke Scale.  
 
Table 12 - Clinical and Safety Outcomes 
 
6.2.5 Safety and Mortality 
Symptomatic intracranial haemorrhage was present in 6% (9/156) of patients. 
Asymptomatic intracranial haemorrhage was detected in 12% (18/156). The 90-day 
mortality rate was 41% (64/156), Table 12. 
 
6.2.6 Outcome Predictors 
The association between individual variables and a good clinical outcome on 
univariate analysis is shown in Table 13. After seeking advice and with help from a 
statistician about how to best analyse this data; the factors shown to be significant on 
univariate analysis: age, NIHSS at presentation and good recanalization grade 
(mTICI 2b – 3), were taken and a binomial logistic regression was performed to 
ascertain the effects of the likelihood that patients will have a good clinical outcome 
(mRS 0-2). The logistic regression model was statistically significant, χ2(3)=27.27, 
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p<.001. The model explained 23.8% of the variance (Nagelkerke R²) in good clinical 
outcome and correctly classified 79.2% of cases. Of the three predictor variables, 
only two were statistically significant, Table 14.  
A patient with a good recanalization grade (mTICI 2b – 3) had 5.31 times higher odds 
(95%CI=1,84-15,29) of a good clinical outcome (mRS 0-2). Increasing NIHSS at 
presentation (OR 0,88, 95%CI=0,82-0,94) was associated with a decreased 
likelihood of good clinical outcome. 
After thrombectomy, a lower 24h NIHSS was strongly predictive of good clinical 
outcome (mRS 0 – 2) at 3 months (OR 0,67, 95%CI=0,58-0,77, p<.001). 
 




Factors Considered mRS 90 days (0-2) mRS 90 days (3-6) P value 
Demographics 
Female 25 (62.5%) 83 (71.6%) 0.32 
Age 84 (81-87%) 85 (81-90) 0.005* 
Baseline Blood Glucose 6.45 (5.5 - 8) 6.4 (5.5 - 8.6) 0.46 
Diabetes 7 (17.5%) 26 (22.4%) 0.34 
Hypertension 30 (75%) 90 (77.6%) 0.44 
Atrial Fibrillation 29 (72.5%) 69 (59.%) 0.09 
Smoking 4 (10%) 22 (19%) 0.23 
Presentation/Intervention   
NIHSS at presentation 13 (10 - 22) 20 (16 - 23) 0.001* 
ASPECTS 9 (8 - 10) 9 (8 - 9) 0.36 
Time symptoms to r-tPA (min) 99 (70 - 145) 105 (79 - 135) 1 
Occlusion site (ICA/Tandem) 13 (32.5%) 38 (32.8%) 0.24 
Good Collaterals 25 (62.5%) 58 (50%) 0.13 
General Anesthesia 3 (7.5%) 21 (18,1%) 0.13 
Symptoms to reperfusion (min) 185 (131 - 253) 251 (215 - 346) 0.44 
TICI2b-3 35 (87.5%) 71 (61.2%) 0.002* 
Post Intervention 
NIHSS at 24h 4 (3 - 8) 15 (11 - 21) 0.001 
* p < 0.05 was considered significant 
Categorical Variables are presented as number of cases and percentages 
Continuous Variables are presented as median values and interquartile ranges 
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Variables OR 95% CI P 
NIHSS at presentation 0.88 0.82 – .94 0.001 
TICI 2b – 3 5.31 1.84 – 15.29 0.002 
 
Table 14 - Results of the binary logistic regression for independent predictors of good 
clinical outcome 
6.3 Discussion 
Thrombectomy in patients of aged 80 years and older represents a real challenge – 
these patients have high rates of comorbidities (Piccirillo et al., 2008) and pose 
procedural technical difficulties to arterial and clot access more frequently (Lin et al., 
2005). For instance, in the present series 14% (21/156) had tandem lesions, 19% 
(30/156) carotid T occlusion, 63% (98/156) atrial fibrillation and 77% (120/156) were 
hypertensive; all appreciably higher compared with other studies (Kastrup et al., 
2018). A greater proportion of patients had contra-indications to IV tPA as they were 
anticoagulated, only 62% (97/156) of them received IV tPA compared to 83% as 
reported in the general mechanical thrombectomy population (Goyal et al., 2016). 
The present study demonstrates that in this patient population thrombectomy 
performed with contemporary devices and techniques is efficient (mTICI 2b/3 rate) 
and can be achieved in the expected timeframe, Table 11.  
Because this study was performed in three different international centres, there was 
some variability in how patients were managed clinically. Although, a breakdown of 
each center was not performed, differences in practice are important to acknowledge. 
For example, in one particular centre, if at 24 hours post thrombectomy there was no 
significant improvement in terms of NIHSS, patients would be managed with palliative 
care. Potentially, some of these patients could have improved in the longer term and 
this practice may have contributed to the larger percentage of death in this patient 
population as compared to other studies.  
Another additional potential factor to consider is patient’s frailty. Although none of 
these patients were assessed pre procedure in terms of their frailty index, this data 
may be very relevant to their clinical outcomes. It is possible that patients recruited in 
international trials were healthier patients at baseline, with less comorbidities, 
therefore leading to improved outcomes and a smaller death percentage. Further 
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prospective studies, especially in this age group, would benefit from collecting frailty 
data at baseline to more accurately describe the population being studied. 
An mTICI 2b - 3 reperfusion was achieved in 68% (106/156) of patients in a median 
time of 240 minutes (IQR 175 - 305). This compares favourably with results published 
by other studies, Table 15.  
Due to the extended times after the publication of the DAWN and DEFUSE-3 trials, 
14% (22/156) patients were reperfused later than 6 hours from symptom onset, 
including 5% (8/156) that were reperfused more than 10 hours from symptom onset. 
In the HERMES meta-analysis, the percentage of good reperfusion was similar, 71% 
across all age groups, but this was achieved within a longer median timeframe of 285 
minutes (IQR 210 - 362) (Goyal et al., 2016). The good reperfusion time and 
technical success rate in this study is attributed to the use of modern devices in 
experienced high-volume centres. 
This cohort presented a higher rate of intracranial haemorrhage (18%) as compared 
with the general population (10%) from the HERMES data. A recently published 
series showed even higher rates (42%) of intracranial haemorrhage in the older 
population (Alawieh et al., 2018). The reason for the increased incidence of 
intracranial bleeding has not been elucidated. Although leukoaraiosis was not 
specifically assessed, worsening severity has been shown in a recent meta-analysis 
to be associated with increased risk of sICH as well as poor outcomes after IV tPA 
administration in the context of acute ischaemic stroke (Kongbunkiat et al., 2017). 
However, other mechanisms, like increased vessel fragility may be involved and may 
have implications for the thrombectomy technique. 
A good functional outcome of mRS 0-2 was achieved in approximately 1 in 4 
patients, which is similar to previous studies in this age group, Table 15. This is 
somewhat lower compared with the HERMES data for patients of age ≥80 which 
showed that 30% achieved mRS of 0-2. In addition, the 90-day mortality rate of 41% 
is higher than the HERMES meta-analysis for this subgroup of patients (28%).  
Some of the differences in mortality and mRS 0-2 outcome are probably accounted 
for by the use of “advanced brain imaging” in patient selection employed in 2/3 of the 
HERMES trials recruiting subjects over 80 years of age, notably the ESCAPE and 
REVASCAT trials (Goyal et al., 2015, 2016; Dávalos et al., 2017). Supporting this, 
ESCAPE demonstrated both appreciably greater mRS 0-2 and lower mortality rates 
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in patients aged 80 and older than results of the non-selective MR CLEAN trial 
(Berkhemer et al., 2015; Goyal et al., 2015). The REVASCAT trial used CTP routinely 
in the triaging patients over 80 years of age (Dávalos et al., 2017), but a cut off of 70 
not 80 years for its’ published age analyses; the mortality in the older mechanical 
thrombectomy group was also 41% compared with 23% in their younger cohort and 
mRS 0-2 was 31% versus 53%. This study also included late presenters, and this is 
slightly different to the HERMES meta-analysis which very largely comprised early 
presenters (Goyal et al., 2016). 
Previous studies have identified low NIHSS at presentation, small infarct core, male 
gender and the use of IV tPA as predictors of good functional outcome at 3 months 
following mechanical thrombectomy (Alawieh et al., 2018; Jayaraman et al., 2018; 
Kastrup et al., 2018). In the present patient population, a lower presenting NIHSS 
score was, similar to previous studies, an independent predictor of good outcome in 
the older population (Sallustio et al., 2017; Alawieh et al., 2018; Barral et al., 2018; 
Kastrup et al., 2018). An mTICI score of 2b – 3 was also an independent predictor of 
good outcome, but previous published studies have shown conflicting data regarding 
this (Cohen, Gomori and Leker, 2016; Barral et al., 2018; Jayaraman et al., 2018; 
Tonetti et al., 2018), Table 15. This could be attributed to the short times from 
symptom onset to reperfusion of 240 min (IQR 175 – 305) which may have 
contributed to lower rates of futile reperfusion.  
Younger age was not statistically related to good outcome in univariate analysis, but 
the result was borderline, consistent with other studies. A recently published series 
showed significantly worse outcomes with increasing age, but it included 
thrombectomies performed in 2013 with older devices and reported longer median 
times from symptom onset to reperfusion of 414 minutes (Alawieh et al., 2018). 
Another study found that for patients who had complete or almost complete 
recanalization, with an mTICI score of 2c – 3, increasing age was not a poor 
prognostic factor (Jayaraman et al., 2018).  
After thrombectomy a lower NIHSS was highly correlated to a good clinical outcome 
at 3 months (OR 0,67, 95%CI=0,58-0,77, p<0,001). Another study comparing 
outcomes in patients aged 80 and older versus the general population similarly 
showed that a lower 24h NIHSS is a predictor of independent functional outcome at 3 
months (Sallustio et al., 2017). 
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The limitations of this study include its retrospective nature, multicentre and selection 
bias, a relatively limited patient population and the subjective grading of reperfusion 
results. Further work using prospective data in a larger study may help elucidate 
clinical and imaging predictors of outcome after thrombectomy in patients aged 80 
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6.4 Conclusion  
In patients aged 80 or older, mechanical thrombectomy may be performed within 
accepted timelines with good reperfusion rates. This patient population is challenging 
with an increased proportion of tandem lesions, carotid T occlusions and an 
increased rate of death and poor functional outcomes at 3 months. A lower 
presenting NIHSS and mTICI 2b – 3 reperfusion grades are independent predictors 
of good outcomes. After thrombectomy, a lower 24h NIHSS is a predictor of good 
long-term outcome. Further work is needed to ensure optimum patient selection for 







Chapter 7. Thesis Conclusion 
 
I started my postgraduate studies with the aim of evaluating the new ERIC and 
SOFIA mechanical thrombectomy devices. This was part of the STABILISE trial and I 
had the opportunity to work extensively on this project from the initial ethical 
submission to developing all the paperwork and online platform for collecting the 
required patient data, enrolling different sites for patient recruitment, developing the 
monitoring systems to ensure adequate running of the trial, reviewing reported 
adverse events and taking action as required and responding to the different queries 
of the enrolling sites. 
Local guidelines for performing initial imaging in patients presenting with acute stroke 
symptoms were developed at the Royal Victoria Infirmary in Newcastle, which is a 
tertiary hospital having a neuroradiology department and neurointerventionists who 
can perform mechanical thrombectomy. After these were developed, I set out a local 
project to assess whether these guidelines were being followed. The results from my 
CTA audit project were presented locally and this helped to improve adherence to 
these guidelines and improve overall patient care.  
The start-up of the STABILISE trial was slow and there was a lack of patients being 
referred for mechanical thrombectomy from the neighbouring district general 
hospitals. One of the problems was that their local radiology departments were not 
comfortable with performing and interpreting acute CTA scans to assess for signs of 
acute stroke and / or LVO.  
The initial lack of recruitment in the STABILISE trial highlighted the fact that there 
was room for improvement in the imaging diagnosis of acute ischaemic stroke within 
the North East of England. Continuing from the CTA audit, which had allowed me to 
review a large number of scans, I decided to develop a validated case archive of CTA 
scans from patients who presented with acute stroke symptoms, to be used for 
teaching purposes. Together with help from my neuroradiology colleagues, all the 
selected scans were reviewed and their findings, including initial patient presentation 
and patient outcomes, collated in a report type document. This data was anonymised 
and with permission from the Newcastle Upon Tyne NHS Trust and with help from 
the HENE (Health Education North East) Radiology MacLab Training Centre, these 
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cases were uploaded onto their servers to be used for teaching. I developed a one-
day course where attendees received lectures and then practiced reviewing scans at 
their own stations and in their own time. This was very successful with radiology 
trainees, general radiology consultants and stroke physicians. It was approved for 6 
RCR (Royal College of Radiologists) CPD (continuing professional development) 
points by the Royal College of Radiology. Its online version that I helped create is 
currently being developed as an online course on the RCR website to be made 
available across the UK. This project was presented orally at the BSNR (British 
Society of Neuroradiologists) annual meeting in 2016 and was awarded the 1st prize 
for a trainee research project, see Appendix Q – Awards, Publications, Presentations, 
Teaching, Conferences and Courses Attended Throughout my Ph.D. Studies.  
This project had helped with recruitment into the STABILISE trial which eventually 
had picked up, although still at a slower rate than initially predicted. Because of this 
and due to the fact that techniques in endovascular therapies were rapidly changing, 
a trial amendment was put in, allowing for more operator flexibility when performing 
these procedures. Together with the team working on the STABILISE trial, we were 
successful in recruiting more sites for enrolment and boosting the number of enrolled 
patients. The trial was extended from its original planned end date and will finish at 
the end of April 2019. This being the date when my thesis is due, I unfortunately 
cannot report on the finalised results and I only have access to preliminary blinded 
data. The preliminary results have been described in the chapter on the STABILISE 
trial, but no definite conclusions can be drawn at this time. After the collection and 
statistical analysis of the final data, I will be involved with writing up the paper to be 
published in a journal for world-wide dissemination.  
Another point to discuss is whether a randomized control trial is the best way to 
evaluate this type of new technology. When the STABILISE trial was developed, 
mechanical thrombectomy was not yet proven and it was not part of normal clinical 
care. At the time, setting up a randomized control trial was considered the best way 
to investigate these new thrombectomy devices. There are other study designs that 
can be considered and another type of study design that may have been efficacious 
to perform is an umbrella or platform trial. In these types of trials, a master protocol is 
used to investigate multiple hypotheses in concurrent studies. The benefit of this is 
being able to add or remove arms throughout the study and this type of trial design 
may have helped with the rate of recruitment. If the study would have been 
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developed later on, once mechanical thrombectomy was already a validated 
treatment, then a stepped wedge trial methodology to study these new devices could 
have potentially been done with better recruitment rates. In this type of trial, initially 
participants could have received the control treatment after which the rest of the 
participants could all receive the new intervention in a wave, and this would have 
been a good way to perform this trial. Conducting this trial with registry data or as a 
type of clinical audit where the data was routinely collected from all patients 
undergoing mechanical thrombectomy could have potentially been done, if the study 
was set-up after mechanical thrombectomy was approved as a treatment nation-
wide. Using either one of these two strategies I believe would have significantly 
increased uptake while at the same time reducing the burden on the research staff 
with following-up on patients and data collection, as most of the data would have 
been readily available in the patient’s clinical charts.   
The initial part of my thesis included an extensive review of literature relating to 
stroke and mechanical thrombectomy. The first chapter discussed stroke and its 
classification, imaging tests and acute treatments, including a short history of devices 
for mechanical thrombectomy. The second chapter focussed on the up to date 
evidence for mechanical thrombectomy and all the major trials were presented. This 
evidence has been rapidly evolving throughout the running of the STABILISE trial 
and this chapter presents the latest evidence up to January 2019. Significant 
developments have been made to the way thrombectomy is performed with new tools 
and techniques as well as how patients are chosen with advanced imaging being 
shown to allow selection of patients up to 24 hours post initial stroke symptoms 
onset.  
Chapter 5 concerns the development of a new scoring tool to predict mechanical 
thrombectomy case difficulty in LVO by assessing the initial CTA scan. This project 
demonstrated great potential as it can help operators decide on the best method and 
devices for a case and this may lead to a more personalised and patient oriented 
approach in delivering mechanical thrombectomy. The aim of this is to attain a faster 
and safer recanalization to ensure improved patient outcomes. The scores’ simplicity 
and robustness have the potential to make it a performant tool for the 
neurointerventional team. This project represents an innovative and original 
contribution and I am looking forward to publishing this study in a prestigious journal. 
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I plan to undertake further research to assess this scoring tool in a prospective 
manner in a multicentric study. 
Endovascular therapies for stroke being relatively new had limited data regarding 
older patients presenting with acute LVO. I worked on a multicentric study to assess 
the safety and efficacy of mechanical thrombectomy in patients that are 80 years of 
age and older. This is the content for Chapter 6 of my thesis and currently represents 
one of the largest cohorts of older patients. The results showed that although their 
types of strokes are more challenging to treat with endovascular therapies and their 
clinical results are poorer than in the younger population, the latest retrieval devices 
and techniques allow for good rates of recanalization. Further data is needed to 
ensure optimum patient selection in this age group, but this study showed that better 
outcomes are achieved in patients that have a lower baseline NIHSS, a good grade 
of reperfusion (mTICI 2b-3) and a lower 24 hours NIHSS. This multicentric study is 
highly relevant in our ageing population in the developed world and adds important 
information to the current literature on stroke and mechanical thrombectomy in the 
older population. This project was partially presented orally at the CAR (Canadian 
Association of Radiologists) annual meeting in 2018 and received the 1st prize for 
research undertaken by a trainee. It was also accepted as a poster presentation at 
the RSNA (Radiological Society of North America) annual meeting in 2018 where it 
was awarded the Student Travel Award.   
From my thesis projects, there is grounds for further research to be undertaken. The 
data from the STABILISE trial will also be used to work on a study looking at MRI 
scans post thrombectomy and its value in predicting outcomes. There has been 
significant research work acute ischaemic stroke due to LVO including collaterals, 
patient selection and outcomes in endovascular therapy and the data will be 
assessed to see whether we can contribute to the current literature. The newly 
developed thrombectomy score needs to be further assessed in a prospective 
fashion and I plan to do this after this paper is published, ideally, I would like this to 
be a collaborative project with multiple sites. The CTA teaching course has been very 
successful in England and I have been asked to deliver and possibly launch another 
online version in Canada.  
This thesis has focused on a variety of research topics related to mechanical 
thrombectomy: new retrieval devices, imaging assessment including the development 
of a course, a new CTA assessment tool and an analysis of outcomes in the older 
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patient population. This work has added significant and original contributions to the 
existing knowledge base related to endovascular treatment with mechanical 
thrombectomy. I plan to continue undertaking further research in this exciting field 
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0 No symptoms at all 
1 
No significant disability despite symptoms; able to carry out all 
usual duties and activities 
2 
Slight disability; unable to carry out all previous activities, but able 
to look after own affairs without assistance 
3 
Moderate disability; requiring some help, but able to walk without 
assistance 
4 
Moderately severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5 
Severe disability; bedridden, incontinent and requiring constant 
























































































Appendix D – STABILISE Inclusion and Exclusion Criteria 
 
Inclusion Criteria 
• Clinical diagnosis of acute ischaemic stroke 
• Male or non-pregnant female ≥18 years of age 
• Clinically significant neurological deficit and NIHSS score ³6 
• Enrolment, randomisation and procedure commencement (groin puncture) 
possible within 90 minutes of the CT/CTA diagnosis of LVO (AND maximum 
5.5h after stroke onset anterior circulation, 8.5h for posterior circulation) 
• Occlusion of the MCA trunk, MCA bifurcation or intracranial internal carotid 
artery (including carotid-T), M1 or ≤2 proximal M2 branches; intracranial 
vertebral/basilar/P1 posterior cerebral artery (PCA) demonstrated on CTA, 
MRA, or DSA 
• Interventional device delivery (guide catheter placed in target artery beyond 
aortic arch and angio obtained) can be achieved within 6 hours of onset of the 
stroke (9h for posterior circulation occlusions) 
• Consent of patient or appropriate consultee 
• Independent prior to the stroke (estimated mRS 0-2) 
• Expected to be able to be followed up at 12 months 
  
 Exclusion Criteria 
• CT evidence of ICH, or evidence of extensive (defined as >1/3 MCA territory 
or Alberta Stroke Program Early CT score (ASPECTS) score ≤6) established 
hypodensity on CT 
• Clinical history suggestive of subarachnoid haemorrhage even if CT normal 
• Eligible for a “treatment policy” (i.e. phase III trial) RCT of stroke 
thrombectomy in that institution & willing to be randomised into such 
• Vascular access contraindications e.g. bilateral femoral bypass surgery, tight 
ipsilateral carotid or vertebral stenosis (if judged not readily amenable to acute 
intervention by Interventional Neuroradiologist [INR] who would carry out the 
procedure), unsuitable proximal vascular anatomy likely to render 
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endovascular catheterisation difficult, unsafe or impossible (as judged by INR 
who would carry out the procedure) 
• Extracranial: chronic/atherosclerotic ipsilateral internal carotid artery (ICA) or 
dominant vertebral artery occlusion 
• Alternative intracranial pathology potentially responsible for the new symptoms 
• Medical co-morbidities which would preclude safe cerebral vessel 
catheterisation or which are expected to limit life expectancy to <3 months 
(e.g. severe cardiac, renal or hepatic failure, significant coagulopathy, 
metastatic malignancy) 
• Known allergy to radiological contrast 
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4. Glossary of Abbreviations 
 
Abbreviation Definition 
AE Adverse event 
ASPECTS Alberta Stroke Program Early CT score 
CI Chief Investigator 
eCRF Electronic Case Report Form 
CRN Clinical Research Network 
CSP NIHR Coordinated System for gaining NHS Permission 
CT Computed tomography 
CTA Computed tomography angiogram 
CTP Computed tomography perfusion 
DSA Digital subtraction angiography 
DWI Diffusion weighted imaging 
ECASS European Cooperative Acute Stroke Study 
eGFR Estimated glomerular filtration rate 
FLAIR Fluid-attenuated inversion recovery 
GP General Practitioner 
IA Intra-arterial 
ICA Internal carotid artery 
IAT Intra-arterial thrombectomy  
ICH Intracerebral haemorrhage 
ICH GCP 
International Conference on Harmonisation of Good Clinical 
Practice 
IDMC Independent Data Monitoring Committee 
IFU Instructions for Use 
IMS Interventional Management of Stroke 
IV Intravenous 
IVT Intravenous thrombolysis 
MCA Middle cerebral artery 
LVO Large vessel occlusion 
MRA Magnetic resonance angiography 
MRI Magnetic resonance imaging 
mRS Modified Rankin Scale 
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NCTU Newcastle Clinical Trials Unit 
NIHR National Institute for Health Research 
NIHSS National Institute of Health Stroke Scale 
NUTH Newcastle upon Tyne Hospitals NHS Foundation Trust 
PCA Posterior cerebral artery 
PH Parenchymal haemorrhage 
PHr Parenchymal haemorrhage remote 
PI Principal Investigator 
PIS Patient Information Sheet 
PV Pharmacovigilence 
rtTPA Recombinant tissue plasminogen activator 
R&D Research and Development 
RCT Randomised controlled trial 
REC Research Ethics Committee 
RFA Rankin Focused Assessment 
SAE Serious adverse event 
SITS-MOST Safe Implementation of Thrombolysis in Stroke-Monitoring Study 
SICH Symptomatic intracranial haemorrhage 
SOP Standard operating procedure 
SRN Stroke Research Network 
STIR Stroke Imaging Repository 
TICI Thrombolysis in cerebral infarction 
TMG Trial Management Group 













Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) will act as the 
sponsor for this trial. 
Funder: NIHR Newcastle University Biomedicine Research Centre and MicroVention 
Terumo Inc. are jointly funding this trial. 
Trial Management:  A Trial Management Group (TMG) will be appointed and will be 
responsible for overseeing the progress of the trial.  The day-to-day management of the trial 
will be co-ordinated by Newcastle Clinical Trial Unit (NCTU). 
Principal Investigator:  The Principal Investigator (PI) will have overall responsibility for the 
conduct of the trial at a particular trial site.  
 
Trial Management: 
The following functions falling under the responsibility of the sponsor will be delegated to Prof 
Phil White and Prof Gary Ford (co-Chief Investigators): 
• Ethics Committee Opinion (including application for research ethics committee favourable 
opinion, notification of protocol amendments and end of trial, site specific assessment & 
local approval) 
• R&D Approval (including application for global checks, via NIHR Coordinated System for 
gaining NHS Permission (CSP)) 
• Good Clinical Practice and Trial Conduct (including GCP arrangements, data monitoring, 
emergency & safety procedures) 
• Administration of funding for the trial 
 
Trial Conduct at Site: 
Investigator Responsibilities: 
• Trial conduct and the welfare of trial subjects 
• Familiarity with the trial intervention(s) 
• Compliance with the protocol, documentation of any protocol deviations and reporting of 
all serious adverse events 
• Screening and recruitment of subjects 
• Ensuring all trial-related medical decisions are made by a qualified physician, who is an 
investigator or co-investigator for the trial. 
• Provision of adequate medical care in the event of an adverse event 
• Obtaining local approval and abiding by the policies of Research Governance 
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• Compliance with the Principles of GCP, the Research Governance Framework for Health 
and Social Care, the Data Protection Act and any other relevant legislation and regulatory 
guidance 
• Ensuring that no participant is recruited into the trial until all relevant regulatory 
permissions and approvals have been obtained 
• Obtaining written informed consent from participants prior to any trial specific procedures 
• The Principal Investigator (PI) shall be qualified by education, training and experience to 
assume responsibility for the proper conduct of the trial.  S/he shall provide a current 
signed & dated curriculum vitae as evidence for the Trial Master File 
• Ensuring Trial Site team members are appropriately qualified by education, training and 
experience to undertake the conduct of the trial 
• Availability for Investigator meetings, monitoring visits and in the case of an audit. 
• Maintaining trial documentation and compliance with reporting requests 
• Maintaining a site file, including copies of trial approval, list of subjects and their signed 
informed consent forms 
• Documenting appropriate delegation of tasks to other trial personnel e.g. Research 
Nurse, Co-Investigator(s), Trial Manager, Database Manager 
• Ensuring data collected is accurate, timely & complete 
• Providing updates on the progress of the trial 
• Ensuring subject confidentiality is maintained during the project and archival period 
• Ensuring archival of trial documentation for a minimum of 5 years following the end of the 
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6. Protocol Summary 
 
Title of Trial: Stroke: an evaluation of Thrombectomy in the Ageing 
Brain - [including] where IV thromboLysis IS 
contraindicatEd 
Short Title: STABILISE 
Protocol Version: 2.1 
Protocol Date: 31 July 2015 
Co-Chief Investigators: Professor Phil White & Professor Gary Ford 
Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust 
(NUTH) 
Funders: NIHR Newcastle Biomedicine Research Centre /  
MicroVention Terumo Inc. 
Trial Design Multicentre prospective phase 2 single-blinded 
randomised controlled trial of novel device (ERIC) versus 
standard thrombectomy device(s) 
Trial Duration: 3 years 
Number of Trial Sites: 6-10 UK 
2-3 EU outside UK  
Trial Population: Patients with an acute ischaemic stroke due to large 
vessel occlusion who on clinical grounds have been 
referred for thrombectomy (and are not suitable for 
enrolment into a treatment policy trial) 
Trial Size: 120 in total 
Rationale: No randomised controlled trial has yet evaluated whether 
thrombectomy is associated with improved clinical 
outcome in a truly heterogeneous stroke population.  
However it is clear that use of mechanical thrombectomy 
devices in acute ischaemic stroke is associated with 
higher rates of recanalisation in large artery occlusions. 
But thrombectomy studies mostly exclude the elderly (>75 
years) or those with a contraindication to IV thrombolysis.  
Outcomes and safety in such populations are unclear.  
Most current thrombectomy devices were adapted 
(crudely) from devices originally designed for a different 
purpose and as such have major limitations in distal or 
tortuous vessels. STABILISE will investigate a novel 
purpose designed thrombectomy device (MV “ERIC”™ 
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device) together with the (MV “SOFIA”) distal access 
catheter. Both of these devices have design features 
making them favourable to accessing distal/tortuous 
vessels. 
Trial Intervention: Randomisation to type of device to be used in clinical 
neurointerventional procedure will be undertaken, 
commencing a maximum of 5-8.5h after stroke onset. 
Participation in the trial will entail follow-up (clinical and 
radiological) for up to 365 days. 
Primary Objective: To determine if a novel thrombectomy device can be 
utilized safely and successfully in the heterogeneous 
population presenting with large vessel occlusion (LVO) 
acute ischaemic stroke 
Secondary Objectives: • To determine the preliminary efficacy (recanalization 
rate) and safety of the thrombectomy device and 
inform design of a phase III clinical trial 
• To determine the procedural safety of thrombectomy in 
a wider stroke population 
• To investigate the use of early MRI post thrombectomy 
as a biomarker of clinical outcome  
Primary Outcome Measure: The proportion of patients with favourable angiographic 
outcome based on independent core lab assessment 
measured by STIR II modification of TICI scale.   
Registration/Randomisation: Web randomisation through Newcastle Clinical Trials Unit. 
Patients randomised on a 2:1 basis in favour of the 
investigational device. 
Inclusion Criteria: • Clinical diagnosis of acute ischaemic stroke 
• Male or non-pregnant female ≥18 years of age 
• Clinically significant neurological deficit and 
NIHSS score ≥6 
• Enrolment and procedure commencement (groin 
puncture) possible within 90 minutes of the 
imaging confirmation of LVO stroke (and within a 
maximum 5.5-8.5h after stroke onset- >5.5h 
ONLY for posterior circulation)  
• Occlusion of the main middle cerebral artery 
(MCA) trunk, MCA bifurcation or intracranial 
internal carotid artery (carotid-T, M1 or ≤2 
proximal M2 branches), or intracranial vertebral or 
basilar artery or P1 PCA demonstrated on CTA, 
MRA, or DSA 
• Interventional device delivery (guide catheter 
placed in target artery beyond aortic arch and 
angio obtained) can be achieved within 6h hours 
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of onset of the stroke (9h for vertebrobasilar 
occlusions)  
• Consent of patient or “appropriate consultee” 
• Independent prior to the stroke (mRS 0-2) 
• Expected to be able to be followed up at 12 months 
Exclusion Criteria: • CT evidence of intracranial haemorrhage, or 
evidence of extensive (>1/3 MCA or ASPECTS 
<6) established hypodensity on CT. In posterior 
circulation strokes pc-ASPECTS <6 or >1/3 of 
territory 
• Clinical history suggestive of subarachnoid 
haemorrhage even if CT normal  
• Eligible & willing to be randomised into a 
treatment policy trial of stroke thrombectomy  
• Known major vascular access contraindications 
e.g. femoral bypass surgery 
• Unsuitable proximal vascular anatomy likely to 
render endovascular catheterisation difficult, 
unsafe or impossible in the view of the 
interventional neuroradiologist.  
• Alternative intracranial pathology potentially 
responsible for the new symptoms 
• Medical co-morbidities which would preclude safe 
cerebral vessel catheterisation or which are expected 
to limit life expectancy to <3 months (e.g. severe 
cardiac, renal or hepatic failure, significant 
coagulopathy, metastatic malignancy) 
• Known allergy to radiological contrast 
Statistical Analysis: All statistical analyses will be conducted according to 
Statistical Analysis Plan, which will be authored by the 
Trial Statistician and agreed by the Trial Steering 
Committee.   
This is a phase II trial to investigate feasibility, safety and 
surrogate measures of efficacy to inform the design of a 
subsequent multicentre definitive trial. This early phase 
trial will investigate angiographic success rate and will 
consider moving to a definitive trial with a rate >75% in 
this unrestricted group of patients and a clinical outcome 
not worse than standard device thrombectomy in an 
unbiased comparator group. 
 





6.1 Trial Flow Chart 
 
 







After arterial occlusion, brain tissue undergoes infarction over a period of minutes to hours 
depending upon the severity of the reduction in cerebral perfusion.1 Restoration of blood flow 
by recanalisation of the occluded artery limits the extent of damage. Reperfusion may occur 
spontaneously due to endogenous clot breakdown, but therapeutic intervention using 
thrombolytic drugs increases the chances of reperfusion2 and is therefore associated with 
increased probability of favourable outcome if delivered promptly after symptom onset. 
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) 
significantly increases the proportion of patients achieving independence 3 months after 
ischaemic stroke when delivered within a maximum of 4.5h after onset of symptoms.3-5 Since 
stroke has not been regarded as a medical emergency in the past, large-scale 
reconfiguration of health care systems has been necessary to deliver rtPA to patients, and 
although the proportion of patients undergoing intravenous (IV) thrombolysis is small 
globally, there has been a rapid expansion in the numbers treated in the UK and elsewhere 
in recent years. However, IV thrombolysis results in recanalisation of the occluded artery in 
only just over 50% of patients,6 and the probability of successful recanalisation is least with 
occlusions in large arteries, reflecting the larger volume of clot.7,8 Patients with large artery 
occlusion also have the most severe clinical presentations and poorest outcomes.9,10 
Recanalisation rates for occlusions of the terminal internal carotid artery (ICA) or main middle 
cerebral artery (MCA M1) are reported to be only 9% and 33% respectively, compared to 
66% in smaller MCA branches (M2 or distal).7 The speed of recanalisation is also important, 
with more rapid recanalisation being associated with higher probability of early neurological 
improvement and independence at 90 days.6  
The intra-arterial (IA) delivery of thrombolytic agents directly into the occluded vessel via 
microcatheter injection offers hypothetical advantages in terms of thrombolytic dose titration, 
but only three randomised controlled trials (RCTs) have evaluated IA thrombolytic drug 
delivery,11,12 and in addition to inconsistent clinical efficacy and control groups that did not 
receive what would now be regarded as best medical care, the specific agents employed in 
these trials (urokinase and pro-urokinase) are no longer available. A combined IV+IA 
thrombolytic drug approach was evaluated in the first open label Interventional Management 
of Stroke (IMS) trial,13 compared with IV rtPA alone. In the more recent Synthesis trial IA 
therapy alone (overwhelmingly IA lysis) was compared with IV thrombolysis and no 
advantage was demonstrated for IA.14 




The use of IA thrombolytic drugs has been superseded by the development in recent years 
of a wide range of mechanical devices which can directly revascularise occluded cerebral 
vessels. However, evidence of efficacy for devices has been limited to case series and 
prospective observational studies, mostly designed simply to establish the mechanical 
characteristics and performance of a device with respect to the limited end-point of 
recanalisation of intracranial vessels, which is all that is currently required for licensing by 
regulatory authorities. Recanalisation rates are higher than expected for IV thrombolysis 
compared with historical controls, in some instances very considerably so.15-19 However, 
despite these high rates of recanalisation, clinical outcomes have in some cases been poorer 
than would be expected based on historical controls given IV thrombolytic treatment. 
Relevant factors that may increase risk of IA thrombectomy include higher reported risks of 
SICH (around 9% compared to 2-4% for IV thrombolysis), and longer procedure duration, 
leading to more prolonged onset-to-treatment time; a marked reduction in the probability of 
favourable outcome with IV thrombolytic therapy over the first 4.5h after onset is well 
documented3 and reflects a combination of reducing volumes of salvageable tissue over time 
as well as increased bleeding risk. The additional time incurred in IA delivery – often up to 6h 
after symptom onset before microcatheter deployment even in experienced centres19,20 - may 
offset any benefit from improved recanalisation rates, since  reperfusion of non-viable brain 
tissue carries no clinical benefit and may increase bleeding risks. On the other hand, patients 
selected for IA treatment usually have more severe strokes, successful recanalisation is 
uncommon with IV treatment alone, and favourable outcomes in registry studies are more 
frequent than expected for IV treatment in groups of equivalent clinical severity with definite 
arterial occlusion.  
In order to define the overall role for mechanical thrombectomy, evaluation in RCTs is 
ongoing. In five recently completed IA trials, thrombectomy was demonstrated to be 
significantly superior to IVT alone.21-25 
Those RCTs that recently concluded mostly excluded the very elderly population and also 
included relatively few patients with a contraindication to IVT – ~90% of patients overall in 
these 5 recently published trials receiving IVT, yet patients with contraindications to IVT 
account for >50% of patients with large vessel occlusion (LVO) stroke in routine practice 
series/registries.  Further studies are required in a more truly representative patient 
population. The non-randomised literature in the real world patient population is also very 
limited – studies have mainly reported average ages far younger than seen in routine clinical 
practice. 





Current thrombectomy devices are mostly based on stents designed as an adjunct to 
intracranial aneurysm endovascular coiling and fortuitously found to be useful in stroke.  
However as a result they are not purpose designed for thrombectomy and can fail to 
access/work in distal and/or tortuous vessels or those with long clot occlusions. Tortuous 
vessels are certainly far more common in the elderly and long clots are more prevalent in 
those who fail to respond to IVT. By contrast the MV “ERIC”™ STROKE DEVICE (Embolus 
retriever with interlinked cage) is specifically designed for thrombectomy and has potential 
advantages in older patients with tortuous vessels and long clots. It has design features that 
lend itself to: 
1) tortuous access – low profile and interlinked but flexible clot retrieval baskets along its 
length 
2) distal access – ability to select a device with fewer baskets and of very low profile so 
enabling smaller diameter microcatheter to be used for better & safer distal access 
3) long segment clot – ability to select a long device with more & larger clot retrieval baskets 
Preliminary work in animals and then in humans in vivo (for CE mark approval) look 
promising and indicate that the MV “ERIC”™ STROKE DEVICE design features do seem to 
work. In addition the MV “SOFIA”™ distal access catheter (Soft torqueable catheter 
Optimized For Intracranial Access) provides easier navigation in tortuous vessels and has 
steerable control around bifurcations. 
As a result there is a clear rationale to investigate these devices in a truly heterogeneous 
stroke population presenting with LVO. This is required to confirm safety and technical 
efficacy and to inform the design of a definitive phase III clinical trial of the devices.  
We know that there is still a paucity of information with regard to the role of advanced brain 
imaging in large vessel occlusive stroke. In particular the use of thrombectomy correlated to 
patient age and the use of advanced brain imaging as a predictor of thrombectomy outcome 
specific to LVO stroke has not been systematically evaluated to date – including arterial 
tortuosity and rigorous assessment of the brain’s collateral circulation. We will perform such 
an evaluation as part of the STABILISE trial. 
If aortic arch/carotid/vertebrobasilar vessel tortuosity is shown to be linked to procedural 
outcome (any one of technical success, complication rates and clinical outcome) then 
development of a clinically applicable “tortuosity scoring tool” would be a very valuable output 
from this trial. Tortuosity by age cohort in LVO stroke has not been evaluated previously, and 
not at all in relation to its role in IAT.  Only one small preliminary non-randomised study  
 





(n=39) has attempted to link age to collateral status26 but that study wasn’t restricted to LVO  
stroke (the most relevant group) nor was any comparative age cohort analysis performed.  
 
But the study did suggest a distinct age related tissue process is occurring as collateral score 
was the only factor found to correlate positively with age. This certainly merits further 
systematic investigation in larger studies and specifically in the most clinically relevant 
population – LVO stroke. 
We already know that outcome for IAT is probably independently linked to time to treatment 
and severity of initial stroke27 but we actually have very limited data on any independent link 
to patient age so far. STABILISE will contribute additional important data on this topic. There 
is early evidence that collateral flow may be a key determinant of response to IA 
thrombectomy28 as well as IV thrombolysis.29,30 However in the only study looking specifically 
at collateral scoring related to IAT outcome to date, collateral scoring did predict eventual 
outcome.30 However there are some major limitations in this study that limit its 
generalizability - a) IAT was not performed with modern stentriever technology, which 
significantly speeds up recanalisation time and has significantly greater recanalisation rates 
over equipment used in the 2011 study;29,30 b) patients did not have proven LVO before going 
to attempt thrombectomy (hence 24% of those included in this IAT study did not actually 
receive thrombectomy!); c) patients were considerably younger (mean age <65years) than 
typically reported in European IAT studies; d) nor did the study specifically examine patient 
age as related to predictive value of collateral score. STABILISE will be able to address most 
of these limitations. 
We do not know currently whether there is any defined link between age and collateral 
scoring in LVO stroke.29,31 STABILISE will be able to investigate such a correlation. 
Additionally the use of magnetic resonance imaging (MRI) early post LVO stroke has only 
been prospectively investigated in one study (n=104) to date.32 However this study almost 
exclusively concentrated on other issues – largely around penumbra size assessed by an 
automated software programme predicting outcome after IAT, rather than use of MRI post 
IAT as a marker of outcomes and age did not feature in the analyses reported. Only 13% of 
the DEFUSE 2 patients had thrombectomy using a stentriever device. 
 
 




In particular the DEFUSE 232 study did not examine: 
i. Role of MRI to evaluate IAT complications that cannot be demonstrated on computed 
tomography (CT) (very small strokes or microbleeds) but which may be relevant to 
immediate further management 
ii. Any link between complications [identified on MRI] to patient age is unknown i.e. is there 
an age specific risk? 
iii. The use of MRI (diffusion weighted imaging (DWI)/fluid-attenuated inversion recovery 
(FLAIR) match for defined infarct core) as a biomarker (predictor) for outcome in the 
subgroup of LVO stroke has not been evaluated nor whether there is any link between 
age and MRI findings. Again STABILISE will explore these potential uses of MRI and 
compare the findings in a middle aged cohort with an elderly cohort of patients. 
 
 
7.2 Rationale - Hypothesis 
We hypothesise that mechanical thrombectomy using the MV “SOFIA” and “ERIC”™ 
STROKE DEVICES will be associated with at least an equivalent rate of occluded vessel 
recanalisation without a better safety profile compared with standard modern thrombectomy 
devices.  We will also examine functional recovery in this prospective and representative 
group of patients with significant LVO stroke treated by IAT compared with standard medical 
care assessed by shift analysis on the modified Rankin Scale (Rankin Focused Assessment) 
at day 90.  
Regarding the advanced brain imaging components of STABILISE: 
• We hypothesise that vessel tortuosity and/or brain collaterals in LVO stroke will be linked 
to “stentriever” IAT outcome. If linked, development of a clinically useful tortuosity 
assessment tool would be initiated  
• Early MRI post LVO stroke will be an accurate determinant of IAT complications and be 
helpful to direct future patient management. It is hypothesised that early MRI will have 
utility as a predictive biomarker of long term clinical outcome in LVO stroke post 
thrombectomy 
• We hypothesise that age will be independently linked to outcomes – technical, safety and 
clinical – of stroke thrombectomy and will undertake an exploratory analysis of influence 
of device used. 
 





The trial will investigate if a novel thrombectomy devise can be utilised safely and 
successfully in the heterogeneous population presenting with large vessel occlusion (LVO) 
acute ischaemic stroke.  This investigation of feasibility, safety and surrogate measures of 
efficacy will be used to inform the design of a subsequent multicentre definitive trial if the 
angiographic success rate is >75% in the complete trial population (unrestricted group) of 
patients and the clinical outcome is not worse than standard device thrombectomy in the 
unbiased comparator group.   
8.1 Primary Objective 
To determine if a novel thrombectomy device (“ERIC”™ DEVICE) and a distal access 
catheter (“SOFIA”™) can be utilized successfully in the heterogeneous population 
presenting with large vessel occlusion (LVO) acute ischaemic stroke with recanalization rate 
by blinded core lab assessment as the primary efficacy assessment.  
8.2 Secondary Objectives 
• To determine safety of the thrombectomy device and inform design of a phase III clinical 
trial 
• To determine the procedural safety of thrombectomy in a wider stroke population 
• To investigate the use of early MRI post thrombectomy as a biomarker of clinical 
outcome 
9. Trial Design  
This is multi-centre prospective phase II single-blinded randomised controlled trial comparing 
a novel thrombectomy device with standard stent based thrombectomy in male and female 
patients aged ≥50 years with acute ischaemic stroke.  Patients will be randomised to either 
the novel thrombectomy device or standard thrombectomy device in a 2:1 ratio. 
A target of up to 120 subjects will be recruited from 8-12 centres in 3-4 European countries 
(6-8 in UK; 2-4 in Austria, Denmark and Sweden) over a period of 2 years. Potential 
participants will be identified on referral to participating acute stroke services and will be 
screened using the clinical inclusion and exclusion criteria listed in section 10.  Data 
collected for routine clinical care will be used for clinical trial documentation (e.g. blood 
results, National Institutes of Health Stroke Scale (NIHSS) score, imaging findings) (further 
details are in Section 10). Consent will specifically include the use of clinically routine data for 
trial purposes, and for review of imaging studies by independent observers.  
 




This early phase trial investigating feasibility, safety and surrogate measures of efficacy will 
be used to inform the design of a subsequent multi-centre definitive trial if the angiographic 
success rate is >75% in the unrestricted group of patients and the clinical outcome is not 
worse than standard device thrombectomy in the unbiased comparator group. 
9.1 Primary Outcome Measure 
Proportion of subjects with good recanalisation (grade 3/2b) based on the STIR (stroke 
imaging) II modified TICI scale as defined by an independent blinded core lab assessment of 
digital subtraction angiography (DSA). 
 
9.2 Secondary Outcome Measures 
• Safety Outcomes: 
o Symptomatic intracranial haemorrhage rates defined as local or remote parenchymal 
haemorrhage type 2 (PH2 or PHr2 intracerebral haemorrhage (ICH) by European 
Cooperative Acute Stroke Study (ECASS) 2 definition) on the 24h post-treatment 
imaging scan, combined with a neurological deterioration of 4 points or more on the 
NIHSS from baseline, or from the lowest NIHSS value between baseline and 24h, or 
leading to death (Safe Implementation of Thrombolysis in Stroke-Monitoring Study 
(SITS-MOST) definition). Defined by local PI 
o Any intracranial haemorrhage on periprocedural or 24h CT or MRI (defined by central 
imaging review) 
o Extracranial bleeding, groin haematoma requiring evacuation / surgery or transfusion 
or definitely prolonging hospital stay. Defined by local PI 
o Other extracranial haemorrhage. Defined by local PI 
o Other clinical complication assessed by operator as procedural – reported by local PI 
• Feasibility Outcomes: 
o Proportion of identified patients consenting and randomised 
o Attrition at day 90 and day 180 
o Time to thrombectomy 
o Duration of thrombectomy procedure 
• Neurological recovery - change in distribution of modified Rankin Scale (mRS) scores 
adjusted by baseline variables (shift analysis) at day 90 and day 365 
• Early major neurological improvement of 8 or more points, or return to NIHSS total score 
of 0 or 1, at 72 hours (or at discharge if earlier)  




• Functional recovery according to Rankin 
• Sustained (i.e. 24h) recanalisation rates in subjects undergoing interventional procedures 
(magnetic resonance angiography (MRA) assessment); any recanalisation rates (TICI 0-1 
versus 2-3 DSA and 24h MRA)  
• Days spent at home in first 90 days after stroke 
• Mortality rates 
• Exploratory analysis of correlation between collateral scoring on computed tomography 
angiogram (CTA) and clinical outcome 
• MRI markers of procedural risk – new acute DWI lesions (outside the clinical/CT stroke 
presentation) & haemorrhage 
 
9.3 Trial Closure/Definition of End of Trial  
The trial will end when the TSC agrees that one or more of the following situations applies: 
i. The planned recruitment target and follow-up has been achieved 
ii. The Independent Data Monitoring Committee (IDMC) has advised discontinuation, 
e.g. because of safety concerns about the trial 
iii. There is insufficient funding to support further recruitment, and no reasonable 
prospect of additional support being obtained 
iv. New information makes it inappropriate to continue to randomise patients to one or 
other arm of the trial 
v. Recruitment is so poor that completion of the trial cannot reasonably be anticipated 
The safety aspects of the trial will be overseen by an IDMC consisting of an independent 
stroke physician, medical statistician and neurointerventionist. The progress of the trial will 
be assessed at regular intervals determined by the IDMC. During the period of recruitment to 
the trial, interim analyses of mortality and of any other information that is available on major 
outcome measures (including SAEs believed to be due to treatment) will be supplied, in strict 
confidence, to the chairman of the IDMC, along with any other analyses that the Committee 
may request.  
The end of the trial is defined as the last participant who has completed the 365 day follow 
up visit. 
 





10. Subject Population 
 
It is anticipated that the trial will run at 8-12 sites in 3-4 European countries, including the UK, 
Austria, Denmark and Sweden.  All the participating hospitals will have acute stroke services 
and neuroscience centre within the same Trust/institution (see Eligibility Criteria for Trial 
Centres section 10.3).  
The trial will recruit male and female patients aged ≥18 years with acute ischaemic stroke. 
Eligible patients must have vascular imaging evidence of a relevant arterial occlusion 
(anticipated to be determined by CTA in the majority, although MRA or DSA are allowable). 
Vascular imaging is expected to be the standard of care at all participating centres for 
patients with clinically suspected LVO stroke and this should be acquired prior to consent. 
Patients eligible for IV rtPA will have treatment initiated as per standard practice, up to 4.5h 
after symptom onset.  
After ascertaining that IAT is feasible within the trial timescale (randomisation and procedure 
commencement (groin puncture) within 90 minutes of confirming LVO diagnosis and 
placement of a guide catheter beyond the aortic arch within 5.5 hours of stroke onset (8.5h 
for posterior circulation strokes)), consent for the STABILISE trial will be sought from patients 
or from their legal representatives (appropriate consultee) if deemed ineligible for any other 
ongoing phase III neurointerventional randomised controlled trial (RCT) at that centre. 
10.1 Inclusion Criteria  
• Clinical diagnosis of acute ischaemic stroke 
• Male or non-pregnant female ≥18 years of age 
• Clinically significant neurological deficit and NIHSS score ≥6 
• Enrolment, randomisation and procedure commencement (groin puncture) 
possible within 90 minutes of the CT/CTA diagnosis of LVO (AND maximum 5.5h 
after stroke onset anterior circulation, 8.5h for posterior circulation)  
• Occlusion of the MCA trunk, MCA bifurcation or intracranial internal carotid artery 
(including carotid-T), M1 or ≤2 proximal M2 branches; intracranial 
vertebral/basilar/P1 posterior cerebral artery (PCA) demonstrated on CTA, MRA, 
or DSA  
 
 




• Interventional device delivery (guide catheter placed in target artery beyond aortic 
arch and angio obtained) can be achieved within 6 hours of onset of the stroke 
(9h for posterior circulation occlusions)  
• Consent of patient or appropriate consultee  
• Independent prior to the stroke (estimated mRS 0-2)  
• Expected to be able to be followed up at 12 months 
10.2 Exclusion Criteria 
• CT evidence of ICH, or evidence of extensive (defined as >1/3 MCA territory or 
Alberta Stroke Program Early CT score (ASPECTS) score ≤6) established 
hypodensity on CT 
• Clinical history suggestive of subarachnoid haemorrhage even if CT normal  
• Eligible for a “treatment policy” (i.e. phase III trial) RCT of stroke thrombectomy in 
that institution & willing to be randomised into such 
• Vascular access contraindications e.g. bilateral femoral bypass surgery, tight 
ipsilateral carotid or vertebral stenosis (if judged not readily amenable to acute 
intervention by Interventional Neuroradiologist [INR] who would carry out the 
procedure), unsuitable proximal vascular anatomy likely to render endovascular 
catheterisation difficult, unsafe or impossible (as judged by INR who would carry 
out the procedure)  
• Extracranial: chronic/atherosclerotic ipsilateral internal carotid artery (ICA) or 
dominant vertebral artery occlusion 
• Alternative intracranial pathology potentially responsible for the new symptoms 
• Medical co-morbidities which would preclude safe cerebral vessel catheterisation or 
which are expected to limit life expectancy to <3 months (e.g. severe cardiac, renal or 
hepatic failure, significant coagulopathy, metastatic malignancy) 
• Known allergy to radiological contrast 
• Absolute contraindication to MRI 
10.3 Eligibility Criteria for Trial Centres 
An accreditation committee (consisting of Prof Phil White, Prof Gary Ford and another TSC 
member) will review data provided by centres to ensure adequate experience by the  
 




interventional team and documentation of protocols for intra-arterial management of acute 
stroke.  
Each centre must have a hyperacute stroke team including consultant stroke physicians or 
neurologist(s) with an on call system e.g. for delivery of IV thrombolysis for ischaemic stroke. 
They must also have a team of interventionists (2 or more) undertaking regular cerebral 
endovascular interventional procedures including thrombectomy for stroke.  
Local protocols for advanced stroke imaging techniques (including CTA and/or CT Perfusion 
(CTP) and MRI techniques including DWI/MRP/MRA) must be in place.  
Intra-arterial thrombectomy procedures will be carried out by designated consultant 
interventionists with substantial expertise in cerebral interventional endovascular procedures 
and the techniques required for stroke thrombectomy. Good collaboration between the 
hyperacute stroke team and interventionists is essential and centres should have regular 
neurovascular meetings.  
Centres will be required to submit documentation of detailed local protocols for the treatment 
of acute stroke. Prospective centres will need to provide documentation that evidence is 
being kept of angiographic and clinical outcomes for their acute ischaemic stroke 
interventions (e.g. audits of recent results for both IVT and their IA experience).  
As a guide, centres will have treated ≥20 patients with hyperacute ischaemic stroke using 
intra-arterial thrombectomy within the preceding 24 months. In addition a much larger 
experience in cerebral endovascular interventional procedures will need to be documented.  
Centres where there is no routine use of advanced imaging in stroke and limited experience 















11. Screening, Recruitment and Consent 
 
11.1 Identification & Screening 
Potential participants will be identified on referral to participating acute stroke services and 
will be screened by the stroke team/stroke research team against clinical inclusion and 
exclusion criteria listed in section 10.   
An eligibility screening form will be completed by the investigator to document participants’ 
fulfilment of the entry criteria for all patients considered for the trial and subsequently 
included or excluded. For subjects/consultees who decline participation, this will document 
any reasons available for non-participation. Sites at which patients are being identified are 
full research sites. 
 
11.2 Recruitment Procedure 
If a patient fulfils clinical criteria, a clinician with delegation to take consent for the trial (and 
GCP trained) will explain the trial to the patient (if deemed to have capacity) or their next of 
kin or other appropriate consultee and invite them to participate. The relevant trial Patient 
Information Sheets (PIS) will be provided at this time and the patient/consultee allowed to 
consider it whilst clinical care towards delivering thrombectomy continues.  
The clinician who approached the patient about participation will answer any questions they 
may have prior to informed consent. 
This clinician will be listed on the site delegation log for this purpose. 
 
11.3 Consent 
A clinical investigator with delegated responsibility will verbally explain the exact nature of the 
trial and also provide each patient/relative/appropriate consultee with a written information 
sheet (PIS).  This will include the known side-effects that may be experienced and the risks 
of participating in this clinical trial.  Written informed consent will be obtained from each trial 
participant, alternatively, if the patient is unable to consent for themselves, then this will be 
provided from an appropriate consultee as required by each participating country. In 
England, a consultee will give an opinion on whether the patient would have wished to 
participate. Trial participants will be informed that they are free to withdraw their consent from 
 




the trial or trial treatment at any time. In the case of patients who were enrolled in the trial by  
a consultee because they were unable to consent at the start of the trial, personal written 
informed consent will be confirmed once they regain capacity. A specific information sheet 
relevant to this situation will be provided to them at this time. 
Due to the clinical urgency of acute stroke treatment and the need to undertake clinical 
thrombectomy the time for reflection is necessarily limited. The time constraints also preclude 
arranging official interpreters.  
The original signed consent form will be retained in the Investigator Site File, with a copy in 
the clinical notes and a copy provided to the participant. The participant will specifically 
consent to their General Practitioner (GP) being informed of their participation in the trial. 
The right to refuse to participate without giving reasons will be made clear. 
 
12. Trial Intervention Details 
 
12.1 Investigational Device Information 
All devices should be used in accordance with the manufacturer’s CE marked Instructions for 
Use (IFU).In the experimental arm, the initial attempt at thrombectomy will be with the 
“SOFIA”™ distal access catheter and the “ERIC”™ MVS devices ± clot aspiration (technique 
as per operator preference within device IFUs). If that fails to recanalises adequately then the 
neurointerventionist may elect to use any other CE-marked device approved for 
thrombectomy. Such devices will be those available as clinical routine at a site, and will not 
be supplied as part of the trial. The ERIC device used as allocated will be provided at a 
research rate by Microvention Terumo Inc. – one per patient (equivalent to $1500 USD). 
The device make and model that is used for a procedure will be documented in trial 
documentation. In the control arm, the neurointerventionist is free to use preferred existing 
thrombectomy device(s) but should only use the “SOFIA” and “ERIC”™ MVS devices in 
exceptional circumstances if other devices have failed and in the best interests of the patient. 
Devices with CE mark and approval for “stentriever” type thrombectomy are the following: 
• Covidien ev3 Solitaire & derivatives 
• Phenox BONNET & derivatives 
• Phenox pRESET & derivatives 
 




• PENUMBRA retriever/thrombectomy system & derivatives including aspiration 
catheter/pump 
• Concentric Trevo/Trevo2 &  derivatives 
• Acandis Aperio 
• Codman ReVive & derivatives 
• Mindframe Capture device & derivatives 
Other devices CE marked for ischaemic stroke thrombectomy may be approved for trial use 


































Patients will be randomised to either novel thrombectomy device or standard stent based 
thrombectomy device (± clot aspiration). 
Stratification will be by :  
- age (18-65 vs >65) 
- severity of stroke at presentation by NIHSS (6-15 versus 16+) 
A central randomisation facility will allocate the randomised therapy per patient.  The system, 
based at the Newcastle Clinical Trials Unit (NCTU) will be web based and accessed by sites 
using a secure password protected website link. Participants will be assigned a unique 
patient trial ID number. Patient details will be entered into the web-based system, which will 
return the allocation status. 
Ratio of allocation to treatment groups will randomise on a patient basis and will be on a 2:1 
ratio (SOFIA/ERIC to control). 
Participants will not be informed of their allocated treatment group.  
14. Blinding 
 
Clinical outcome (Rankin Focused Assessment (RFA)) assessors will be blinded to device 
treatment allocation. Assessors will be medical or nursing or therapist with current Rankin 
assessment accreditation 
Core lab neurointerventionist assessing TICI score (under modified STIR II criteria) at end of 
procedure will be blinded to treatment allocation.  
In this trial emergency unblinding is not required as the same clinical intervention is 
undertaken in both arms and the operator is not blinded. 
15. Trial Data 
 
15.1 Assessments/Data Collection 
Clinical evaluations will include standard neurological impairment and outcome 
scales as outlined in the trial flow chart in section 6.1 and the schedule of 
assessments below. In addition, at around 90 days post stroke the outcome will 
include the number of days spent at home in the first 90 days after stroke, an 
objective index of functional outcome that also contributes health economic data.  








X   trial-specific procedure 
*   clinically routine procedure (data captured for trial) 
+   procedure clinically routine in some/most patients 
 
 
Visit 1: Pre Randomisation/Randomisation  
Procedures that are part of routine patient care for assessment of eligibility for treatment of 
LVO strokes will be used also for assessment for eligibility of the trial, these include: 
 




• Medical history, including symptom onset time, past history, medication, level of function 
or disability 
• CT/A/P brain (or MRI/A) 
• Blood samples for biochemistry (including estimated glomerular filtration rate (eGFR) and 
blood glucose) and haematology (including coagulation) 
• Blood pressure, heart rate and temperature  
• [Capillary] Blood glucose 
• Weight 
• Physical examination including NIHSS (see appendix B) 
 
Trial specific procedures will take place following informed consent, these include: 
• Pregnancy test for females of childbearing potential 
• Web based trial entry 
• Allocation of randomised treatment and patient unique trial number 
• Completion of electronic Case Report Form (eCRF) 
 
Visit 2: Thrombectomy Procedure 
General anaesthesia or sedation may be used for the procedure as locally required. Intra-
arterial mechanical thrombectomy will be undertaken using the CE marked MICROVENTION 
“SOFIA”™ distal access catheter along with “ERIC”™ STROKE retriever Device (MSD) or 
other CE marked thrombectomy devices at the discretion of the Interventional 
Neuroradiologist. The procedure should commence (i.e. groin puncture) within 90 minutes of 
the onset of IV thrombolysis or confirmation of diagnosis of LVO stroke (whichever is later) 
and a guide catheter should be placed beyond the aortic arch within a maximum of 6h of 
stroke onset (9h for posterior circulation) and angiographic run performed to confirm LVO.  
Procedure documentation will include drug administration (including anaesthesia or 
sedation), total duration, device used, number of passes, adverse events (AEs). If the 
“SOFIA”™ and “ERIC”™ MSD fails to recanalise to TICI 2b or better after 3 passes, the 
neurointerventionist is free to use other CE marked thrombectomy device(s). In control arm 
standard stroke thrombectomy devices will be utilised as per local centre protocol. If after 3 
passes these fail to recanalise to TICI 2b or better, the neurointerventionist is free to use 
other CE marked thrombectomy device(s) – including SOFIA &/or ERIC. 





All assessments before discharge will take place in an acute stroke unit or neurointensive 
care facility and will be performed by the clinical stroke team with support from research 
nurses as required. 
Post-treatment monitoring: will be documented on a trial worksheet for transcription into 
the eCRF. This includes the following items that are collected routinely in patients treated 
with IAT &/or IVT:  
• Blood pressure hourly for 24 hours, then four hourly for 24 hours 
 
Visit 3: 24 hours (22-36h) post treatment: 
• Brain imaging will be with MRI and MRA (repeat CT and CTA only if MRI impossible) 
• Vital signs 
• NIHSS 
• Blood samples for biochemistry 
• Adverse event assessment 
• Completion of eCRF 
 
Visit 4: 72±8 hours post treatment (or hospital discharge if earlier): 
• Vital signs 
• NIHSS 
• Adverse event assessment 
• Completion of eCRF 
 
Visit 5: 7(±2) days post treatment (or hospital discharge if earlier): 
• Vital signs 
• NIHSS 
• Adverse event assessment 








Visit 6: 30 days 
• Adverse event assessment (by local team) 
• Completion of eCRF 
• Carried out by local trial team from medical records plus call to GP/patient if required 
 
Visit 7: ~90 days (±3) 
• mRS (by patient or carer) 
• Home time evaluation (number of days spent at home in first 90 days after stroke) 
• Adverse event assessment  (by local team) 
• Undertaken at standard clinic follow-up or if patient is unfit/unable to come to clinic then 
will be undertaken by telephone interview by local research team to complete RFA and 
home time evaluation 
 
Visit 8: 365 days (±10) 
• mRS  (by patient or carer) 
• Adverse event assessment  (by local team) 
• Completion of eCRF  (by local team) 
• Undertaken either by postal questionnaire, telephone interview or at clinic visit 
• Trial completion 
 
Modified Rankin Scale (mRS) 
The mRS is a hierarchical ordinal scale used to assess disability in stroke trials, with seven 
discrete levels that range from No Symptoms (mRS=0) to death (mRS=6). Inter-observer 
agreement is significantly enhanced by use of a standardised structured interview. All 
investigators undertaking outcome assessment will document training in use of Rankin 
scoring.  
Imaging 
Routine brain imaging in acute stroke consists of brain CT, an X-ray based examination 
involving ionizing radiation. This identifies stroke caused by ICH with very high sensitivity and 
specificity, and may additionally show areas of established ischaemic damage that define 
eligibility for treatment. In patients with suspected LVO stroke centres undertaking regular  




thrombectomy will undertake vascular imaging- usually CTA, but some may use magnetic 
resonance imaging (MRI), including MRA, as an alternative. Enrolment will occur after 
vascular imaging confirms eligibility. 
CT angiography acquires thin axial sections during the first arterial passage of approximately 
50ml of an iodinated contrast agent delivered via an IV cannula sited in a large forearm vein, 
delivered at a controlled rate (usually 4-6 ml/second) by a power injector. CTA acquisition 
that covers the arch of the aorta to the circle of Willis is recommended. Alternative vascular 
imaging is permitted (MRA or DSA). 
Follow-up imaging at 24 (22-36) hours in patients treated with IV thrombolysis usually 
includes CT brain to define infarct size, haemorrhagic complications and brain swelling. For 
STABILISE trial-specific imaging will be MRI/MRA to define infarct better, and confirm vessel 
recanalisation and enable assessment of the role of early MRI as a possible predictor of long 
term outcome. Follow-up imaging may be with CT brain and CTA only in exceptional 
circumstances. 
MRI is a very common and safe clinical imaging investigation utilising radio waves within a 
powerful magnetic field to build up detailed structural images of the body. But due to the 
logistics and availability involved, MRI is underutilised in many stroke centres. Furthermore it 
is very rarely used as an early follow-up examination following a major stroke. 
 
Image Processing and Analysis 
Trial imaging studies will be transferred from clinical scanners or radiology archives after 
removal of individual identifiers from the DICOM file (patient name, date of birth, NHS 
number or similar unique identifier) which will be replaced with the site and trial specific 
patient ID number. Imaging studies will be uploaded to or forwarded on removable media for 
central review.  
 
Blood Testing/Venepuncture 
Additional blood testing for trial purposes is not required. Blood results relevant to acute 
stroke with thrombolytic treatment will be reviewed for trial purposes and routinely include the 
following:  
• Biochemistry – blood glucose, urea and creatinine (and calculated estimated 
Glomerular Filtration Rate, eGFR), blood glucose  
• Haematology – platelet count and coagulation studies (including prothrombin time, 
INR and activated partial thromboplastin time) 




Because of the emergency nature of stroke treatment and the potential for patients to have 
been transferred from other hospitals for care, lab results may be derived from a number of 
different hospitals. Any EU acute care hospital laboratory will be acceptable as the source of 
pre-treatment blood results. 
15.3 Data Handling & Record Keeping 
An electronic case report form (eCRF) will be used to collect trial data.  The eCRF will be 
developed by the Newcastle University Clinical Trials Unit and Newcastle University Institute 
for Ageing and Health and access to the eCRF will be restricted, with only authorised site-
specific personnel able to make entries or amendments to their patients’ data. It is the 
investigator's responsibility to ensure completion and to review and approve all data captured 
in the eCRF.  
All data handling procedures will be detailed in a Trial Specific Data Management Plan.  Data 
will be validated at the point of entry into the eCRF and at regular intervals during the trial.  
Data discrepancies will be flagged to the trial site and any data changes will be recorded in 




To enable evaluations and/or audits from regulatory authorities, the investigator agrees to 
keep records, including the identity of all participating subjects (sufficient information to link 
records), all original signed informed consent forms, serious adverse event forms, source 
documents, and detailed records of treatment disposition in accordance with International 
Conference on Harmonisation of Good Clinical Practice (ICH GCP), local regulations, or as 
specified in the Clinical Trial Agreement, whichever is longer.  Data will be retained at the 
Data Centre for a minimum of 5 years. 
Data will be recorded by authorised site staff on electronic Case Report Forms (eCRF).  Data 
transferred from site to the secure validated database by remote access will be secure and 
encrypted. Data will be handled, computerised and stored in accordance with the Data 
Protection Act 1998.  No participant identifiable data will leave the trial site. The quality and 
retention of trial data will be the responsibility of the CI.  All trial data will be retained in 
accordance with the latest Directive on GCP (2005/28/EC) and local policy. 
 





16. Statistical Considerations 
 
16.1 Statistical Analysis 
The trial will have a comprehensive Statistical Analysis Plan, which will govern all statistical 
aspects of the trial, and will be authored by the Trial Statistician and agreed by the Trial 
Steering Committee (TSC) before any comparative analysis is undertaken or any unblinded 
data is released.  
As an early phase trial the majority of the statistical analysis will be descriptive carried out on 
an intention to treat basis retaining patients in their randomised group and including any 
ineligible patients or protocol violators. 
The primary outcome measure is the proportion of patients in each randomised group who 
achieve good recanalisation at end of procedure as a proportion of all randomised patients 
based on independent core lab adjudication (blinded to allocation to experimental or control 
arm) and defined as STIR II modified TICI grade 2b/3.  
Secondary outcome measures (defined in section 2) will be summarised (overall and by 
randomised group)  according to their data type: categorical measures will be summarised as 
proportions of the total number of randomised patients, continuous measures will be 
summarised as means (sd), integer continuous measures as medians (IQR).  
Specifically, the mRS score at day 90 (±7) will be treated as a continuous ordinal variable 
and also categorised as favourable (scores of 0-2) or unfavourable (scores 3-6) and by 
change from baseline pre stroke mRS.   
Safety data (serious adverse events) – both numbers of subjects and events – will be 
summarised by randomised group and overall using descriptive statistics, including mortality 
rates within 365 days. Feasibility will be reported descriptively as i) acceptability to patients 
defined as  the total number of patients randomised as a proportion of those identified as 
eligible to participate; ii) feasibility of the procedure defined as time to thrombectomy and 
duration of thrombectomy; iii) compliance to data collection procedures at 3 and 12 months. 
Summary statistics of the primary and secondary outcome measures will be presented by 
stratification factors, specifically age cohort (50-65 versus >65y) and also clinically relevant 
groups according to type of occlusion (internal carotid artery, basilar artery, proximal middle 
cerebral artery, MCA distal). The relationship between age (as a continuous measure) and 
other clinical variables will be explored descriptively as well as investigating the risk 
associated with increased age as a potential predictor of the primary outcome.  
 





16.2 Sample Size Calculation 
It is intended that this phase II early clinical trial will gather feasibility, safety and provisional 
outcome data which will inform the design of a subsequent powered, definitive phase III trial. 
We intend to recruit between 120 patients over 24-30 months to do this.  
The number of patients is predominantly based on pragmatic considerations, around feasible 
recruitment of patients given available time and resources. The design is a randomised 
controlled trial randomising patients to the novel SOFIA/ERIC devices on a 2:1 basis in 
favour of SOFIA/ERIC. In this design the control device group will provide an indication of 
activity and adverse effects in patients receiving current standard of care. This trial is not 
designed or powered to statistically compare the control and experimental groups using 
formal hypothesis testing. The control group are recruited primarily to provide an unbiased 
‘benchmark’ of activity and adverse events, hence the justification for the 2:1 randomisation. 
The primary outcome measure for this early phase trial is recanalisation rate (as a shorter-
term surrogate for longer term outcome measures of function more suitable for phase 3 
trials). The number of patients is based on achieving a specified recanalisation rate in the 
experimental device group, with acceptable error levels, which would justify further research 
of the device. As an indication, assuming a recanalisation rate to reject SOFIA/ERIC (p0) 
<75% and a recanalisation rate to justify investigating SOFIA/ERIC further (p1) >90%, 
recruiting a minimum of 67 patients to the SOFIA/ERIC arm would allow alpha and beta error 
levels of 2.5% and 10% respectively (Fleming-A’Hern single stage early phase trial 
methodology). Assuming a conservative anticipated drop-out rate of up to 20% over 6-
months increases the recruitment target for the experimental device arm to 80 patients. An 
additional 40 patients will be randomised to the control device on as 2:1 basis total 
recruitment target of 120 patients. There is no formal comparison between the two groups 
and the trial data will be presented as per the single-arm Fleming-A’Hern design. However 
the dropout rate has been 0 to date, so as few as 100 patients may be required.  
The overall aim is to move through the clinical trial pathway, to later phase studies, quickly. 
This trial will provide initial estimates of therapeutic activity, and incorporate planned 
investigation of stratification subgroups and biomarkers to inform future trials. At the end of 
the trial we will be in a position to make an informed decision regarding progression of the 
SOFIA/ERIC devices into definitive phase III trials.  
 
 







Management and Delivery 
The Newcastle University Clinical Trials Unit, a fully registered UK Clinical Research Network 
(CRN) Clinical Trials Unit, in conjunction with CIs and Trial Steering Committee, will manage 


























17. Compliance and Withdrawal 
 
17.1 Participant Compliance 
Where feasible, trial visits will coincide with routine clinical follow-up, to enhance the 
likelihood of good compliance.  Visit windows as outlined in the table in section 15.2 should 
ensure visit attendance; non-attendance for trial visits will prompt follow-up by telephone. 
Data collected for routine clinical care will be used for clinical trial documentation (e.g. blood 
results, NIHSS score, imaging findings). Consent will specifically include the use of clinically 
routine data for trial purposes, and for review of imaging studies by independent observers. 
 
17.2 Withdrawal of Participants  
Patients have the right to withdraw from the trial at any time for any reason, and without 
giving a reason.   
It is understood by all concerned that an excessive rate of withdrawals can render the trial 
uninterpretable; therefore, unnecessary withdrawal of patients should be avoided.  Should a 
patient decide to withdraw from the trial, all efforts will be made to report the reason for 
withdrawal as thoroughly as possible.   
Consent will be sought from patients to retain data collected up to the point of withdrawal. 
















18. Data Monitoring, Quality Control and Quality Assurance  
 
18.1 Discontinuation Rules 
The trial may be prematurely discontinued on the basis of new safety information, or for other 
reasons given by the Data Monitoring & Ethics Committee and/or Trial Steering Committee, 
Sponsor, Regulatory Authority or Ethics Committee concerned. 
 
18.2 Monitoring, Quality Control and Assurance 
Routine Management of Trial: Trial Management Group (TMG) 
The trial will be coordinated by a Trial Management Group that will include those individuals 
responsible for the day-to-day management of the trial; namely the CIs, clinical research 
fellow, statistician, trial manager and database manager. The role of the group is to monitor 
all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and 
take appropriate action to safeguard participants and the quality of the trial itself. 
Trial Steering Committee (TSC) 
The role of the TSC is to provide overall supervision of the trial and ensure that it is being 
conducted in accordance with the principles of GCP and the relevant regulations. The TSC 
should: 
• agree the trial protocol and any protocol amendments 
• provide advice to the investigators on all aspects of the trial 
• have members who are independent of the investigators, in particular an independent 
chairperson 
Decisions about continuation or termination of the trial or substantial amendments to the 
protocol are usually the responsibility of the TSC. 
Independent Data Monitoring Committee (IDMC) 
The role of the IDMC is to review the accruing trial data and to assess whether there are any 
safety issues that should be brought to participants’ attention or any reasons for the trial not 
to continue. The IDMC will be independent of both the investigators and the funder/sponsor 
and will be the only body that has access to unblinded data. It will make recommendations to 
the TSC. 
 






18.3 Trial Monitoring and Auditing  
Trial monitoring visits will be conducted as appropriate by NHS Sponsor designated 
Monitor(s) e.g. from Newcastle Clinical Trials Unit.  The level of monitoring will be based on 
the outcome of the completed monitoring risk assessment; however, the minimum 
requirement per site will be an initiation visit following the issue of all approvals, and prior to 
the start of recruitment and a close out visit at each site after the last patient has completed 
the last visit.  
 
Prior to commencement of the trial a Monitoring Plan will be written by the monitors and 
approved by the Sponsor’s Research Governance Manager. In addition, the trial may be 
subject to routine or for-cause audit visits. Investigators and site staff will notified in advance 
























19. Adverse Event Monitoring and Reporting 
 
19.1 Definitions  
• Adverse Event (AE) – Any untoward medical occurrence in a subject to whom a trial 
intervention or procedure has been administered, including occurrences which are not 
necessarily caused by or related to that intervention/procedure. 
 
• Serious Adverse Event (SAE) - Any untoward occurrence that: 
a. results in death  
b. is life threatening  
c. requires hospitalisation or prolongation of existing hospitalisation  
d. results in persistent or significant disability or incapacity  
e. consists of a congenital anomaly or birth defect 
f. is otherwise considered medically significant by the investigator  
 
• Causality -  AEs should be assessed for causality and whether the event was related or 
unrelated to the intervention under trial. 
 
• Severity – the term ‘severe’ is used to describe the intensity of a specific event: 
o Mild: discomfort is noticed, but there is no disruption of normal daily 
activities 
o Moderate: discomfort is sufficient to reduce or affect normal daily activities 
o Severe: discomfort is incapacitating, with inability to work or to perform 
normal daily activities 
  
19.2 Expected Adverse Events 
The following AEs are considered to be expected: 
• AEs related to acute stroke: 
o Brain swelling / brain oedema (including brain herniation, raised intracranial 
pressure, mass effect, “malignant oedema”) 
 





o Haemorrhagic transformation of the infarct (symptomatic and asymptomatic) 
o Recurrent stroke (new or extension) 
o Neurological deterioration 
o Seizures 
o Infections, including pneumonia, urinary tract infection, cellulitis, C. Difficile 
o Complications of immobility (deep vein thrombosis, pulmonary embolism, falls, 
fractures, pressure sores, spasticity, joint immobility or pain) 
o Troponin T elevation without criteria of myocardial infarction 
o Myocardial infarction 
o Depression & other related psychological sequelae 
o Frailty 
o Death 
• AEs related to thrombolytic drug administration (these are detailed in relevant SmPCs): 
o Intracranial haemorrhage (symptomatic and asymptomatic) 
o Angio-oedema 
o Anaphylactoid reaction 
o Hypotension 




o Venous or arterial thrombosis (failure of response or subtherapeutic) 
• AEs related to thrombectomy devices and associated guiding catheter(s)/balloons: 




o New stroke 
o Arterial wall damage including arterial laceration, puncture and dissection 
 





o Femoral/Brachial/Radial arterial puncture site haematoma, pseudoaneurysm or 
haemorrhage 
o Device fracture 
o Device embolism 
o Failure to withdraw device successfully 
o Failure to retrieve some / all of the thrombus 
o De novo arterial stenoses / occlusions 
 
19.3 Protocol Specifications 
 
19.4 Recording and Reporting of Adverse Events 
AEs (from randomisation to 365 days) will be identified by observation and/or enquiry at trial 
visits. AEs that do not meet criteria for seriousness will be recorded in the medical notes 
only. Details of SAEs will be recorded to the eCRF in addition to the medical notes and 
followed until resolution. Expected SAEs as listed above (section 19.2) should be followed 
until resolution. The relationship with the trial procedures will be assessed for any 
unexpected SAEs: if possibly or definitely related, unexpected SAEs will be communicated 
by local PI to the Chief Investigator (CI) for review and will be reported to the Research 
Ethics Committee (REC) as detailed below. Unrelated and unexpected SAEs will be followed 
until resolution. 
 
Reporting to Sponsor 
All unexpected SAEs arising during the trial must be reported by the Principal Investigator (or 
designee) to the Sponsor and NCTU via fax using the SOHO 66 system as soon as 
reasonably practicable and in any event within 24 hours of first becoming aware of the event. 
Any follow up information should also be reported. 
The initial report can be made verbally, but must be promptly followed with a detailed, written 
SAE report faxed via SOHO 66. The SAE form should be completed and faxed using SOHO 
66 (Fax No: tbc) 
 






Reporting to the Research Ethics Committee (REC): 
Any SAE occurring to a research participant will be reported to the main REC (i.e. the REC 
that gave a favourable opinion of the trial) where in the opinion of the Chief Investigator (CI), 
the event was: 
• “Related” – that is, it resulted from administration of any of the research procedures, 
and 
• “Unexpected” – that is, the type of event is not listed in the protocol as an expected 
occurrence. 
Reports of related and unexpected SAEs should be submitted to the REC within 15 days of 
CI becoming aware of the event, using the ‘report of serious adverse event form’ for non-
CTIMPs published on the National Research Ethics Service (NRES) website.  
http://www.nres.nhs.uk/applications/after-ethical-review/safetyreports/safety-reports-for-all-
other-research/ 
The form should be completed in typescript and signed by the CI (or designee). The Sponsor 
will assist in the preparation and submission of the report. 
The co-ordinator of the main REC will acknowledge receipt of safety reports within 30 days. 
 
Annual Progress Report 
The CIs are also responsible for providing an annual progress report to the REC using an 
NRES “Annual Progress Report form for all other research”. This form is available at: 
http://www.hra.nhs.uk/resources/during-and-after-your-study/nhs-rec-annual-progress-report-
forms/ 
The report will be prepared by the Trial Management Group. A section on the safety of 
patients is included in this report. The Sponsor will assist in the collation of the safety 
information required for the report. 
 
Reporting to Local Research and Development (R&D) Departments 
The Principal Investigator at each site is responsible for the provision of reports to their local 
R&D department per the conditions of Management approval. 
 




20. Ethics & Regulatory Issues 
 
The trial will be carried out in accordance with the World Medical Association Declaration of 
Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong Kong [1989], South 
Africa [1996] and Edinburgh [2000]). 
Favourable ethical opinion will be sought from the relevant REC before patients are entered 
into this clinical trial.  Patients will only be allowed to enter the trial once they have provided 
written informed consent or it has been given by an appropriate consultee. 
The CI will be responsible for updating the REC of any new information related to the trial. 
 
20.1 Protocol Amendments 
Any change in the trial protocol will require an amendment.  Any proposed protocol 
amendments will be initiated by the CIs following discussion with the TSC and any required 
amendment forms will be submitted to the Regulatory Authority, Ethics Committee and 
Sponsor.  The CIs and the TSC will determine whether an amendment is non-substantial or 
substantial.  All amended versions of the protocol will be signed by the CI and Sponsor’s 
representative (NUTH R&D).  Before the amended protocol can be implemented favourable 
opinion/approval must be sought from the original reviewing REC, and participating site 




















Personal data will be regarded as strictly confidential. To preserve anonymity, any data 
leaving the site will identify participants by their initials and a unique trial identification code 
only. The trial will comply with the Data Protection Act, 1998. All trial records and Investigator 





























22. Insurance and Finance 
 
The STABILISE trial is sponsored by Newcastle Upon Tyne Teaching Hospitals (NUTH).  
The sponsor will be liable for negligent harm caused by the design of the trial.  NHS 
indemnity is provided under the Clinical Negligence and Other Risks Indemnity Scheme 
(CNORIS).   
The NHS has a duty of care to patients treated, whether or not the patient is taking part in a 
clinical trial, and the NHS remains liable for clinical negligence and other negligent harm to 
patients under its duty of care. 
Indemnity in respect of potential liability arising from negligent harm related to trial design is 
provided by NHS schemes for those protocol authors who have their substantive contracts of 
employment with the NHS and by Newcastle University Insurance schemes for those 
protocol authors who have their substantive contract of employment with the University.  This 























23. Trial Report/Publications 
 
An annual progress report will be submitted to the funders, the first being submitted 12 
months from the date that all trial related approvals are in place.  Annual reports will be 
submitted to the ethics committee, regulatory authority and sponsor with the first submitted 
one year after the date that all trial related approvals are in place. 
The trial will be submitted for adoption by the Stroke Research Network (SRN). It will be 
disseminated via SRN, presentations at relevant professional meetings and publications in 
peer reviewed journals. SRN will aid with dissemination to the wider public as will Newcastle 
University. All manuscripts, abstracts or other modes of presentation will be reviewed by the 
Trial Steering Committee and Funder prior to submission.  Individuals will not be identified 
from any trial report. 
The data will be the property of the Chief Investigators, Co-Investigators and Principal 
Investigators.  Publication will be the responsibility of the Chief Investigators and published 
under the authorship agreed with the Co-Investigators and all the Principal Investigators who 
have entered patients into the trial. 
Participants will be informed about the results at the end of the trial, including a lay summary 


















1 Jones TH, Morawetz RB, Crowell RM, Marcoux FW, Fitzgibbon SJ, DeGirolami U, 
Ojemann RG. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 
1981;54:773-82. 
2 Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin 
C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, 
Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM. Effects of alteplase beyond 3 h 
after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a 
placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309. 
3 Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, 
Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, 
Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin 
C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an 
updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 
2010;375:1695-703. 
4 Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, 
Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis 
with alteplase 3 to 4.5 hours after acute ischemic stroke. N.Engl.J.Med. 2008;359:1317-
29. 
5 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 
Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7. 
6 Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallee PC, Cabrejo L, 
Slaoui T, Guidoux C, Lapergue B, Klein IF, Olivot JM, Raphaeli G, Gohin C, Claeys ES, 
Amarenco P. Comparison of intravenous alteplase with a combined intravenous-
endovascular approach in patients with stroke and confirmed arterial occlusion 
(RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8:802-9. 
7 del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin 
JA, Wechsler L, Busse O, et al. Recombinant tissue plasminogen activator in acute 
thrombotic and embolic stroke. Ann Neurol 1992;32:78-86. 
 
 





8 Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. 
Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue 
plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 
1993;14:3-13. 
9 Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, Schroth G, 
Mattle HP. NIHSS score and arteriographic findings in acute ischemic stroke. Stroke 
2005;36:2121-5. 
10 Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin 
R, Mauldin P, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, Broderick JP. Methodology of 
the Interventional Management of Stroke III Trial. Int.J.Stroke 2008;3:130-7. 
11 Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, 
Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic 
stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral 
Thromboembolism. JAMA 1999;282:2003-11. 
12 Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, 
Inoue T. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle 
cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention 
trial (MELT) Japan. Stroke 2007;38:2633-9. 
13 Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the 
Interventional Management of Stroke Study. Stroke 2004;35:904-11. 
14 Kidwell CS, Jahan R, Gornbein P et al. A Trial of Imaging Selection and Endovascular 
Treatment for Ischemic Stroke. NEJM 2013;368:914-23 
15 Ciccone A, Valvassori L, Nichelatti M et al. Endovascular Treatment for Acute Ischemic 
Stroke. NEJM 2013;368:904-13. 
16 Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, Khoury J. 
Revascularization results in the Interventional Management of Stroke II trial. AJNR 
Am.J.Neuroradiol. 2008;29:582-7. 
17 The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35. 
18 The penumbra pivotal stroke trial: safety and effectiveness of a new generation of 
mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 
2009;40:2761-8. 
 





19 Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer 
MM, Higashida RT, Starkman S, Gobin YP, Frei D, Grobelny T, Hellinger F, Huddle D, 
Kidwell C, Koroshetz W, Marks M, Nesbit G, Silverman IE. Mechanical thrombectomy for 
acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008;39:1205-12. 
20 Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, 
Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP. Safety and 
efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. 
Stroke 2005;36:1432-8. 
21 Berkhemer OA, Fransen PS B, D et al. A Randomized Trial of Intraarterial Treatment for 
Acute Ischemic Stroke. N Engl J Med. 2015;372:11–20 
22 Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized 
Assessment of Rapid Endovascular Treatment of Ischemic Stroke. N Engl J Med. 2015;  
372:1019-1030 
23 Campbell BCV, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. 
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. N Engl J 
Med. 2015; 372:1009-1018 
24 Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-Retriever 
Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. N Engl J Med [Internet]. 
2015 Apr 17 [cited 2015 Apr 20];1–11 
25 Jovin TG, Chamorro A, Cobo E, de Miquel M a., Molina C a., Rovira A, et al. 
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. N Engl J Med 
[Internet]. 2015 Apr 17 [cited 2015 Apr 20]; 
26 Miley JT, Memon MZ, Hussein HM, Valenta DA, Suri MF, Vazquez G, Qureshi AI. A 
Multicenter Analysis of "Time to Microcatheter" for Endovascular Therapy in Acute 
Ischemic Stroke. J.Neuroimaging 2009. 
27 Kidwell CS, Jahan R, Gornbein J et al. A trial of imaging selection and endovascular 
treatment for ischemic stroke. NEJM 2013;368:914-923. 
28 Broderick JP, Palesch YY, Demchuk AM et al. Endovascular therapy afte intravenous t-
PA versus t-PA alone for stroke. NEJM 2013;368:893-903. 
29 Agarwal S, Scoffings DJ, Jones PS et al. Interaction of age with ischaemic penumbra, 
leptomeningeal collateral circulation and haemodynamic variables in acute stroke: a pilot 
study. J Neurol Neurosurg Psychiatry 2012;0:1-6  
 





30 Bang OY, Saver JL, Kim SJ et al. Collateral flow predicts response to endovascular 
therapy for acute ischemic stroke. Stroke 2011;42:693-699. 
31 Miteff F, Levi CR, Bateman GA et al. The independent predictive utility of computed 
tomography angiographic collateral status in acute ischaemic stroke. Brain 
2009;132:2231-2238. 
32 Lansberg MG, Straka M, Kemp S et al. MRI profile and response to endovascular 







































Appendix B: Declaration of Helsinki 
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
Ethical Principles for Medical Research Involving Human Subjects 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 
and amended by the 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
 
A. Introduction 
1. The World Medical Association has developed the Declaration of Helsinki as a statement 
of ethical principles to provide guidance to physicians and other participants in medical 
research involving human subjects. Medical research involving human subjects includes 
research on identifiable human material or identifiable data. 
2. It is the duty of the physician to promote and safeguard the health of the people. The 
physician's knowledge and conscience are dedicated to the fulfilment of this duty. 
3. The Declaration of Geneva of the World Medical Association binds the physician with the 
words, "The health of my patient will be my first consideration," and the International 
Code of Medical Ethics declares that, "A physician shall act only in the patient's interest 
when providing medical care which might have the effect of weakening the physical and 
mental condition of the patient."  
4. Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
5. In medical research on human subjects, considerations related to the well-being of the 
human subject should take precedence over the interests of science and society. 
6. The primary purpose of medical research involving human subjects is to improve 
prophylactic, diagnostic and therapeutic procedures and the understanding of the 
aetiology and pathogenesis of disease. Even the best proven prophylactic, diagnostic, 
and therapeutic methods must continuously be challenged through research for their 
effectiveness, efficiency, accessibility and quality.  
 




7. In current medical practice and in medical research, most prophylactic, diagnostic and 
therapeutic procedures involve risks and burdens.  
8. Medical research is subject to ethical standards that promote respect for all human 
beings and protect their health and rights. Some research populations are vulnerable and 
need special protection. The particular needs of the economically and medically 
disadvantaged must be recognised. Special attention is also required for those who 
cannot give or refuse consent for themselves, for those who may be subject to giving 
consent under duress, for those who will not benefit personally from the research and for 
those for whom the research is combined with care.  
9. Research Investigators should be aware of the ethical, legal and regulatory requirements 
for research on human subjects in their own countries as well as applicable international 
requirements. No national ethical, legal or regulatory requirement should be allowed to 
reduce or eliminate any of the protections for human subjects set forth in this Declaration. 
 
B. Basic Principles for All Medical Research 
10. It is the duty of the physician in medical research to protect the life, health, privacy, and 
dignity of the human subject.  
11. Medical research involving human subjects must conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literature, other relevant 
sources of information, and on adequate laboratory and, where appropriate, animal 
experimentation. 
12. Appropriate caution must be exercised in the conduct of research which may affect the 
environment, and the welfare of animals used for research must be respected. 
13. The design and performance of each experimental procedure involving human subjects 
should be clearly formulated in an experimental protocol. This protocol should be 
submitted for consideration, comment, guidance, and where appropriate, approval to a 
specially appointed ethical review committee, which must be independent of the 
investigator, the sponsor or any other kind of undue influence. This independent 
committee should be in conformity with the laws and regulations of the country in which 
the research experiment is performed. The committee has the right to monitor ongoing 
trials. The researcher has the obligation to provide monitoring information to the 
committee, especially any serious adverse events. The researcher should also submit to 
the committee, for review, information regarding funding, sponsors, institutional 
affiliations, other potential conflicts of interest and incentives for subjects.  
 





14. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that there is compliance with the principles enunciated in 
this Declaration. 
15. Medical research involving human subjects should be conducted only by scientifically 
qualified persons and under the supervision of a clinically competent medical person. The 
responsibility for the human subject must always rest with a medically qualified person 
and never rest on the subject of the research, even though the subject has given 
consent.  
16. Every medical research project involving human subjects should be preceded by careful 
assessment of predictable risks and burdens in comparison with foreseeable benefits to 
the subject or to others. This does not preclude the participation of healthy volunteers in 
medical research. The design of all studies should be publicly available. 
17. Physicians should abstain from engaging in research projects involving human subjects 
unless they are confident that the risks involved have been adequately assessed and can 
be satisfactorily managed. Physicians should cease any investigation if the risks are 
found to outweigh the potential benefits or if there is conclusive proof of positive and 
beneficial results.  
18. Medical research involving human subjects should only be conducted if the importance of 
the objective outweighs the inherent risks and burdens to the subject. This is especially 
important when the human subjects are healthy volunteers.  
19. Medical research is only justified if there is a reasonable likelihood that the populations in 
which the research is carried out stand to benefit from the results of the research.  
20. The subjects must be volunteers and informed participants in the research project. 
21. The right of research subjects to safeguard their integrity must always be respected. 
Every precaution should be taken to respect the privacy of the subject, the confidentiality 
of the patient's information and to minimise the impact of the trial on the subject's 












22. In any research on human beings, each potential subject must be adequately informed of 
the aims, methods, sources of funding, any possible conflicts of interest, institutional 
affiliations of the researcher, the anticipated benefits and potential risks of the trial and 
the discomfort it may entail. The subject should be informed of the right to abstain from 
participation in the trial or to withdraw consent to participate at any time without reprisal. 
After ensuring that the subject has understood the information, the physician should then 
obtain the subject's freely-given informed consent, preferably in writing. If the consent 
cannot be obtained in writing, the non-written consent must be formally documented and 
witnessed.  
23. When obtaining informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship with the physician or may 
consent under duress. In that case the informed consent should be obtained by a well-
informed physician who is not engaged in the investigation and who is completely 
independent of this relationship.  
24. For a research subject who is legally incompetent, physically or mentally incapable of 
giving consent or is a legally incompetent minor, the investigator must obtain informed 
consent from the legally authorised representative in accordance with applicable law. 
These groups should not be included in research unless the research is necessary to 
promote the health of the population represented and this research cannot instead be 
performed on legally competent persons.  
25. When a subject deemed legally incompetent, such as a minor child, is able to give assent 
to decisions about participation in research, the investigator must obtain that assent in 
addition to the consent of the legally authorised representative.  
26. Research on individuals from whom it is not possible to obtain consent, including proxy or 
advance consent, should be done only if the physical/mental condition that prevents 
obtaining informed consent is a necessary characteristic of the research population. The 
specific reasons for involving research subjects with a condition that renders them unable 
to give informed consent should be stated in the experimental protocol for consideration 
and approval of the review committee. The protocol should state that consent to remain 









27. Both authors and publishers have ethical obligations. In publication of the results of 
research, the investigators are obliged to preserve the accuracy of the results. Negative 
as well as positive results should be published or otherwise publicly available. Sources of 
funding, institutional affiliations and any possible conflicts of interest should be declared 
in the publication. Reports of experimentation not in accordance with the principles laid 
down in this Declaration should not be accepted for publication.  
 
C. Additional Principles for Medical Research Combined with Medical Care  
28. The physician may combine medical research with medical care, only to the extent that 
the research is justified by its potential prophylactic, diagnostic or therapeutic value. 
When medical research is combined with medical care, additional standards apply to 
protect the patients who are research subjects. 
29. The benefits, risks, burdens and effectiveness of a new method should be tested against 
those of the best current prophylactic, diagnostic, and therapeutic methods. This does not 
exclude the use of placebo, or no treatment, in studies where no proven prophylactic, 
diagnostic or therapeutic method exists. 
30. At the conclusion of the trial, every patient entered into the trial should be assured of 
access to the best proven prophylactic, diagnostic and therapeutic methods identified by 
the trial. 
31. The physician should fully inform the patient which aspects of the care are related to the 
research. The refusal of a patient to participate in a trial must never interfere with the 
patient-physician relationship. 
32. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic 
methods do not exist or have been ineffective, the physician, with informed consent from 
the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic 
measures, if in the physician's judgement it offers hope of saving life, re-establishing 
health or alleviating suffering. Where possible, these measures should be made the 
object of research, designed to evaluate their safety and efficacy. In all cases, new 
information should be recorded and, where appropriate, published. The other relevant 









Appendix C: NIH Stroke Scale 
 
0 No Stroke Symptoms 
1-4 Minor Stroke 
5-15 Moderate Stroke 
16-20 Moderate to Severe Stroke 



























Appendix D: Modifed Rankin Scale (mRS) 
 
Provided by the Internet Stroke Center — www.strokecenter.org 
 
MODIFIED             Trial ID: ___________________________ 
 
RANKIN                   Rater Name: ___________________________ 
 
SCALE (mRS)                  Date: ___________________________ 
 
Score Description 
0 No symptoms at all 
1 No significant disability despite symptoms; able to carry out all usual duties and activities 
2 Slight disability; unable to carry out all previous activities, but able to look after own affairs 
without assistance 
3 Moderate disability; requiring some help, but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to attend to 
own bodily 
needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention 
6 Dead 
 
TOTAL (0–6): _______ 
 




Appendix L - Stabilise Trial - Patient Pathway Flowchart 
Patient consents to undergo stroke
thrombectomy procedure
Patient signs Consent Form 
Or
Consultee/Relative signs Consultee Declaration Form




with ERIC™  device and/or 
SOFIA DAC
24 Hours post-thrombectomy
• Follow-up MRI scan
• Copy of image made with all personal details 
removed
• Anonymised copy sent for trial analysis






90 Days and 365 days post-thrombectomy:
• Short queestionnaire to be completed at standard 
hospital visit or by telephone
• End of trial participation at 365 days
STABILISE Trial Clinician:
• Explains trial to patient/relative/consultee
• Provides appropriate information sheet(s)
• Answers any questions that arise
Patient undergoes 
thrombectomy procedure 
with standard  device
Patient undergoes 
thrombectomy procedure 
with standard  device
24 Hours post-thrombectomy
• Follow-up MRI scan
Hospital discharge
90 Days and 365 days post-thrombectomy:
• Standard hospital follow-up visit
Patient invited
 to participate in 
STABILISE trial

















































Appendix N – CTA Training Day Agenda 
 
Registration: 09:00-9:15  
Introduction: 9:15-9:30 - Setting out the Priorities for the Training Day 
 
9:30-10:00 – Radiographic considerations for CT Angiograms in acute stroke patients 
10:00-10:30 – Evidence for performing immediate CT/CTA imaging: review of recent 
thrombectomy trials 
10:30-11:00 - How to read CT and CT Angiograms in acute stroke cases: applied vascular 
anatomy and implications on decision making 
11:00-11:40 – Cases: Hands-on session at reading intracranial CT and CT Angiogram scans 
 
Coffee break - 11:40-11:55 
 
11:55-12:15 – Cases Review and Discussion 
12:15-13:00 – Cases: Hands-on session at reading intracranial CT and CTA scans 
 
Lunch Break – 13:00-14:00 
 
14:00-14:20 – Cases Review and Discussion 
14:20-15:00 – Cases: Hands-on session at reading intracranial CT and CTA scans 
 
Coffee break - 15:00-15:15 
 
15:15-15:30 - Cases Review and Discussion 




16:00-16:30 - Cases Review and Discussion 
 
16:30 – 17:00: Feedback and Collection of Certificate 
 
























Appendix P – Thrombectomy Technical Difficulty Index (TTDI) 
 
Minimal Difficulty ≤ 4  
Mild to Moderate  > 4 and < 8   
Severe Difficulty ≥ 8  
 
 
A) Aortic Arch Elongation / Atheroma Classification  
Elongation Classification  Score 
Grade I 1 
Grade II 2 
Grade II + appreciable atheroma or Grade III 3 
Grade III + appreciable atheroma 4 
 
 
B) Target Vessel (TV) Tortuosity  
TV proximal (Beneath skull base) Score & TV (Intracranial) Score 
None / Mild 0  None / Mild 0 
Moderate 1  Moderate 1 
Severe 2  Severe 2 
Score: (TV Proximal + TV Distal) / 2  
 
 
C) Stenosis along target vessel  
Stenosis grade  Score 
Mild <50% 0 
Grade I – 50 - 70% 1 
Grade II – 70 – 95%  2 






D) Abbreviated Clot Burden Score* 
Anterior Circulation Score or Posterior Circulation* Score 
Mild (CBS ≥8) 0  Mild  0 
Moderate (CBS 6-7) 1  Moderate  1 
Severe (CBS ≤5) 2  Severe 2 
 
 
E) Any other extra problems - to add another 1 point.  
E.g. tandem stenosis/occlusion, aortic coarctation, common brachiocephalic trunk 
(bovine arch), variant origin of the vertebral artery (if target artery), right aortic arch, 
double aortic arch and any other variant anatomy / pathology which is presumed to 
add complexity to the case - including known severe PVD, INR/PT significantly 
prolonged  or other arterial access problem. 
 






Appendix Q – Awards, Publications, Presentations, Teaching, 
Conferences and Courses Attended Throughout my Ph.D. Studies 
 
Awards 
Travel Award Program for Students, Radiological Society of North America 2018, 
USA 
 
1st Place, trainee research project, Canadian Association of Radiologists ASM 
2018, Canada 
 




Drake B, Patro S, Quateen A, Cora EA, Finitsis S, Sinclair J, lesiuk H, Iancu D. 
Metameric Spinal AVM: Long-Term Symptomatic Relief Achieved by Embolization 
of the Extradural Component. Interventional Neuroradiology, 2019 Mar. 
 
Lun R, Cora EA, Iancu D, Graveline J, Figurado P, Shamy M. Thrombolysis in 
Acute Stroke Due to Thrombosed Aneurysm. The Neurohospitalist, 2019 Jan. 
 
Essbaiheen F, AlQahtani H, Almansoori TM, Cora EA, Patro S, Tsehmaister-
Abitbul V, et al. Transient in-stent stenosis at mid-term angiographic follow-up in 
patients treated with SILK flow diverter stents: incidence, clinical significance and 
long-term follow-up. J Neurointerv Surg, 2018 Sep.  
 
Cora EA, Finitsis S, Woulfe J, Essbaiheen F, AlQahtani H, Drake B, et al. Stent-
assisted coiling of posterior inferior cerebellar artery aneurysm complicated by 





Flynn D, Francis R, Halvorsrud K, Gonzalo-Almorox E, Craig D, Robalino S, 
McMeekin P, Cora A, Balami, J, Ford GA, White P. Intra-arterial mechanical 
thrombectomy stent retrievers and aspiration devices in the treatment of acute 
ischaemic stroke: A systematic review and meta-analysis with trial sequential 
analysis. Eur Stroke J. 2017;2(4):308–18.  
 
Cora EA, Ford GA, Flynn D, Gonsalves P, White P. CTA in acute stroke: short 
intensive training intervention is highly effective in improving radiologists’ 
performance. Clin Radiol. The Royal College of Radiologists; 2017;72(10):871–7. 
 
Cora EA, White PM, Wardlaw JM. Stroke imaging in the age of thrombolysis. 




Acute Thrombectomy in the Ageing Population: A retrospective analysis of 
radiological and clinical outcomes in acute thrombectomies performed in 
patients 80 years and older with an intention to treat analysis  
24-30/11/18 Poster presentation, Radiological Society of North America 2018, 
Chicago, USA 
Selected for the Student Travel Award 
 
Acute thrombectomy in the Ageing Population: A retrospective analysis of 
radiological and clinical outcomes in acute thrombectomies performed in 
patients over 80 years in a multicentre study 
17-20/10/18 Oral presentation, World Stroke Conference 2018, Montreal, Canada 
 
Acute thrombectomy in the ageing population: a retrospective analysis of 
radiological and clinical outcomes in acute thrombectomies performed in 
patients ≥ 80 years of age 
28/04/2018 Oral presentation, Canadian Association of Radiologists ASM 2018, 
Montreal, Canada 







Development of a technical scoring tool to assess the predicted 
thrombectomy difficulty in patients with acute ischaemic stroke 
8/10/2016 Oral presentation, British Society of Neuroradiologists, York, 
UK 
 
Using a validated case archive to train radiology SpRs in reporting acute CT 
angiograms in patients with suspected ischaemic stroke due to large vessel 
occlusion 
7/10/16 Oral presentation, British Society of Neuroradiologists, York, UK 
Awarded best trainee oral presentation 
 
STABILISE Trial and Research Outputs 
30/6/16 Poster presentation, NAHP, Newcastle University, Newcastle, UK 
 
CT Angiography in Acute Ischaemic Stroke: A Validated Case Archive Based 
on an Audit of Local Practice 
11/2015 ION Poster Evening, Newcastle University, Newcastle, UK 
 
CT Angiograms in Patients with Suspected Acute Ischaemic Stroke - Audit 
06/2015 Oral presentation, Northern Radiologists ASM, Durham, UK 
 
Stroke: an evaluation of thrombectomy in the ageing brain – [including] where 
IV thrombolysis fails or is contraindicated [STABILISE] 
04/2015 Poster presentation, European Stroke Organization Conference, 
Glasgow UK 
12/2014 Poster presentation, UK Stroke Conference, Hull, UK 
12/2014 Poster Presentation, Newcastle University, UK 
 
Update on UK led thrombectomy trials  





CT angiography in acute ischaemic stroke: a validated case archive based on 
an audit of local practice  
04/2015 Poster, European Stroke Organization Conference, Glasgow, UK 
Teaching 
Neuroradiology Teaching 
2014 – 2019  Bi-monthly informal junior doctors teaching 
 
Thrombectomy and Care of the Post-thrombectomy Patient 
Presented to intensive care nurses from the Ottawa hospital and from the 
Champlain Local Health Integration Network   
26/10/2018 Civic Hospital, Ottawa, Canada 
 
Radiology Resident Teaching – Neuroradiology cases 
25/04/2018 Formal trainee teaching, The Ottawa Hospital, Canada 
 
Acute Thrombectomy and Stroke Therapy Trials and Implementation Day  
Organized, presented and helped to deliver a one-day course aimed at Consultant 
Physicians and Radiologists  
14/02/2017 London, UK 
Recognized by RCR UK for 6 CPD points 
 
Developed CTA Course at the Durham MacLab for Radiologists and 
Physicians 
2016 – 2017   4 Full day sessions delivered in Durham, UK 
   Recognized by RCR UK for 6 CPD points 
 
Future of Neurological Interventions: Recent Advances and Concepts in 
Neuroradiology 
07/2015 Invited Lecturer, International Medical Summer School, Manchester, 
UK 
 
Neuroradiological Emergencies for Radiology Registrars  








Courses and Conferences 
Radiological Society of North America Annual Meeting   
27/11/2018 – 29/11/2018 Chicago, USA 
 
Advanced Neurointervention for Hemorrhagic Conditions and Acute 
Ischaemic Stroke Treatment - Fellows Course   
19/11/2018 – 20/11/2018 Toronto, Canada 
 
World Stroke Congress 2018   
17/10/2018 – 20/10/2018 Montreal, Canada 
 
AVM 2018 World Congress   
14/10/2018 – 16/10/2018 Montreal, Canada 
 
Canadian Interventional Neuro-Group 2018 Meeting   
12/10/2018 – 14/10/2018 Montreal, Canada 
 
Canadian Neurological Sciences Federation Congress   
24/06/2018 – 27/06/2018 Halifax, Canada 
 
American Society of Neuroradiology Annual Meeting 2018   
02/06/2018 – 07/06/2018 Vancouver, Canada 
 
Canadian Association of Radiologists 2018 Annual Scientific Meeting   
26/04/2018 – 29/04/2018 Montreal, Canada 
 
Ottawa Stroke Summit 
17/11/2017   Ottawa, Canada 
 
International Neuroradiology Symposium and 3rd Terbrugge Lectureship 





Canadian Interventional Neuro-Group 2017 Meeting 
07/09/2017 – 09/09/2017 Alberta, Canada 
 
Practical Statistics 1 
06/03/2017 – 07/03/2017 Newcastle University, UK 
 
European Course in Minimally Invasive Neurological Therapy 
12/12/2016 – 16/12/2016 Oxford, UK 
 
UK Neurovascular Group Meetings 
25/11/2016 – 26/11/2016 Hull, UK 
10/06/2016 – 11/06/2016  Manchester, UK 
 
British Society of Neuroradiologists Annual Meeting 
6/10/2016 – 8/10/2016 York, UK 
 
Newcastle University Institute for Ageing Research Day  
30/06/2016   Newcastle, UK 
 
Brainstorm Neurointerventional Meeting 
13/06/2016 – 15/06/2016 Edinburgh, UK 
 
European Stroke Conference 
17/04/2015 – 19/04/2015 Glasgow, UK 
 
Radiological Society of North America Annual Meeting 
30/12/2014 – 05/12/2014 Chicago, USA 
 
British Society of Neuroradiologists Annual Scientific Meeting 
10/10/2014 – 11/10/2014 Belfast, Ireland 
 
UK Neurovascular Group Meetings 




13/06/2014 – 14/06/2014  Liverpool, UK 
04/04/2014   London, UK 
 
Brainstorm Neurointerventional Meeting 
02/06/2014 – 04/06/2014 Edinburgh, UK 
 
Hull Interventional Neuroradiology Course 
15/05/2014 – 16/05/2014 Hull, UK  
 
Advanced Stroke Neurovascular Intervention 
20/03/2014 – 21/03/2014 Newcastle, UK 
